{"name":"Biotech layoff tracker","description":"Announced layoffs across biotech and life sciences, one row per event, each checked by a person against a regulatory filing or a named report.","source":"https://thebench.bio/layoffs","licence":"CC BY 4.0","licence_url":"https://creativecommons.org/licenses/by/4.0/","attribution":"thebench.bio","generated_at":"2026-10-04T13:47:34Z","record_began_on":"2023-01-01","notes":["One row is one announced layoff at one company on one date.","roles_reported is what the company or the filing stated. null means nobody stated a figure. It never means nought.","Summing roles_reported gives a floor rather than a total wherever a row has none.","verification is Confirmed when a filing or the company said it, and Rumoured when a publication reported it and the company has not confirmed it.","This is what we have checked. It is not a census of what has happened."],"event_count":789,"events":[{"company":"Century Therapeutics","company_slug":"century-therapeutics","country":"US","city":null,"announced_on":"2023-01-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Century Therapeutics announced a 25% workforce reduction and closure of lab operations in Seattle and Hamilton while consolidating research in Philadelphia.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Fate Therapeutics","company_slug":"fate-therapeutics","country":"US","city":null,"announced_on":"2023-01-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Fate Therapeutics announced a workforce reduction of more than half its staff after its Janssen partnership ended.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"TCR2 Therapeutics","company_slug":"tcr2-therapeutics","country":"US","city":null,"announced_on":"2023-01-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"TCR2 Therapeutics announced a 40% workforce reduction alongside new development priorities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Y-mAbs Therapeutics","company_slug":"y-mabs-therapeutics","country":"US","city":null,"announced_on":"2023-01-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"35.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Y-mAbs Therapeutics announced a 35% workforce reduction after an FDA rejection forced a strategic reset.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Elevation Oncology","company_slug":"elevation-oncology","country":"US","city":null,"announced_on":"2023-01-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Elevation Oncology announced a 30% workforce reduction while pausing development of seribantumab and reshaping its pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Editas Medicine","company_slug":"editas-medicine","country":"US","city":null,"announced_on":"2023-01-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Editas Medicine announced a 20% workforce reduction and pipeline reorganization after a difficult clinical year for its lead program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Zymergen","company_slug":"zymergen","country":"US","city":null,"announced_on":"2023-01-13","effective_on":null,"roles_reported":29,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Zymergen announced 29 layoffs following its acquisition by Ginkgo Bioworks.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Cyteir Therapeutics","company_slug":"cyteir-therapeutics","country":"US","city":null,"announced_on":"2023-01-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"restructuring","summary":"Cyteir Therapeutics announced a 70% workforce reduction as it narrowed its oncology strategy, leaving 15 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"ReNeuron","company_slug":"reneuron","country":"GB","city":null,"announced_on":"2023-01-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"funding","summary":"ReNeuron announced a 40% workforce reduction to extend its cash runway after difficulty raising additional capital.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Merck KGaA","company_slug":"merck-kgaa","country":"US","city":"Billerica","announced_on":"2023-01-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Merck KGaA confirmed layoffs at EMD Serono's Billerica, Massachusetts R&D operation, affecting more than 130 employees and about 26% of the site team.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Finch Therapeutics","company_slug":"finch-therapeutics","country":"US","city":null,"announced_on":"2023-01-24","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"95.0","verification":"Confirmed","cause":"funding","summary":"Finch Therapeutics announced a 95% workforce reduction as it stopped a Phase 3 trial and conserved cash amid a difficult funding environment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Amgen","company_slug":"amgen","country":"US","city":null,"announced_on":"2023-01-30","effective_on":null,"roles_reported":300,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Amgen announced approximately 300 U.S. job cuts, concentrated mainly in commercial roles.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Quince Therapeutics","company_slug":"quince-therapeutics","country":"US","city":null,"announced_on":"2023-01-30","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"47.0","verification":"Confirmed","cause":"restructuring","summary":"Quince Therapeutics announced a cost-reduction plan that would cut approximately 47% of its workforce between February and April.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Inovio","company_slug":"inovio","country":"US","city":null,"announced_on":"2023-01-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"11.0","verification":"Confirmed","cause":"restructuring","summary":"Inovio announced another restructuring that would reduce its remaining workforce by approximately 11%.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Evelo Biosciences","company_slug":"evelo-biosciences","country":"US","city":null,"announced_on":"2023-02-01","effective_on":null,"roles_reported":48,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Evelo Biosciences announced approximately 48 layoffs, about 45% of staff, alongside disappointing clinical data.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Instil Bio","company_slug":"instil-bio","country":"US","city":null,"announced_on":"2023-02-01","effective_on":null,"roles_reported":15,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Instil Bio announced approximately 15 layoffs at a California manufacturing site as operations shifted to the U.K.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Eisai","company_slug":"eisai","country":"US","city":null,"announced_on":"2023-02-03","effective_on":"2023-04-30","roles_reported":91,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Eisai disclosed 91 U.S. layoffs effective April 30; only three affected employees were based in Nutley despite the New Jersey WARN location.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Johnson & Johnson","company_slug":"johnson-johnson","country":null,"city":null,"announced_on":"2023-02-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Johnson & Johnson's Janssen pharmaceutical unit announced a broad overhaul of its infectious-disease and vaccine organizations that would include layoffs globally.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Vyant Bio","company_slug":"vyant-bio","country":"US","city":null,"announced_on":"2023-02-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Vyant Bio announced steps to wind down operations, including an undisclosed workforce reduction.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Magenta Therapeutics","company_slug":"magenta-therapeutics","country":"US","city":null,"announced_on":"2023-02-06","effective_on":null,"roles_reported":56,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Magenta Therapeutics cut 56 positions, approximately 84% of staff, after announcing plans to close down and preserve financial resources.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Neurona Therapeutics","company_slug":"neurona-therapeutics","country":"US","city":null,"announced_on":"2023-02-06","effective_on":null,"roles_reported":18,"workforce_before":68,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Neurona Therapeutics laid off 18 of its 68 employees after a financial review.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aligos Therapeutics","company_slug":"aligos-therapeutics","country":"US","city":"South San Francisco","announced_on":"2023-02-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"10.0","verification":"Confirmed","cause":"funding","summary":"Aligos Therapeutics announced an approximately 10% workforce reduction intended to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Eliem Therapeutics","company_slug":"eliem-therapeutics","country":"US","city":null,"announced_on":"2023-02-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"funding","summary":"Eliem Therapeutics announced a 55% workforce reduction and pivot to preclinical work to extend its cash runway in a difficult capital environment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Frequency Therapeutics","company_slug":"frequency-therapeutics","country":"US","city":null,"announced_on":"2023-02-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Frequency Therapeutics announced a 55% workforce reduction after its Phase 2b hearing-loss program failed and two programs were discontinued.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Chimera Bioengineering","company_slug":"chimera-bioengineering","country":"US","city":null,"announced_on":"2023-02-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"funding","summary":"Chimera Bioengineering announced a 40% workforce reduction to preserve cash while seeking additional financing.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Talaris Therapeutics","company_slug":"talaris-therapeutics","country":"US","city":null,"announced_on":"2023-02-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Talaris Therapeutics announced a workforce reduction of roughly one third as part of a pipeline restructure and strategic review.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"La Jolla","announced_on":"2023-02-17","effective_on":"2023-03-27","roles_reported":111,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer disclosed a phased workforce reduction affecting 111 employees at its La Jolla research site, beginning March 27.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aileron Therapeutics","company_slug":"aileron-therapeutics","country":"US","city":null,"announced_on":"2023-02-21","effective_on":null,"roles_reported":6,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Aileron Therapeutics announced six layoffs out of its remaining nine employees after disappointing Phase 1b data.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Bayer","company_slug":"bayer","country":"US","city":"Berkeley","announced_on":"2023-02-22","effective_on":"2023-03-31","roles_reported":55,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bayer disclosed 55 layoffs at its Berkeley, California campus, effective March 31.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Graphite Bio","company_slug":"graphite-bio","country":"US","city":null,"announced_on":"2023-02-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Graphite Bio announced a 50% workforce reduction after a strategic review as it sought to minimize cash burn and explore alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Quantum Genomics","company_slug":"quantum-genomics","country":"FR","city":null,"announced_on":"2023-02-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Quantum Genomics announced an organizational restructuring that included an undisclosed number of layoffs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Cybin","company_slug":"cybin","country":null,"city":null,"announced_on":"2023-02-23","effective_on":"2023-02-22","roles_reported":null,"workforce_before":null,"share_of_workforce":"15.0","verification":"Confirmed","cause":"restructuring","summary":"Cybin announced that it had reduced its workforce by 15% on Feb. 22 as part of a cost-reduction effort.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"EQRx","company_slug":"eqrx","country":"US","city":null,"announced_on":"2023-02-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"18.0","verification":"Confirmed","cause":"restructuring","summary":"EQRx announced an 18% workforce reduction as part of a restructuring intended to lower annual operating costs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Impel Pharmaceuticals","company_slug":"impel-pharmaceuticals","country":"US","city":null,"announced_on":"2023-02-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"16.0","verification":"Confirmed","cause":"restructuring","summary":"Impel Pharmaceuticals announced a 16% workforce reduction focused heavily on R&D roles to reduce cash use.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Jounce Therapeutics","company_slug":"jounce-therapeutics","country":"US","city":null,"announced_on":"2023-02-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"57.0","verification":"Confirmed","cause":"restructuring","summary":"Jounce Therapeutics announced a 57% workforce reduction while preparing for a reverse merger and winding down internal development work.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aptinyx","company_slug":"aptinyx","country":"US","city":null,"announced_on":"2023-02-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"60.0","verification":"Confirmed","cause":"restructuring","summary":"Aptinyx announced a 60% workforce reduction to reduce costs and align staffing with its remaining business needs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Apexigen","company_slug":"apexigen","country":"US","city":null,"announced_on":"2023-02-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"restructuring","summary":"Apexigen announced a 55% workforce reduction while exploring strategic alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Theravance Biopharma","company_slug":"theravance-biopharma","country":null,"city":null,"announced_on":"2023-02-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"17.0","verification":"Confirmed","cause":"restructuring","summary":"Theravance Biopharma announced a 17% workforce reduction as part of a pipeline cleanup.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"G1 Therapeutics","company_slug":"g1-therapeutics","country":"US","city":null,"announced_on":"2023-03-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"G1 Therapeutics announced a 30% workforce reduction to reduce costs while preserving its Cosela commercial team.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Jaguar Gene Therapy","company_slug":"jaguar-gene-therapy","country":"US","city":null,"announced_on":"2023-03-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"funding","summary":"Jaguar Gene Therapy announced an approximately 20% workforce reduction, citing a challenging financing environment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"MorphoSys","company_slug":"morphosys","country":"DE","city":null,"announced_on":"2023-03-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"17.0","verification":"Confirmed","cause":"restructuring","summary":"MorphoSys announced a 17% reduction of headquarters staff while ending preclinical work and concentrating on mid- and late-stage oncology programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Novo Nordisk","company_slug":"novo-nordisk","country":"US","city":null,"announced_on":"2023-03-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novo Nordisk announced job eliminations affecting about 20 employees in Seattle and around 80 in Indianapolis while expanding in the Boston area.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Atai Life Sciences","company_slug":"atai-life-sciences","country":null,"city":null,"announced_on":"2023-03-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Atai Life Sciences announced a 30% workforce reduction two months after a Phase 2 depression study failed.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"CODA Biotherapeutics","company_slug":"coda-biotherapeutics","country":"US","city":null,"announced_on":"2023-03-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"CODA Biotherapeutics shut down, with an undisclosed number of employees affected.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Coherus BioSciences","company_slug":"coherus-biosciences","country":"US","city":null,"announced_on":"2023-03-09","effective_on":"2023-03-10","roles_reported":60,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Coherus BioSciences announced 60 layoffs, about 20% of staff, beginning March 10 as it reduced costs and reassessed part of its pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Neoleukin Therapeutics","company_slug":"neoleukin-therapeutics","country":"US","city":null,"announced_on":"2023-03-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"restructuring","summary":"Neoleukin Therapeutics announced a 70% reduction of its remaining workforce while exploring strategic alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Olema Oncology","company_slug":"olema-oncology","country":"US","city":null,"announced_on":"2023-03-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Olema Oncology announced a 25% workforce reduction after an R&D reprioritization.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Evofem Biosciences","company_slug":"evofem-biosciences","country":"US","city":null,"announced_on":"2023-03-21","effective_on":null,"roles_reported":8,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Evofem Biosciences announced eight additional layoffs, including its chief commercial officer, to reduce payroll expenses.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Gamida Cell","company_slug":"gamida-cell","country":null,"city":null,"announced_on":"2023-03-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"17.0","verification":"Confirmed","cause":"restructuring","summary":"Gamida Cell announced a 17% workforce reduction after discontinuing work on an NK-cell therapy.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Alector","company_slug":"alector","country":"US","city":null,"announced_on":"2023-03-28","effective_on":null,"roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Alector announced a restructuring expected to affect 30 employees, about 11% of headcount, while prioritizing later-stage immuno-neurology programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Applied Molecular Transport","company_slug":"applied-molecular-transport","country":"US","city":null,"announced_on":"2023-03-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"57.0","verification":"Confirmed","cause":"restructuring","summary":"Applied Molecular Transport announced a 57% workforce reduction while exploring strategic alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Evaxion Biotech","company_slug":"evaxion-biotech","country":"DK","city":null,"announced_on":"2023-03-28","effective_on":null,"roles_reported":10,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Evaxion Biotech disclosed 10 direct layoffs as it reduced staffing and scaled back planned hiring.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Ferring Pharmaceuticals","company_slug":"ferring-pharmaceuticals","country":"US","city":null,"announced_on":"2023-03-28","effective_on":null,"roles_reported":89,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Ferring Pharmaceuticals announced closure of its U.S. research institute, affecting approximately 89 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Molecular Templates","company_slug":"molecular-templates","country":"US","city":null,"announced_on":"2023-03-30","effective_on":null,"roles_reported":null,"workforce_before":222,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Molecular Templates announced plans to halve its 222-person workforce while narrowing clinical development and collaboration work.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aridis Pharmaceuticals","company_slug":"aridis-pharmaceuticals","country":"US","city":null,"announced_on":"2023-03-31","effective_on":null,"roles_reported":7,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Aridis Pharmaceuticals laid off seven full-time employees after AstraZeneca terminated a pneumonia-development agreement.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Vedere Bio II","company_slug":"vedere-bio-ii","country":"US","city":null,"announced_on":"2023-03-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Vedere Bio II announced that it was shutting down after disappointing preclinical results.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Freeline Therapeutics","company_slug":"freeline-therapeutics","country":null,"city":null,"announced_on":"2023-04-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Freeline Therapeutics announced another 30% workforce reduction as it continued restructuring and prioritizing its gene-therapy pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"VBI Vaccines","company_slug":"vbi-vaccines","country":null,"city":null,"announced_on":"2023-04-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"VBI Vaccines announced an organizational restructuring that could reduce its workforce by up to 35% while focusing on hepatitis B vaccine development.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"NGM Bio","company_slug":"ngm-bio","country":"US","city":null,"announced_on":"2023-04-05","effective_on":null,"roles_reported":75,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"NGM Bio announced a workforce reduction of 75 employees, approximately 33% of staff, after a Phase 2 solid-tumor program failure.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"US","city":null,"announced_on":"2023-04-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Takeda announced workforce changes tied to its move away from early-stage AAV gene-therapy and rare-hematology research in Massachusetts.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Biogen","company_slug":"biogen","country":"US","city":null,"announced_on":"2023-04-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Biogen confirmed that some U.S. employees had been informed their roles were affected as the company optimized business strategies and its cost base.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aeglea BioTherapeutics","company_slug":"aeglea-biotherapeutics","country":"US","city":null,"announced_on":"2023-04-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Aeglea BioTherapeutics announced that it would reduce its workforce to 10 employees while exploring strategic alternatives after lackluster clinical data.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"GentiBio","company_slug":"gentibio","country":"US","city":null,"announced_on":"2023-04-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"GentiBio confirmed a relatively small workforce reduction that had occurred several weeks earlier.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Talaris Therapeutics","company_slug":"talaris-therapeutics","country":"US","city":null,"announced_on":"2023-04-14","effective_on":null,"roles_reported":80,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Talaris Therapeutics announced termination of about 80 employees, approximately 95% of its remaining workforce, while preserving a small team for strategic alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Nektar Therapeutics","company_slug":"nektar-therapeutics","country":"US","city":"San Francisco","announced_on":"2023-04-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"60.0","verification":"Confirmed","cause":"restructuring","summary":"Nektar Therapeutics announced a reorganization that would reduce its San Francisco-based workforce by approximately 60%.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Evelo Biosciences","company_slug":"evelo-biosciences","country":"US","city":null,"announced_on":"2023-04-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Evelo Biosciences announced another workforce reduction after additional atopic-dermatitis data disappointed and the company moved on from its lead asset.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Sangamo Therapeutics","company_slug":"sangamo-therapeutics","country":"US","city":null,"announced_on":"2023-04-27","effective_on":null,"roles_reported":120,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sangamo Therapeutics announced a workforce reduction of around 120 employees, about 27% of its U.S. workforce, while refocusing its genomic-medicine portfolio.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Selecta Biosciences","company_slug":"selecta-biosciences","country":"US","city":null,"announced_on":"2023-05-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Selecta Biosciences announced a 25% workforce reduction as part of an effort to streamline operations and prioritize investment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Acasti Pharma","company_slug":"acasti-pharma","country":"CA","city":null,"announced_on":"2023-05-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Acasti Pharma announced a severe headcount reduction, discontinued Canadian operations and replaced parts of management while focusing on GTX-104.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"EQRx","company_slug":"eqrx","country":"US","city":null,"announced_on":"2023-05-08","effective_on":null,"roles_reported":170,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"EQRx announced a second 2023 workforce reduction eliminating 170 roles, about 57% of its team, while narrowing its pipeline and partnerships.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"ADC Therapeutics","company_slug":"adc-therapeutics","country":null,"city":null,"announced_on":"2023-05-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"17.0","verification":"Confirmed","cause":"restructuring","summary":"ADC Therapeutics announced a 17% workforce reduction while narrowing its pipeline and reducing costs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":null,"announced_on":"2023-05-09","effective_on":null,"roles_reported":48,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed 48 layoffs in New Jersey beginning at the end of May.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Novavax","company_slug":"novavax","country":"US","city":null,"announced_on":"2023-05-09","effective_on":null,"roles_reported":500,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novavax announced a workforce reduction of around 500 employees, approximately 25% of staff, as it aligned spending with lower COVID-19 demand.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Gossamer Bio","company_slug":"gossamer-bio","country":"US","city":null,"announced_on":"2023-05-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Gossamer Bio announced a 25% workforce reduction and stopped work on other assets to focus resources on a Phase 3 pulmonary-arterial-hypertension program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Athenex","company_slug":"athenex","country":"US","city":null,"announced_on":"2023-05-12","effective_on":"2023-05-12","roles_reported":123,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"Athenex disclosed 123 layoffs at two manufacturing plants after filing for bankruptcy, with workforce reductions beginning May 12 and continuing in phases.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Affimed","company_slug":"affimed","country":"DE","city":null,"announced_on":"2023-05-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Affimed disclosed that it had reduced full-time-equivalent headcount by approximately 25% during an April reorganization after a Phase 2 lymphoma setback.","sources":"https://www.sec.gov/Archives/edgar/data/1608390/000119312523151054/d483852dex991.htm","recorded_on":"2026-10-04"},{"company":"PTC Therapeutics","company_slug":"ptc-therapeutics","country":"US","city":null,"announced_on":"2023-05-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"8.0","verification":"Confirmed","cause":"pipeline_setback","summary":"PTC Therapeutics announced an 8% workforce reduction alongside discontinuation of preclinical and early research gene-therapy programs after a Phase 3 setback.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"BenevolentAI","company_slug":"benevolentai","country":"GB","city":null,"announced_on":"2023-05-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"BenevolentAI announced a restructuring after a midstage setback that could eliminate up to 180 jobs, reduce laboratory space and pause programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"GreenLight Biosciences","company_slug":"greenlight-biosciences","country":"US","city":"Lexington","announced_on":"2023-05-30","effective_on":"2023-07-29","roles_reported":null,"workforce_before":null,"share_of_workforce":"51.0","verification":"Confirmed","cause":"restructuring","summary":"GreenLight Biosciences announced a restructuring expected to reduce its workforce by approximately 51%; a later Massachusetts WARN notice identified 96 affected workers at state facilities.","sources":"https://www.sec.gov/Archives/edgar/data/1822691/000095017023025357/grna-20230530.htm","recorded_on":"2026-10-04"},{"company":"Rain Oncology","company_slug":"rain-oncology","country":"US","city":null,"announced_on":"2023-05-30","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"65.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Rain Oncology announced a 65% workforce reduction after a Phase 3 failure, while halting programs and reducing operations.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Frequency Therapeutics","company_slug":"frequency-therapeutics","country":"US","city":null,"announced_on":"2023-05-31","effective_on":"2023-06-09","roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"restructuring","summary":"Frequency Therapeutics announced a second 2023 workforce reduction of 55%, expected to be completed by June 9.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Oncorus","company_slug":"oncorus","country":"US","city":null,"announced_on":"2023-06-02","effective_on":null,"roles_reported":55,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Oncorus announced a workforce reduction of 55 employees, representing substantially all of its workforce, as it wound down operations.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Rejuvenate Bio","company_slug":"rejuvenate-bio","country":"US","city":null,"announced_on":"2023-06-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Rejuvenate Bio confirmed a workforce reduction and pipeline reprioritization intended to better position the organization.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Encoded Therapeutics","company_slug":"encoded-therapeutics","country":"US","city":null,"announced_on":"2023-06-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Encoded Therapeutics announced a workforce reduction described as close to 10% of staff after reviewing its priorities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Xalud Therapeutics","company_slug":"xalud-therapeutics","country":"US","city":null,"announced_on":"2023-06-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Xalud Therapeutics announced a downsizing as it pivoted internal development toward an earlier-stage ALS program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Surface Oncology","company_slug":"surface-oncology","country":"US","city":null,"announced_on":"2023-06-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"merger","summary":"Surface Oncology announced a 50% workforce reduction after agreeing to be acquired by Coherus BioSciences.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Molecular Templates","company_slug":"molecular-templates","country":"US","city":null,"announced_on":"2023-06-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"44.0","verification":"Confirmed","cause":"restructuring","summary":"Molecular Templates announced another workforce reduction affecting 44% of its remaining staff.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Nutcracker Therapeutics","company_slug":"nutcracker-therapeutics","country":"US","city":null,"announced_on":"2023-06-21","effective_on":"2023-06-15","roles_reported":12,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":null,"summary":"Fierce reported that Nutcracker Therapeutics had laid off 12 employees on June 15.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Federation Bio","company_slug":"federation-bio","country":"US","city":null,"announced_on":"2023-06-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Federation Bio confirmed a recent reduction in force involving an undisclosed number of employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Intercept Pharmaceuticals","company_slug":"intercept-pharmaceuticals","country":"US","city":null,"announced_on":"2023-06-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Intercept Pharmaceuticals announced a restructuring that would trim about one third of its workforce after a second FDA rejection for Ocaliva in NASH.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Eiger BioPharmaceuticals","company_slug":"eiger-biopharmaceuticals","country":"US","city":null,"announced_on":"2023-06-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Eiger BioPharmaceuticals announced a 25% workforce reduction while concentrating spending on its Phase 3 metabolic-disease program after an earlier COVID-19 regulatory setback.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"BAKX Therapeutics","company_slug":"bakx-therapeutics","country":"US","city":null,"announced_on":"2023-07-11","effective_on":"2023-07-01","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BAKX Therapeutics disclosed that the company had dissolved, with most rank-and-file employees let go July 1 and remaining executives expected to depart Aug. 1.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Avrobio","company_slug":"avrobio","country":"US","city":null,"announced_on":"2023-07-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Avrobio announced a 50% workforce reduction, stopped work on three gene-therapy programs and began exploring strategic alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Theratechnologies","company_slug":"theratechnologies","country":"CA","city":null,"announced_on":"2023-07-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Theratechnologies announced an undisclosed reduction in R&D headcount as sales of its approved medicines fell below expectations.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Capsida Biotherapeutics","company_slug":"capsida-biotherapeutics","country":"US","city":null,"announced_on":"2023-07-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Capsida Biotherapeutics announced an undisclosed workforce reduction to conserve resources.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Pieris Pharmaceuticals","company_slug":"pieris-pharmaceuticals","country":"US","city":null,"announced_on":"2023-07-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"restructuring","summary":"Pieris Pharmaceuticals announced a 70% workforce reduction after AstraZeneca ended a licensing agreement for its asthma program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Amarin","company_slug":"amarin","country":"US","city":null,"announced_on":"2023-07-19","effective_on":null,"roles_reported":120,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Amarin announced a restructuring that would eliminate its U.S. sales force and reduce non-sales staffing, affecting 120 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"FibroGen","company_slug":"fibrogen","country":"US","city":null,"announced_on":"2023-07-19","effective_on":null,"roles_reported":104,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"FibroGen announced a restructuring expected to eliminate approximately 104 U.S. positions, about 32% of its U.S. workforce, after multiple clinical setbacks.","sources":"https://www.sec.gov/Archives/edgar/data/921299/000095017023033458/fgen-20230714.htm","recorded_on":"2026-10-04"},{"company":"ImmuneID","company_slug":"immuneid","country":"US","city":null,"announced_on":"2023-07-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"ImmuneID confirmed a restructuring that included layoffs as it prepared for future clinical development of its lead asset.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Passage Bio","company_slug":"passage-bio","country":"US","city":null,"announced_on":"2023-07-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"26.0","verification":"Confirmed","cause":"restructuring","summary":"Passage Bio announced an organizational redesign that would reduce its workforce by approximately 26%, primarily in chemistry, manufacturing and controls.","sources":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923082546/tm2321606d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Heron Therapeutics","company_slug":"heron-therapeutics","country":"US","city":null,"announced_on":"2023-07-24","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Heron Therapeutics announced a 25% workforce reduction as part of another cost-reduction program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Biogen","company_slug":"biogen","country":"US","city":null,"announced_on":"2023-07-25","effective_on":null,"roles_reported":1000,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Biogen announced its Fit for Growth program, including a net headcount reduction of approximately 1,000 employees by 2025.","sources":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/exhibit991-q22023pressrele.htm","recorded_on":"2026-10-04"},{"company":"Infinity Pharmaceuticals","company_slug":"infinity-pharmaceuticals","country":"US","city":null,"announced_on":"2023-07-26","effective_on":null,"roles_reported":21,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Infinity Pharmaceuticals announced 21 layoffs, about 78% of staff, after its planned merger with MEI Pharma collapsed.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Mersana Therapeutics","company_slug":"mersana-therapeutics","country":"US","city":null,"announced_on":"2023-07-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Mersana Therapeutics announced an approximately 50% workforce reduction after its lead ovarian-cancer program failed to meet the primary endpoint in Phase 1/2.","sources":"https://www.globenewswire.com/news-release/2023/07/27/2712053/0/en/Mersana-Therapeutics-Announces-Topline-Data-from-UPLIFT-Clinical-Trial-in-Patients-with-Platinum-Resistant-Ovarian-Cancer-and-Strategic-Reprioritization.html","recorded_on":"2026-10-04"},{"company":"Homology Medicines","company_slug":"homology-medicines","country":"US","city":null,"announced_on":"2023-07-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"87.0","verification":"Confirmed","cause":"funding","summary":"Homology Medicines announced an 87% workforce reduction and stopped most development work, citing the current financing environment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Ribon Therapeutics","company_slug":"ribon-therapeutics","country":"US","city":null,"announced_on":"2023-07-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ribon Therapeutics discontinued its preclinical platform work and laid off an undisclosed number of employees while prioritizing two clinical programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Intergalactic Therapeutics","company_slug":"intergalactic-therapeutics","country":"US","city":null,"announced_on":"2023-08-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":null,"summary":"The Boston Business Journal reported that Intergalactic Therapeutics had laid off all staff and was seeking a buyer.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Karyopharm Therapeutics","company_slug":"karyopharm-therapeutics","country":"US","city":null,"announced_on":"2023-08-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Karyopharm Therapeutics announced a 20% workforce reduction after lowering projected Xpovio revenue.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Celsius Therapeutics","company_slug":"celsius-therapeutics","country":"US","city":null,"announced_on":"2023-08-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Rumoured","cause":"restructuring","summary":"STAT reported that Celsius Therapeutics was reducing its workforce by approximately 75% while retaining a smaller team to advance CEL383.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Salarius Pharmaceuticals","company_slug":"salarius-pharmaceuticals","country":"US","city":null,"announced_on":"2023-08-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"funding","summary":"Salarius Pharmaceuticals announced a 50% workforce reduction in an effort to extend remaining resources while evaluating the company's future.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Galera Therapeutics","company_slug":"galera-therapeutics","country":"US","city":null,"announced_on":"2023-08-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Galera Therapeutics announced a 70% workforce reduction after receiving an FDA complete response letter for its radiotherapy-complication drug.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Inovio","company_slug":"inovio","country":"US","city":null,"announced_on":"2023-08-09","effective_on":null,"roles_reported":58,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Inovio announced 58 layoffs in its third workforce reduction in 13 months while narrowing its development priorities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Atreca","company_slug":"atreca","country":"US","city":null,"announced_on":"2023-08-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"Atreca announced a 40% workforce reduction while ending work on its lead candidate and shifting focus to preclinical antibody-drug conjugates.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2023-08-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb confirmed a New Jersey workforce reduction affecting more than 100 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"BioXcel Therapeutics","company_slug":"bioxcel-therapeutics","country":"US","city":"New Haven","announced_on":"2023-08-14","effective_on":null,"roles_reported":110,"workforce_before":190,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BioXcel Therapeutics announced a strategic reprioritization reducing its workforce from approximately 190 to 80 employees, a reduction of 110.","sources":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923090891/tm2323591d1_ex99-1.htm","recorded_on":"2026-10-04"},{"company":"Thermo Fisher Scientific","company_slug":"thermo-fisher-scientific","country":"US","city":"Alachua","announced_on":"2023-08-14","effective_on":"2023-10-09","roles_reported":205,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Thermo Fisher Scientific disclosed 205 layoffs across two Alachua, Florida sites, with reductions beginning Oct. 9.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Alaunos Therapeutics","company_slug":"alaunos-therapeutics","country":"US","city":null,"announced_on":"2023-08-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"60.0","verification":"Confirmed","cause":"restructuring","summary":"Alaunos Therapeutics announced a 60% workforce reduction while discontinuing its only clinical-stage asset.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"BlueRock Therapeutics","company_slug":"bluerock-therapeutics","country":null,"city":null,"announced_on":"2023-08-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"12.0","verification":"Confirmed","cause":"restructuring","summary":"BlueRock Therapeutics announced a 12% workforce reduction across three sites while narrowing its pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aravive","company_slug":"aravive","country":"US","city":null,"announced_on":"2023-08-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Aravive announced a 70% workforce reduction after a Phase 3 ovarian-cancer trial failed and the company sought financing or a partner.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"LAVA Therapeutics","company_slug":"lava-therapeutics","country":null,"city":null,"announced_on":"2023-08-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"36.0","verification":"Confirmed","cause":"restructuring","summary":"Lava Therapeutics announced a 36% workforce reduction after reprioritizing its pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2023-08-22","effective_on":null,"roles_reported":103,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis announced 103 layoffs at its East Hanover, New Jersey headquarters, with the cuts scheduled to take effect in November.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Agenus","company_slug":"agenus","country":"US","city":null,"announced_on":"2023-08-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Agenus announced a 25% workforce reduction while pausing unpartnered programs and concentrating resources on its lead immuno-oncology combination.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Apellis Pharmaceuticals","company_slug":"apellis-pharmaceuticals","country":"US","city":null,"announced_on":"2023-08-23","effective_on":null,"roles_reported":225,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Apellis Pharmaceuticals announced a workforce reduction of around 225 employees, about 25% of staff, while cutting preclinical programs and targeting cost savings.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Notch Therapeutics","company_slug":"notch-therapeutics","country":null,"city":null,"announced_on":"2023-08-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Notch Therapeutics announced closure of one of its three centers, affecting about 25 people while offering some employees relocation opportunities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"NexImmune","company_slug":"neximmune","country":"US","city":"Gaithersburg","announced_on":"2023-08-31","effective_on":"2023-09-05","roles_reported":25,"workforce_before":47,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"NexImmune announced a workforce reduction from 47 to 22 full-time employees, eliminating 25 positions, to reduce cash expenditures.","sources":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523226404/d689875d8k.htm","recorded_on":"2026-10-04"},{"company":"Sage Therapeutics","company_slug":"sage-therapeutics","country":"US","city":"Cambridge","announced_on":"2023-08-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"Sage Therapeutics announced an approximately 40% workforce reduction alongside a pipeline and operating reorganization.","sources":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523225406/d530485d8k.htm","recorded_on":"2026-10-04"},{"company":"Sana Biotechnology","company_slug":"sana-biotechnology","country":"US","city":null,"announced_on":"2023-08-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sana Biotechnology confirmed another workforce reduction as it sought further operational efficiencies.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"2seventy bio","company_slug":"2seventy-bio","country":"US","city":null,"announced_on":"2023-09-12","effective_on":null,"roles_reported":176,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"2seventy bio announced a restructuring eliminating 176 roles, approximately 40% of headcount, alongside a CEO transition.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Kinnate Biopharma","company_slug":"kinnate-biopharma","country":"US","city":null,"announced_on":"2023-09-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"restructuring","summary":"Kinnate Biopharma announced a 70% workforce reduction, including separation from all employees of its China subsidiary, while cutting operating expenses.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Fresh Tracks Therapeutics","company_slug":"fresh-tracks-therapeutics","country":"US","city":"Boulder","announced_on":"2023-09-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"Fresh Tracks Therapeutics announced a plan of liquidation and dissolution, discontinued development programs and said it would terminate most employees by early October.","sources":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/a202309188kex991.htm","recorded_on":"2026-10-04"},{"company":"NightHawk Biosciences","company_slug":"nighthawk-biosciences","country":"US","city":null,"announced_on":"2023-09-20","effective_on":"2023-09-20","roles_reported":13,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"NightHawk Biosciences eliminated 13 R&D positions, about 14% of staff, as it exited internal R&D and focused on its CDMO business.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"ImmunityBio","company_slug":"immunitybio","country":"US","city":null,"announced_on":"2023-09-22","effective_on":null,"roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"ImmunityBio laid off around 50 employees across California and Florida after an FDA rejection earlier in the year.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"AM-Pharma","company_slug":"am-pharma","country":"NL","city":null,"announced_on":"2023-09-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"AM-Pharma announced a workforce reduction and leadership change after its Phase 3 sepsis-associated kidney-injury study failed.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Galecto","company_slug":"galecto","country":"US","city":"Boston","announced_on":"2023-09-27","effective_on":null,"roles_reported":29,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Galecto announced 29 layoffs, about 70% of its workforce, after a Phase 2 idiopathic-pulmonary-fibrosis program failed.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"PTC Therapeutics","company_slug":"ptc-therapeutics","country":"US","city":null,"announced_on":"2023-09-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"pipeline_setback","summary":"PTC Therapeutics announced a further strategic prioritization and approximately 25% workforce reduction following regulatory and portfolio setbacks.","sources":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000053/tmb-20230928x8k.htm","recorded_on":"2026-10-04"},{"company":"Syros Pharmaceuticals","company_slug":"syros-pharmaceuticals","country":"US","city":null,"announced_on":"2023-10-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"35.0","verification":"Confirmed","cause":"restructuring","summary":"Syros Pharmaceuticals announced a 35% workforce reduction after partnership setbacks and alongside a CEO transition.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Kezar Life Sciences","company_slug":"kezar-life-sciences","country":"US","city":"South San Francisco","announced_on":"2023-10-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"41.0","verification":"Confirmed","cause":"restructuring","summary":"Kezar Life Sciences announced a 41% workforce reduction and pipeline restructuring to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"uniQure","company_slug":"uniqure","country":null,"city":null,"announced_on":"2023-10-05","effective_on":null,"roles_reported":114,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"uniQure announced 114 layoffs, about 20% of staff, while discontinuing more than half of its research and technology projects.","sources":"https://www.fiercebiotech.com/biotech/uniqure-offloads-fifth-staff-half-rd-projects-keep-gene-therapies-clinic-2027","recorded_on":"2026-10-04"},{"company":"Atsena Therapeutics","company_slug":"atsena-therapeutics","country":"US","city":null,"announced_on":"2023-10-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Atsena Therapeutics confirmed a workforce reduction to redirect resources toward its lead inherited-retinal-disease program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"NanoString Technologies","company_slug":"nanostring-technologies","country":"US","city":null,"announced_on":"2023-10-06","effective_on":"2023-12-31","roles_reported":110,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"NanoString Technologies announced a workforce reduction of 110 positions, about 20% of its global workforce.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Eikon Therapeutics","company_slug":"eikon-therapeutics","country":"US","city":null,"announced_on":"2023-10-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Eikon Therapeutics cut staff as part of an effort to become more selective and efficient in allocating resources.","sources":"https://www.fiercebiotech.com/biotech/eikon-cuts-staff-effort-become-more-efficient-letter-ceo-perlmutter-reveals","recorded_on":"2026-10-04"},{"company":"Sana Biotechnology","company_slug":"sana-biotechnology","country":"US","city":null,"announced_on":"2023-10-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"29.0","verification":"Confirmed","cause":"restructuring","summary":"Sana Biotechnology announced a 29% workforce reduction while narrowing its focus and pulling back from its in vivo delivery platform.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Biogen","company_slug":"biogen","country":"US","city":null,"announced_on":"2023-10-11","effective_on":null,"roles_reported":113,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Biogen disclosed 113 layoffs at recently acquired Reata Pharmaceuticals operations in Texas.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Nkarta","company_slug":"nkarta","country":"US","city":null,"announced_on":"2023-10-17","effective_on":null,"roles_reported":18,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Nkarta announced 18 layoffs, about 10% of staff, while focusing resources on later-stage cell-therapy programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Beam Therapeutics","company_slug":"beam-therapeutics","country":"US","city":null,"announced_on":"2023-10-19","effective_on":null,"roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Beam Therapeutics announced approximately 100 layoffs, about 20% of staff, while reprioritizing its base-editing pipeline.","sources":"https://www.fiercebiotech.com/biotech/beam-lays-about-100-employees-and-deprioritizes-car-t-programs-push-runway-2026","recorded_on":"2026-10-04"},{"company":"Amgen","company_slug":"amgen","country":"US","city":null,"announced_on":"2023-10-24","effective_on":null,"roles_reported":350,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Amgen announced 350 layoffs among former Horizon Therapeutics employees after completing the acquisition.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"BrainStorm Cell Therapeutics","company_slug":"brainstorm-cell-therapeutics","country":"US","city":null,"announced_on":"2023-10-24","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"pipeline_setback","summary":"BrainStorm Cell Therapeutics announced a 30% workforce reduction after failing to secure FDA approval for NurOwn in ALS.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Idorsia","company_slug":"idorsia","country":"CH","city":null,"announced_on":"2023-10-24","effective_on":null,"roles_reported":300,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Idorsia announced 300 layoffs, mainly in R&D and related functions, while separately eliminating about 175 positions through vacancies and attrition.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"ElevateBio","company_slug":"elevatebio","country":"US","city":null,"announced_on":"2023-10-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"13.0","verification":"Confirmed","cause":"restructuring","summary":"ElevateBio announced a 13% workforce reduction while scaling back some preclinical work.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"Peapack","announced_on":"2023-10-30","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Pfizer disclosed a WARN affecting 791 positions at its Peapack, New Jersey facility ahead of the site's closure, but said the vast majority of workers would be reassigned to New York.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Galapagos","company_slug":"galapagos","country":null,"city":null,"announced_on":"2023-10-31","effective_on":null,"roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Galapagos announced approximately 100 job cuts alongside the transfer of roughly 400 Jyseleca-focused employees to Alfasigma.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Rani Therapeutics","company_slug":"rani-therapeutics","country":"US","city":null,"announced_on":"2023-11-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"funding","summary":"Rani Therapeutics announced a 25% workforce reduction and halted several programs to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/rani-and-sangamo-jettison-staff-offices-and-assets-keep-businesses-afloat-next-year","recorded_on":"2026-10-04"},{"company":"Sangamo Therapeutics","company_slug":"sangamo-therapeutics","country":"US","city":"Brisbane","announced_on":"2023-11-01","effective_on":null,"roles_reported":162,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sangamo Therapeutics announced 162 layoffs, about 40% of its U.S. workforce, and closure of its Brisbane headquarters.","sources":"https://www.fiercebiotech.com/biotech/rani-and-sangamo-jettison-staff-offices-and-assets-keep-businesses-afloat-next-year","recorded_on":"2026-10-04"},{"company":"Seres Therapeutics","company_slug":"seres-therapeutics","country":"US","city":null,"announced_on":"2023-11-02","effective_on":null,"roles_reported":160,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Seres Therapeutics announced a workforce reduction affecting about 160 employees, approximately 41% of staff.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Foster City","announced_on":"2023-11-03","effective_on":"2023-12-15","roles_reported":45,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead disclosed a Foster City workforce reduction affecting around 45 employees, with most of the layoffs effective Dec. 15.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Arbutus Biopharma","company_slug":"arbutus-biopharma","country":"US","city":null,"announced_on":"2023-11-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"24.0","verification":"Confirmed","cause":"restructuring","summary":"Arbutus Biopharma announced a 24% workforce reduction as it redirected resources from research programs toward clinical development.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"CRISPR Therapeutics","company_slug":"crispr-therapeutics","country":"US","city":null,"announced_on":"2023-11-07","effective_on":null,"roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":null,"summary":"Fierce reported that CRISPR Therapeutics laid off about 50 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Lyell Immunopharma","company_slug":"lyell-immunopharma","country":"US","city":null,"announced_on":"2023-11-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"funding","summary":"Lyell Immunopharma announced a 25% workforce reduction to extend its cash runway while deprioritizing earlier-stage work.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Pyxis Oncology","company_slug":"pyxis-oncology","country":"US","city":null,"announced_on":"2023-11-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"funding","summary":"Pyxis Oncology announced a 40% workforce reduction and portfolio reprioritization to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/hoping-pave-little-longer-runway-pyxis-cuts-staff-re-prioritizes-and-eyes-monetization","recorded_on":"2026-10-04"},{"company":"Novavax","company_slug":"novavax","country":"US","city":null,"announced_on":"2023-11-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novavax announced additional cost cuts for 2024 that included focused headcount reductions beyond its earlier savings plan.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Regenxbio","company_slug":"regenxbio","country":"US","city":null,"announced_on":"2023-11-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"15.0","verification":"Confirmed","cause":"restructuring","summary":"Regenxbio announced a 15% workforce reduction under a pipeline-prioritization plan.","sources":"https://www.fiercebiotech.com/biotech/difficult-necessary-steps-sqz-lays-80-staff-regenxbio-also-reduces-headcount","recorded_on":"2026-10-04"},{"company":"SQZ Biotechnologies","company_slug":"sqz-biotechnologies","country":"US","city":null,"announced_on":"2023-11-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"80.0","verification":"Confirmed","cause":"funding","summary":"SQZ Biotechnologies announced an 80% workforce reduction while pursuing strategic alternatives and reducing ongoing expenses.","sources":"https://www.fiercebiotech.com/biotech/difficult-necessary-steps-sqz-lays-80-staff-regenxbio-also-reduces-headcount","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"GB","city":"Sandwich","announced_on":"2023-11-14","effective_on":null,"roles_reported":500,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer announced approximately 500 job cuts at its Sandwich, U.K. site as part of its enterprise-wide cost realignment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Theseus Pharmaceuticals","company_slug":"theseus-pharmaceuticals","country":"US","city":null,"announced_on":"2023-11-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Theseus Pharmaceuticals announced a workforce reduction of almost three quarters while considering strategic alternatives after a safety setback.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Atreca","company_slug":"atreca","country":"US","city":null,"announced_on":"2023-11-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"funding","summary":"Atreca announced another 40% workforce reduction, its second in three months, while conserving cash and exploring strategic alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"858 Therapeutics","company_slug":"858-therapeutics","country":"US","city":"New York","announced_on":"2023-11-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"858 Therapeutics confirmed that it had laid off an undisclosed number of research employees and closed its New York office during 2023.","sources":"https://www.fiercebiotech.com/biotech/versant-backed-858-recently-laid-select-researchers-and-closed-new-york-site-tied-gotham","recorded_on":"2026-10-04"},{"company":"Kintara Therapeutics","company_slug":"kintara-therapeutics","country":"US","city":null,"announced_on":"2023-11-20","effective_on":null,"roles_reported":1,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Kintara Therapeutics disclosed the layoff of its chief scientific officer as part of broader cost-reduction measures and reduced its use of consultants.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Candel Therapeutics","company_slug":"candel-therapeutics","country":"US","city":null,"announced_on":"2023-11-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"funding","summary":"Candel Therapeutics announced a 50% workforce reduction to conserve cash for upcoming clinical readouts and partnership efforts.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"AbCellera Biologics","company_slug":"abcellera-biologics","country":"CA","city":"Vancouver","announced_on":"2023-11-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"10.0","verification":"Confirmed","cause":"restructuring","summary":"AbCellera Biologics announced a 10% workforce reduction to concentrate resources on antibody-medicine development.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Generation Bio","company_slug":"generation-bio","country":"US","city":null,"announced_on":"2023-11-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"Generation Bio announced a 40% workforce reduction as part of an R&D pivot intended to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Kite Pharma","company_slug":"kite-pharma","country":"US","city":null,"announced_on":"2023-11-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"7.0","verification":"Confirmed","cause":"restructuring","summary":"Kite Pharma announced a 7% workforce reduction as part of a refreshed business strategy while simultaneously creating about 90 roles aligned to new priorities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Axcella Health","company_slug":"axcella-health","country":"US","city":null,"announced_on":"2023-12-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Axcella Health announced that it was shutting down after 12 years, creating a closure-stage workforce event following its earlier large 2022 restructuring.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"IGM Biosciences","company_slug":"igm-biosciences","country":"US","city":null,"announced_on":"2023-12-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"22.0","verification":"Confirmed","cause":"funding","summary":"IGM Biosciences announced a 22% workforce reduction to strengthen its financial runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Orna Therapeutics","company_slug":"orna-therapeutics","country":"US","city":null,"announced_on":"2023-12-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Orna Therapeutics confirmed an undisclosed workforce reduction.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"ReNAgade Therapeutics","company_slug":"renagade-therapeutics","country":"US","city":null,"announced_on":"2023-12-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"10.0","verification":"Confirmed","cause":"restructuring","summary":"ReNAgade Therapeutics announced an approximately 10% workforce reduction while concentrating resources on programs approaching development-candidate and IND milestones.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Travere Therapeutics","company_slug":"travere-therapeutics","country":"US","city":"San Diego","announced_on":"2023-12-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Travere Therapeutics announced a 20% workforce reduction while focusing on the Filspari launch and development of pegtibatinase.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Ventyx Biosciences","company_slug":"ventyx-biosciences","country":"US","city":null,"announced_on":"2023-12-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Ventyx Biosciences announced a 20% workforce reduction following difficult R&D updates and a sharp fall in its share price.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Altamira Therapeutics","company_slug":"altamira-therapeutics","country":null,"city":null,"announced_on":"2023-12-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Altamira Therapeutics announced a 25% workforce reduction while reducing cash spend and pivoting toward RNA delivery.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Ferring Pharmaceuticals","company_slug":"ferring-pharmaceuticals","country":"US","city":null,"announced_on":"2023-12-12","effective_on":"2024-02-05","roles_reported":134,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ferring Pharmaceuticals announced 134 U.S. job cuts across its Parsippany headquarters and Minnesota microbiome hub.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Vir Biotechnology","company_slug":"vir-biotechnology","country":"US","city":"San Francisco","announced_on":"2023-12-13","effective_on":null,"roles_reported":75,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Vir Biotechnology announced 75 job eliminations, about 12% of headcount, and closure of two U.S. facilities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Reneo Pharmaceuticals","company_slug":"reneo-pharmaceuticals","country":"US","city":null,"announced_on":"2023-12-14","effective_on":"2023-12-31","roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Reneo Pharmaceuticals announced a 70% workforce reduction after its only clinical asset missed primary and secondary endpoints.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Asher Bio","company_slug":"asher-bio","country":"US","city":null,"announced_on":"2023-12-19","effective_on":null,"roles_reported":34,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Asher Bio announced a 34-person workforce reduction, about 60% of staff, while focusing on a single immunotherapy program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aclaris Therapeutics","company_slug":"aclaris-therapeutics","country":"US","city":null,"announced_on":"2023-12-20","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"46.0","verification":"Confirmed","cause":"restructuring","summary":"Aclaris Therapeutics announced an approximately 46% workforce reduction, beginning immediately and expected to be completed by the end of June 2024.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Ipsen","company_slug":"ipsen","country":null,"city":null,"announced_on":"2023-12-29","effective_on":null,"roles_reported":21,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ipsen confirmed that it had let go 21 laboratory employees during an April 2023 program termination.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Oxurion","company_slug":"oxurion","country":"BE","city":null,"announced_on":"2023-12-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Oxurion announced a shift to preclinical activity that would leave only 10 employees, with the remaining workforce entering a voluntary redundancy program as the company sought to avoid bankruptcy.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023","recorded_on":"2026-10-04"},{"company":"Aera Therapeutics","company_slug":"aera-therapeutics","country":"US","city":null,"announced_on":"2024-01-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Rumoured","cause":"restructuring","summary":"Aera Therapeutics reduced its workforce by about one quarter.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Intellia Therapeutics","company_slug":"intellia-therapeutics","country":"US","city":null,"announced_on":"2024-01-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"15.0","verification":"Confirmed","cause":"restructuring","summary":"Intellia Therapeutics announced a 15% workforce reduction after pausing exploratory research work.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"Pearl River","announced_on":"2024-01-04","effective_on":"2024-02-01","roles_reported":285,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer disclosed 285 layoffs at its Pearl River, New York vaccine R&D site, beginning in February and concluding by March 25.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Thermo Fisher Scientific","company_slug":"thermo-fisher-scientific","country":"US","city":"Petaluma","announced_on":"2024-01-04","effective_on":null,"roles_reported":74,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Thermo Fisher Scientific announced closure of its Petaluma, California site, affecting 74 employees.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Allogene Therapeutics","company_slug":"allogene-therapeutics","country":"US","city":null,"announced_on":"2024-01-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"22.0","verification":"Confirmed","cause":"restructuring","summary":"Allogene Therapeutics announced a 22% workforce reduction as part of a clinical and pipeline reprioritization.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"AlloVir","company_slug":"allovir","country":"US","city":null,"announced_on":"2024-01-05","effective_on":"2024-04-15","roles_reported":null,"workforce_before":null,"share_of_workforce":"95.0","verification":"Confirmed","cause":"pipeline_setback","summary":"AlloVir announced a 95% workforce reduction after three Phase 3 studies failed, with cuts expected to finish by April 15.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"NanoString Technologies","company_slug":"nanostring-technologies","country":"US","city":null,"announced_on":"2024-01-05","effective_on":"2024-03-31","roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"NanoString Technologies announced a reduction of about 50 employees, roughly 9% of its global workforce, expected to be completed by March 31.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Senti Biosciences","company_slug":"senti-biosciences","country":"US","city":null,"announced_on":"2024-01-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"37.0","verification":"Confirmed","cause":"restructuring","summary":"Senti Biosciences announced a 37% workforce reduction while prioritizing its SENTI-202 program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Affimed","company_slug":"affimed","country":null,"city":null,"announced_on":"2024-01-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Affimed announced a 50% workforce reduction as it dissolved research and preclinical development teams to focus on clinical-stage programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Atara Biotherapeutics","company_slug":"atara-biotherapeutics","country":"US","city":null,"announced_on":"2024-01-08","effective_on":null,"roles_reported":44,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Atara Biotherapeutics announced a strategic workforce reduction of approximately 25%; a later California WARN notice quantified the January action at 44 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/d703405d8k.htm","recorded_on":"2026-10-04"},{"company":"Enveric Biosciences","company_slug":"enveric-biosciences","country":"US","city":null,"announced_on":"2024-01-08","effective_on":null,"roles_reported":7,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Enveric Biosciences announced a reduction expected to eliminate approximately 7 positions, about half of its global workforce.","sources":"https://www.sec.gov/Archives/edgar/data/890821/000149315224001717/form8-k.htm","recorded_on":"2026-10-04"},{"company":"Exelixis","company_slug":"exelixis","country":"US","city":null,"announced_on":"2024-01-08","effective_on":null,"roles_reported":175,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Exelixis announced a workforce reduction of around 175 employees, representing about 13% of its workforce.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"C4 Therapeutics","company_slug":"c4-therapeutics","country":"US","city":null,"announced_on":"2024-01-10","effective_on":null,"roles_reported":45,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"C4 Therapeutics announced a 45-position workforce reduction, about 30% of staff, after discontinuing a cancer program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Allakos","company_slug":"allakos","country":"US","city":null,"announced_on":"2024-01-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Allakos announced a 50% workforce reduction after discontinuing its lead asset following mid-stage trial failures.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Kinnate Biopharma","company_slug":"kinnate-biopharma","country":"US","city":"San Francisco","announced_on":"2024-01-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"56.0","verification":"Confirmed","cause":"restructuring","summary":"Kinnate Biopharma publicly disclosed a further workforce reduction of approximately 56% as it explored strategic alternatives, leaving 12 full-time employees.","sources":"https://www.sec.gov/Archives/edgar/data/1797768/000114036124002334/ef20018834_8k.htm","recorded_on":"2026-10-04"},{"company":"Dewpoint Therapeutics","company_slug":"dewpoint-therapeutics","country":"US","city":null,"announced_on":"2024-01-17","effective_on":null,"roles_reported":18,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Dewpoint Therapeutics laid off 18 employees and narrowed its pipeline after two pharma collaborations ended.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bayer","company_slug":"bayer","country":null,"city":null,"announced_on":"2024-01-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bayer announced a broad organizational overhaul expected to eliminate managerial positions through 2025.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ikena Oncology","company_slug":"ikena-oncology","country":"US","city":null,"announced_on":"2024-01-19","effective_on":null,"roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ikena Oncology announced a workforce reduction of around 20 employees, about 35% of staff, concentrated mainly in drug discovery.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"PMV Pharmaceuticals","company_slug":"pmv-pharmaceuticals","country":"US","city":null,"announced_on":"2024-01-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"PMV Pharmaceuticals announced a 30% workforce reduction while prioritizing its lead solid-tumor program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Cara Therapeutics","company_slug":"cara-therapeutics","country":"US","city":null,"announced_on":"2024-01-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Cara Therapeutics announced a restructuring that could reduce its workforce by up to half while narrowing its clinical ambitions.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Strand Therapeutics","company_slug":"strand-therapeutics","country":"US","city":null,"announced_on":"2024-01-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"18.0","verification":"Confirmed","cause":"restructuring","summary":"Strand Therapeutics announced an 18% workforce reduction while continuing to invest in discovery programs and its first clinical trial.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"DermTech","company_slug":"dermtech","country":"US","city":"San Diego","announced_on":"2024-01-29","effective_on":null,"roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"DermTech announced a restructuring that reduced its workforce by approximately 30 employees, about 15% of staff.","sources":"https://www.sec.gov/Archives/edgar/data/1651944/000165194424000005/dmtk-20240129.htm","recorded_on":"2026-10-04"},{"company":"HOOKIPA Pharma","company_slug":"hookipa-pharma","country":null,"city":null,"announced_on":"2024-01-29","effective_on":null,"roles_reported":55,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"HOOKIPA Pharma announced an approximately 55-person workforce reduction, about 30% of staff, after Roche ended an alliance.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"South San Francisco","announced_on":"2024-01-29","effective_on":null,"roles_reported":52,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer disclosed 52 layoffs at a South San Francisco facility in a California WARN filing.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"2seventy bio","company_slug":"2seventy-bio","country":"US","city":null,"announced_on":"2024-01-30","effective_on":null,"roles_reported":55,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"2seventy bio transferred 160 employees to Regeneron and separately laid off about 55 employees as it narrowed its remaining operations around Abecma.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Rakuten Medical","company_slug":"rakuten-medical","country":null,"city":null,"announced_on":"2024-01-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Rakuten Medical conducted an undisclosed workforce reduction.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Xencor","company_slug":"xencor","country":"US","city":null,"announced_on":"2024-01-31","effective_on":null,"roles_reported":25,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Xencor reduced its workforce by 25 positions, about 10%, while focusing resources on higher-priority T-cell engager programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Rallybio","company_slug":"rallybio","country":"US","city":null,"announced_on":"2024-02-06","effective_on":null,"roles_reported":19,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Rallybio announced a 19-person workforce reduction, about 45% of staff, while focusing on two Phase 2-ready programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sandoz","company_slug":"sandoz","country":"US","city":"Wilson","announced_on":"2024-02-08","effective_on":"2024-10-04","roles_reported":213,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Sandoz announced closure of its Wilson, North Carolina facility, with 213 employees set to be laid off by October 4.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Science 37","company_slug":"science-37","country":"US","city":null,"announced_on":"2024-02-08","effective_on":null,"roles_reported":73,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Science 37 commenced a cost-reduction program affecting approximately 73 employees, about 23.2% of staff.","sources":"https://www.sec.gov/Archives/edgar/data/1819113/000181911324000004/snce-20240207.htm","recorded_on":"2026-10-04"},{"company":"Roche","company_slug":"roche","country":null,"city":null,"announced_on":"2024-02-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Roche proposed a reduction in its product-development organization affecting a few hundred positions, mostly external contractors, with fewer than 6% of permanent staff potentially affected.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Synlogic","company_slug":"synlogic","country":"US","city":null,"announced_on":"2024-02-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Synlogic announced it would discontinue a pivotal Phase 3 study, wind down operations and eliminate more than 90% of its workforce.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"LianBio","company_slug":"lianbio","country":null,"city":null,"announced_on":"2024-02-13","effective_on":"2024-03-31","roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"LianBio announced plans to lay off 50 full-time employees by the end of March as part of a longer dissolution process.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Aurinia Pharmaceuticals","company_slug":"aurinia-pharmaceuticals","country":null,"city":null,"announced_on":"2024-02-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Aurinia Pharmaceuticals announced a 25% workforce reduction and pipeline restructuring after failing to attract a buyer.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Clade Therapeutics","company_slug":"clade-therapeutics","country":"US","city":null,"announced_on":"2024-02-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":"restructuring","summary":"Clade Therapeutics carried out an undisclosed workforce reduction.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Kenvue","company_slug":"kenvue","country":"US","city":null,"announced_on":"2024-02-16","effective_on":null,"roles_reported":135,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Kenvue disclosed 135 layoffs across New Jersey and California, consisting of 51 positions in New Jersey and 84 in California.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Sonata Therapeutics","company_slug":"sonata-therapeutics","country":"US","city":null,"announced_on":"2024-02-16","effective_on":null,"roles_reported":21,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sonata Therapeutics laid off 21 employees, roughly one third of staff, while refocusing around near-term priorities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ring Therapeutics","company_slug":"ring-therapeutics","country":"US","city":null,"announced_on":"2024-02-20","effective_on":null,"roles_reported":19,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ring Therapeutics laid off 19 employees, representing less than 20% of the company.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Adaptive Biotechnologies","company_slug":"adaptive-biotechnologies","country":"US","city":null,"announced_on":"2024-02-21","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"6.7","verification":"Rumoured","cause":"restructuring","summary":"Adaptive Biotechnologies reduced its workforce by 6.7% following a strategic review.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Galapagos","company_slug":"galapagos","country":null,"city":null,"announced_on":"2024-02-22","effective_on":null,"roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Galapagos disclosed that it had streamlined operations and reduced around 100 positions while refocusing its portfolio.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Denali Therapeutics","company_slug":"denali-therapeutics","country":"US","city":null,"announced_on":"2024-02-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Denali Therapeutics announced a reorganization involving layoffs and transfers to a new spinout.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Perrigo","company_slug":"perrigo","country":null,"city":null,"announced_on":"2024-02-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"6.0","verification":"Confirmed","cause":"restructuring","summary":"Perrigo announced a restructuring plan involving a workforce reduction of about 6%.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Johnson & Johnson","company_slug":"johnson-johnson","country":"US","city":"Brisbane","announced_on":"2024-02-28","effective_on":"2024-04-26","roles_reported":55,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Johnson & Johnson announced 55 permanent layoffs tied to closure of its Brisbane, California R&D site.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Longeveron","company_slug":"longeveron","country":"US","city":null,"announced_on":"2024-02-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Longeveron announced staff reductions tied to discontinuation of a Phase 2 aging-related frailty study in Japan.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Nicox","company_slug":"nicox","country":null,"city":null,"announced_on":"2024-02-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Nicox announced operating reductions in France and Italy and a corporate restructuring as part of a debt-repayment amendment and cost-cutting plan.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"ObsEva","company_slug":"obseva","country":null,"city":null,"announced_on":"2024-02-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"ObsEva decided to wind down operations and lay off all employees as its financial options narrowed.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Gritstone bio","company_slug":"gritstone-bio","country":"US","city":null,"announced_on":"2024-02-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"funding","summary":"Gritstone bio announced a 40% workforce reduction after delaying a Phase 2 COVID-19 vaccine study and the associated federal funding.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Kineta","company_slug":"kineta","country":"US","city":null,"announced_on":"2024-02-29","effective_on":null,"roles_reported":7,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Kineta announced a corporate restructuring eliminating seven positions, about 64% of its workforce.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bionano Genomics","company_slug":"bionano-genomics","country":"US","city":null,"announced_on":"2024-03-01","effective_on":null,"roles_reported":120,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bionano Genomics announced a cost-savings plan that ultimately reduced overall headcount by approximately 120 employees.","sources":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000021/bngo-20240331.htm","recorded_on":"2026-10-04"},{"company":"Moderna","company_slug":"moderna","country":null,"city":null,"announced_on":"2024-03-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Moderna reduced staffing in its manufacturing organization as it resized COVID-19 production.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Arrakis Therapeutics","company_slug":"arrakis-therapeutics","country":"US","city":null,"announced_on":"2024-03-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Arrakis Therapeutics announced a 20% workforce reduction, with 71 employees expected to remain after the cuts.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sumitomo Pharma","company_slug":"sumitomo-pharma","country":"US","city":null,"announced_on":"2024-03-04","effective_on":null,"roles_reported":446,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sumitomo Pharma announced a major U.S. rationalization initially expected to affect about 400 employees; a later company disclosure reported that 446 employees actually left in the March 2024 action.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sumitomo-pharma.com/news/20240430-2.html","recorded_on":"2026-10-04"},{"company":"Meissa Vaccines","company_slug":"meissa-vaccines","country":"US","city":null,"announced_on":"2024-03-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Meissa Vaccines halted development activities and conducted an undisclosed workforce reduction amid a difficult fundraising environment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Kronos Bio","company_slug":"kronos-bio","country":"US","city":null,"announced_on":"2024-03-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"21.0","verification":"Confirmed","cause":"restructuring","summary":"Kronos Bio announced a second workforce reduction in five months, cutting 21% of staff to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Coherus BioSciences","company_slug":"coherus-biosciences","country":"US","city":null,"announced_on":"2024-03-13","effective_on":"2024-03-07","roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Coherus BioSciences announced a 30% workforce reduction, begun March 7, as part of a cost-reduction program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sangamo Therapeutics","company_slug":"sangamo-therapeutics","country":"FR","city":null,"announced_on":"2024-03-13","effective_on":"2024-04-01","roles_reported":93,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Sangamo Therapeutics announced the wind-down of its French research and manufacturing operations, eliminating all 93 positions in France.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"AT","city":null,"announced_on":"2024-03-13","effective_on":null,"roles_reported":190,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Takeda announced shutdown of production and R&D operations at an Austrian AAV gene-therapy site, affecting 190 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Spruce Biosciences","company_slug":"spruce-biosciences","country":"US","city":null,"announced_on":"2024-03-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"21.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Spruce Biosciences announced a 21% workforce reduction after a Phase 2 trial setback, extending its cash runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"CureVac","company_slug":"curevac","country":"DE","city":null,"announced_on":"2024-03-19","effective_on":null,"roles_reported":150,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"CureVac said about 150 employees accepted voluntary exits as the company cut costs and moved away from COVID-19 vaccine development.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"NextCure","company_slug":"nextcure","country":"US","city":null,"announced_on":"2024-03-21","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"37.0","verification":"Confirmed","cause":"restructuring","summary":"NextCure disclosed a 37% workforce reduction in the first quarter while pausing internal manufacturing to reduce costs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"GSK","company_slug":"gsk","country":"CA","city":null,"announced_on":"2024-03-22","effective_on":"2024-03-31","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Following GSK's acquisition of Bellus Health, most remaining Bellus employees were expected to leave after transition activities concluded.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"San Diego","announced_on":"2024-03-26","effective_on":null,"roles_reported":252,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Bristol Myers Squibb disclosed 252 layoffs at Mirati Therapeutics' California headquarters following its acquisition of the biotech.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"AlmataBio","company_slug":"almatabio","country":"US","city":null,"announced_on":"2024-03-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Avalo Therapeutics acquired AlmataBio's lead asset while none of AlmataBio's employees were retained by the new owner.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bayer","company_slug":"bayer","country":"US","city":"Whippany","announced_on":"2024-03-27","effective_on":"2024-06-19","roles_reported":90,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bayer disclosed 90 layoffs at its Whippany, New Jersey U.S. headquarters, effective June 19.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Omega Therapeutics","company_slug":"omega-therapeutics","country":"US","city":null,"announced_on":"2024-03-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"35.0","verification":"Confirmed","cause":"restructuring","summary":"Omega Therapeutics announced a 35% workforce reduction as part of a cost-reduction and strategic-prioritization initiative.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Xilio Therapeutics","company_slug":"xilio-therapeutics","country":"US","city":null,"announced_on":"2024-03-28","effective_on":null,"roles_reported":15,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Xilio Therapeutics cut 15 employees, about 21% of its workforce, as it narrowed its pipeline and licensed an IL-12 program to Gilead.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Mustang Bio","company_slug":"mustang-bio","country":"US","city":null,"announced_on":"2024-03-29","effective_on":null,"roles_reported":47,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Mustang Bio conducted a workforce reduction later quantified at 47 employees in a Massachusetts WARN notice.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Carisma Therapeutics","company_slug":"carisma-therapeutics","country":"US","city":null,"announced_on":"2024-04-01","effective_on":null,"roles_reported":39,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Carisma Therapeutics reduced its workforce by approximately 39 full-time employees, about 37%, as it reprioritized its pipeline and conserved cash.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1485003/000110465924053507/tm2412214d2_ars.pdf","recorded_on":"2026-10-04"},{"company":"Thermo Fisher Scientific","company_slug":"thermo-fisher-scientific","country":"US","city":"Carlsbad","announced_on":"2024-04-03","effective_on":"2024-05-31","roles_reported":74,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Thermo Fisher Scientific disclosed 74 layoffs at its Carlsbad, California plasmid DNA manufacturing site beginning May 31.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Amylyx Pharmaceuticals","company_slug":"amylyx-pharmaceuticals","country":"US","city":null,"announced_on":"2024-04-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Amylyx Pharmaceuticals announced a roughly 70% workforce reduction after withdrawing Relyvrio following a failed confirmatory trial.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Boehringer Ingelheim","company_slug":"boehringer-ingelheim","country":null,"city":null,"announced_on":"2024-04-05","effective_on":"2024-06-30","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Boehringer Ingelheim announced layoffs in customer-facing teams for its Cyltezo biosimilar as it moved toward a hybrid sales model by June 30.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sanofi","company_slug":"sanofi","country":null,"city":null,"announced_on":"2024-04-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sanofi announced a simplified global R&D structure centered on immunology that would result in an undisclosed number of layoffs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":null,"city":null,"announced_on":"2024-04-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis announced plans to reshape its global development organization, including around 440 positions in Switzerland and up to 240 roles in the United States.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Genentech","company_slug":"genentech","country":"US","city":"South San Francisco","announced_on":"2024-04-10","effective_on":null,"roles_reported":436,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Genentech announced a workforce reduction across several departments; a California WARN notice identified 436 affected employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sanofi","company_slug":"sanofi","country":"US","city":"South San Francisco","announced_on":"2024-04-10","effective_on":"2024-06-03","roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Sanofi disclosed 100 layoffs at the former Amunix site in South San Francisco as it divested the operation.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Molecular Templates","company_slug":"molecular-templates","country":"US","city":"Austin","announced_on":"2024-04-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Molecular Templates disclosed a workforce reduction of approximately 30% to extend resources for its remaining clinical programs.","sources":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524094733/d827658d8k.htm","recorded_on":"2026-10-04"},{"company":"Fujifilm Diosynth Biotechnologies","company_slug":"fujifilm-diosynth-biotechnologies","country":null,"city":null,"announced_on":"2024-04-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Fujifilm Diosynth Biotechnologies announced a restructuring of its Small Scale Business Unit that could eliminate up to 240 jobs across U.S. and U.K. sites.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Vedanta Biosciences","company_slug":"vedanta-biosciences","country":"US","city":null,"announced_on":"2024-04-16","effective_on":null,"roles_reported":24,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Vedanta Biosciences announced a workforce reduction of roughly 24 jobs, including 12 positions in its CMC team, after completing a peak period of manufacturing campaigns.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ultimovacs","company_slug":"ultimovacs","country":"NO","city":null,"announced_on":"2024-04-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Ultimovacs announced a 40% workforce reduction after a melanoma trial setback as it sought to preserve cash.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sanofi","company_slug":"sanofi","country":"BE","city":null,"announced_on":"2024-04-19","effective_on":null,"roles_reported":99,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sanofi's Belgium restructuring affected 99 positions: 67 employees were laid off in Ghent and 32 additional jobs were slated for elimination at its Diegem headquarters.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrenceville","announced_on":"2024-04-22","effective_on":null,"roles_reported":75,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb began a Lawrenceville, New Jersey layoff round affecting 75 employees as part of its broader cost-savings program.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"Boulder","announced_on":"2024-04-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Pfizer announced closure of a Boulder, Colorado research facility, resulting in an undisclosed number of job losses.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"BenevolentAI","company_slug":"benevolentai","country":null,"city":null,"announced_on":"2024-04-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"BenevolentAI announced another restructuring that cut 30% of staff and closed its U.S. office as it abandoned plans to launch software products.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Tessera Therapeutics","company_slug":"tessera-therapeutics","country":"US","city":null,"announced_on":"2024-04-23","effective_on":null,"roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Tessera Therapeutics announced a 50-person workforce reduction, about 13%–14% of employees, as it shifted resources from preclinical work toward clinical development.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"DermTech","company_slug":"dermtech","country":"US","city":"San Diego","announced_on":"2024-04-26","effective_on":"2024-09-06","roles_reported":51,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"DermTech filed a California WARN notice for 51 San Diego layoffs effective Sept. 6 during its bankruptcy wind-down.","sources":"https://www.warntracker.com/layoff/dermtech-2024-09-06","recorded_on":"2026-10-04"},{"company":"Emergent BioSolutions","company_slug":"emergent-biosolutions","country":"US","city":null,"announced_on":"2024-05-01","effective_on":null,"roles_reported":300,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Emergent BioSolutions announced a turnaround plan that included reducing its workforce by about 300 employees and closing two Maryland facilities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Chroma Medicine","company_slug":"chroma-medicine","country":"US","city":"Boston","announced_on":"2024-05-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Chroma Medicine confirmed an undisclosed workforce reduction affecting both general and administrative and R&D roles.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Foster City","announced_on":"2024-05-03","effective_on":"2024-06-28","roles_reported":58,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead Sciences disclosed 58 layoffs at a Foster City, California site, with the cuts scheduled to be complete by June 28.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Kenvue","company_slug":"kenvue","country":null,"city":null,"announced_on":"2024-05-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"4.0","verification":"Confirmed","cause":"restructuring","summary":"Kenvue announced a plan to reduce its global workforce by 4% as transition arrangements with Johnson & Johnson wound down.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"BioXcel Therapeutics","company_slug":"bioxcel-therapeutics","country":"US","city":null,"announced_on":"2024-05-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"15.0","verification":"Confirmed","cause":"restructuring","summary":"BioXcel Therapeutics initiated an additional workforce reduction of approximately 15% while preserving cash for its core clinical programs.","sources":"https://www.sec.gov/Archives/edgar/data/1720893/000155837025003985/btai-20241231x10k.htm","recorded_on":"2026-10-04"},{"company":"Marinus Pharmaceuticals","company_slug":"marinus-pharmaceuticals","country":"US","city":null,"announced_on":"2024-05-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Marinus Pharmaceuticals announced a 20% workforce reduction alongside broader R&D and administrative cost cuts.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ginkgo Bioworks","company_slug":"ginkgo-bioworks","country":"US","city":null,"announced_on":"2024-05-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ginkgo Bioworks announced a cost-reduction program that would include a reduction in force across G&A and R&D functions.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"CH","city":null,"announced_on":"2024-05-09","effective_on":null,"roles_reported":74,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Pfizer proposed eliminating 74 positions at Seagen's European headquarters in Switzerland after acquiring the biotech, with additional employees potentially affected if transfers were unavailable.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"US","city":"San Diego","announced_on":"2024-05-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Takeda announced plans to close its San Diego research site, where about 340 employees worked, while encouraging some staff to apply for roles at other Takeda locations.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bolt Biotherapeutics","company_slug":"bolt-biotherapeutics","country":"US","city":null,"announced_on":"2024-05-14","effective_on":null,"roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bolt Biotherapeutics announced a workforce reduction of approximately 50 employees, about half of staff, as it prioritized its pipeline and discontinued BDC-1001.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1641281/000095017024059564/bolt-20240331.htm","recorded_on":"2026-10-04"},{"company":"BioMarin Pharmaceutical","company_slug":"biomarin-pharmaceutical","country":"US","city":null,"announced_on":"2024-05-15","effective_on":"2024-07-31","roles_reported":170,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BioMarin Pharmaceutical announced that 170 employees would leave as part of an R&D restructuring and pipeline reduction.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Tenaya Therapeutics","company_slug":"tenaya-therapeutics","country":"US","city":null,"announced_on":"2024-05-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"22.0","verification":"Confirmed","cause":"restructuring","summary":"Tenaya Therapeutics announced a 22% workforce reduction as part of cost-containment measures supporting its lead gene-therapy programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Trevena","company_slug":"trevena","country":"US","city":null,"announced_on":"2024-05-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"35.0","verification":"Confirmed","cause":"restructuring","summary":"Trevena disclosed that it had implemented a 35% workforce reduction since the end of 2023 while continuing a strategic review of Olinvyk.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Akari Therapeutics","company_slug":"akari-therapeutics","country":null,"city":null,"announced_on":"2024-05-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"67.0","verification":"Confirmed","cause":"restructuring","summary":"Akari Therapeutics announced a 67% workforce reduction as part of a plan to lower operating costs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Erasca","company_slug":"erasca","country":"US","city":"San Diego","announced_on":"2024-05-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"18.0","verification":"Confirmed","cause":"restructuring","summary":"Erasca announced an 18% workforce reduction while deprioritizing parts of its cancer pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Biotechnology Innovation Organization","company_slug":"biotechnology-innovation-organization","country":"US","city":null,"announced_on":"2024-05-20","effective_on":null,"roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"The Biotechnology Innovation Organization announced a strategic restructuring that included 30 layoffs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Exscientia","company_slug":"exscientia","country":null,"city":null,"announced_on":"2024-05-21","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Exscientia announced efficiency measures expected to reduce its workforce by between 20% and 25% by year-end.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Lyra Therapeutics","company_slug":"lyra-therapeutics","country":"US","city":null,"announced_on":"2024-05-21","effective_on":"2024-05-21","roles_reported":87,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Lyra Therapeutics announced 87 layoffs, with 80 employees affected immediately and seven more on June 20.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"US","city":null,"announced_on":"2024-05-28","effective_on":"2024-07-01","roles_reported":641,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Takeda disclosed 641 planned layoffs across two Massachusetts sites: 495 at its Cambridge headquarters and 146 at its Lexington campus.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ikena Oncology","company_slug":"ikena-oncology","country":"US","city":null,"announced_on":"2024-05-29","effective_on":null,"roles_reported":18,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ikena Oncology announced another workforce reduction of about 18 employees, more than half of staff, while narrowing its pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ocular Therapeutix","company_slug":"ocular-therapeutix","country":"US","city":"Bedford","announced_on":"2024-06-03","effective_on":null,"roles_reported":37,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ocular Therapeutix disclosed a strategic reduction in force eliminating 37 full-time employees, about 13% of staff, to prioritize AXPAXLI development.","sources":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924067544/tm2416236d1_8k.htm","recorded_on":"2026-10-04"},{"company":"DermTech","company_slug":"dermtech","country":"US","city":"San Diego","announced_on":"2024-06-12","effective_on":null,"roles_reported":15,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"DermTech approved a 15-person workforce reduction after filing for Chapter 11 protection as it sought to preserve value during bankruptcy proceedings.","sources":"https://www.sec.gov/Archives/edgar/data/1651944/000165194424000060/dmtk-20240612.htm","recorded_on":"2026-10-04"},{"company":"Barinthus Biotherapeutics","company_slug":"barinthus-biotherapeutics","country":"GB","city":null,"announced_on":"2024-06-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Barinthus Biotherapeutics announced a 25% workforce reduction as it restructured its pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Cara Therapeutics","company_slug":"cara-therapeutics","country":"US","city":null,"announced_on":"2024-06-18","effective_on":"2024-06-30","roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Cara Therapeutics announced a second 2024 workforce reduction of approximately 70% after discontinuing its notalgia paresthetica clinical program.","sources":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924072821/tm2417536d1_8k.htm","recorded_on":"2026-10-04"},{"company":"eFFECTOR Therapeutics","company_slug":"effector-therapeutics","country":"US","city":null,"announced_on":"2024-06-24","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"eFFECTOR Therapeutics laid off its team, including its CEO, as the company moved to wind down operations.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"G1 Therapeutics","company_slug":"g1-therapeutics","country":"US","city":null,"announced_on":"2024-06-24","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"G1 Therapeutics announced targeted headcount reductions outside its existing commercial organization after Cosela failed a Phase 3 breast cancer study.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ovid Therapeutics","company_slug":"ovid-therapeutics","country":"US","city":null,"announced_on":"2024-06-26","effective_on":"2024-07-11","roles_reported":17,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ovid Therapeutics announced a 17-person workforce reduction, representing 43% of staff, to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Aerovate Therapeutics","company_slug":"aerovate-therapeutics","country":"US","city":null,"announced_on":"2024-06-28","effective_on":null,"roles_reported":39,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Aerovate Therapeutics began laying off nearly all employees after ending a late-stage pulmonary arterial hypertension trial, with an initial round affecting 39 staff.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"GeNeuro","company_slug":"geneuro","country":"CH","city":null,"announced_on":"2024-06-28","effective_on":null,"roles_reported":7,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"GeNeuro made redundant 7 of its 9 employees after its Phase 2 long-COVID study failed, retaining only two staff while the board evaluated next steps.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Organon","company_slug":"organon","country":null,"city":null,"announced_on":"2024-06-30","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"2.0","verification":"Confirmed","cause":"restructuring","summary":"Organon announced an additional 2% workforce reduction, focused mainly on R&D roles, following an earlier restructuring program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"US","city":null,"announced_on":"2024-07-02","effective_on":null,"roles_reported":220,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Takeda disclosed another Massachusetts workforce reduction affecting 220 employees across Cambridge and Lexington.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Apollomics","company_slug":"apollomics","country":null,"city":null,"announced_on":"2024-07-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Apollomics announced an undisclosed workforce reduction, including two executives, while narrowing the focus of a key clinical trial.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"CureVac","company_slug":"curevac","country":null,"city":null,"announced_on":"2024-07-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"CureVac announced a 30% workforce reduction as part of a restructuring intended to extend its cash runway into 2028.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Indivior","company_slug":"indivior","country":"US","city":null,"announced_on":"2024-07-11","effective_on":null,"roles_reported":130,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Indivior announced approximately 130 sales-force layoffs as it ceased sales and marketing of Perseris.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Lifecore Biomedical","company_slug":"lifecore-biomedical","country":"US","city":null,"announced_on":"2024-07-12","effective_on":null,"roles_reported":46,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Lifecore Biomedical disclosed a strategic workforce reduction terminating 46 full-time employees, about 9% of staff.","sources":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000086/lndc-20240708.htm","recorded_on":"2026-10-04"},{"company":"Spark Therapeutics","company_slug":"spark-therapeutics","country":"US","city":"Philadelphia","announced_on":"2024-07-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Spark Therapeutics confirmed layoffs and a pipeline refocus affecting its Philadelphia organization.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Caribou Biosciences","company_slug":"caribou-biosciences","country":"US","city":null,"announced_on":"2024-07-16","effective_on":null,"roles_reported":21,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Caribou Biosciences announced a 21-person workforce reduction, equal to 12% of staff, while discontinuing preclinical CAR-NK research.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"RAPT Therapeutics","company_slug":"rapt-therapeutics","country":"US","city":null,"announced_on":"2024-07-16","effective_on":null,"roles_reported":47,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"RAPT Therapeutics announced a 47-person workforce reduction, around 40% of staff, after a Phase 2 immunology trial had been placed on hold.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"ASLAN Pharmaceuticals","company_slug":"aslan-pharmaceuticals","country":null,"city":null,"announced_on":"2024-07-17","effective_on":"2024-07-17","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"ASLAN Pharmaceuticals entered voluntary liquidation and terminated all positions effective immediately.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"MEI Pharma","company_slug":"mei-pharma","country":"US","city":null,"announced_on":"2024-07-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"MEI Pharma began a staged reduction in force and halted work on voruciclib as it sought to preserve its remaining cash.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":null,"city":null,"announced_on":"2024-07-24","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":"restructuring","summary":"Merck implemented a reduction in its early-research organization affecting an estimated 75 to 80 workers.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Anokion","company_slug":"anokion","country":null,"city":null,"announced_on":"2024-07-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Anokion confirmed an undisclosed workforce reduction while concentrating resources on its Phase 2 celiac disease program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"GlycoMimetics","company_slug":"glycomimetics","country":"US","city":null,"announced_on":"2024-07-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"80.0","verification":"Confirmed","cause":"pipeline_setback","summary":"GlycoMimetics announced an 80% workforce reduction after the FDA determined that uproleselan would require another clinical trial.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Relay Therapeutics","company_slug":"relay-therapeutics","country":"US","city":null,"announced_on":"2024-07-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Relay Therapeutics confirmed a workforce reduction affecting less than 5% of employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Cue Biopharma","company_slug":"cue-biopharma","country":"US","city":null,"announced_on":"2024-07-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Cue Biopharma announced a 25% workforce reduction as it prioritized preclinical autoimmune programs over clinical-stage oncology work.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"TRACON Pharmaceuticals","company_slug":"tracon-pharmaceuticals","country":"US","city":null,"announced_on":"2024-07-26","effective_on":"2024-07-31","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"TRACON Pharmaceuticals approved a reduction of substantially all employees as it prepared to wind down operations and pursue dissolution.","sources":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024087947/tcon-20240726.htm","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"Rocky Mount","announced_on":"2024-07-29","effective_on":null,"roles_reported":60,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer announced 60 layoffs at its Rocky Mount, North Carolina sterile injectables facility.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"Sanford","announced_on":"2024-07-29","effective_on":null,"roles_reported":150,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Pfizer announced 150 layoffs at its Sanford, North Carolina site following a high-profile Phase 3 setback in Duchenne muscular dystrophy gene therapy.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Viracta Therapeutics","company_slug":"viracta-therapeutics","country":"US","city":"San Diego","announced_on":"2024-07-29","effective_on":"2024-07-22","roles_reported":null,"workforce_before":null,"share_of_workforce":"23.0","verification":"Confirmed","cause":"restructuring","summary":"Viracta Therapeutics implemented a workforce reduction affecting approximately 23% of employees as it reprioritized resources around its lymphoma program.","sources":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024087020/virx-20240722.htm","recorded_on":"2026-10-04"},{"company":"Bayer","company_slug":"bayer","country":"US","city":"Whippany","announced_on":"2024-07-31","effective_on":"2024-10-25","roles_reported":70,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bayer announced another 70 layoffs at its Whippany, New Jersey headquarters as part of its broader organizational overhaul.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"FibroGen","company_slug":"fibrogen","country":"US","city":null,"announced_on":"2024-07-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Confirmed","cause":"pipeline_setback","summary":"FibroGen announced a 75% reduction of its U.S. workforce after two late-stage cancer trials failed and the company stopped investment in pamrevlumab.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"HilleVax","company_slug":"hillevax","country":"US","city":null,"announced_on":"2024-07-31","effective_on":null,"roles_reported":41,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"HilleVax announced a 41-person workforce reduction, about 40% of staff, to lower costs while continuing development of its norovirus vaccine programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Arbutus Biopharma","company_slug":"arbutus-biopharma","country":null,"city":null,"announced_on":"2024-08-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"Arbutus Biopharma announced a 40% workforce reduction as it cut discovery work and a mid-stage trial.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sumitomo Pharma America","company_slug":"sumitomo-pharma-america","country":"US","city":"Marlborough","announced_on":"2024-08-01","effective_on":null,"roles_reported":53,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sumitomo Pharma America filed a Massachusetts WARN notice for 53 layoffs in Marlborough.","sources":"https://www.warntracker.com/company/sumitomo-pharma-america","recorded_on":"2026-10-04"},{"company":"uniQure","company_slug":"uniqure","country":null,"city":null,"announced_on":"2024-08-01","effective_on":null,"roles_reported":300,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"uniQure announced a restructuring that would reduce headcount by 65%, or 300 roles, with completion expected in the fourth quarter.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Vir Biotechnology","company_slug":"vir-biotechnology","country":null,"city":null,"announced_on":"2024-08-02","effective_on":null,"roles_reported":140,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Vir Biotechnology announced a reduction of around 140 employees, roughly 25% of its workforce, while focusing resources on hepatitis programs and other near-term opportunities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrenceville","announced_on":"2024-08-05","effective_on":null,"roles_reported":117,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed a 117-person Lawrenceville, New Jersey layoff round under its broader cost-reduction program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Precigen","company_slug":"precigen","country":"US","city":null,"announced_on":"2024-08-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"funding","summary":"Precigen announced a 20% workforce reduction and paused several programs to stretch its limited funds while prioritizing its lead gene therapy.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"23andMe","company_slug":"23andme","country":"US","city":null,"announced_on":"2024-08-08","effective_on":"2024-08-09","roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"23andMe announced closure of its Therapeutics Discovery operation, terminating 30 employees effective Aug. 9.","sources":"https://www.sec.gov/Archives/edgar/data/1804591/000180459124000045/me-20240805.htm","recorded_on":"2026-10-04"},{"company":"Entero Therapeutics","company_slug":"entero-therapeutics","country":"US","city":"Boca Raton","announced_on":"2024-08-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Entero Therapeutics laid off all non-essential employees, vacated its Boca Raton office and paused non-essential R&D after a creditor demanded loan repayment.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"AN2 Therapeutics","company_slug":"an2-therapeutics","country":"US","city":null,"announced_on":"2024-08-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"pipeline_setback","summary":"AN2 Therapeutics announced a 50% workforce reduction and stopped a Phase 3 study while pivoting to earlier-stage programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Boundless Bio","company_slug":"boundless-bio","country":"US","city":null,"announced_on":"2024-08-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Boundless Bio modestly reduced its workforce and discovery operations as enrollment in its first clinical-stage program progressed more slowly than expected.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Acelyrin","company_slug":"acelyrin","country":"US","city":null,"announced_on":"2024-08-13","effective_on":null,"roles_reported":40,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Acelyrin announced a workforce reduction of about 40 employees, roughly one third of staff, as it pivoted toward lonigutamab.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Lexicon Pharmaceuticals","company_slug":"lexicon-pharmaceuticals","country":"US","city":null,"announced_on":"2024-08-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Lexicon Pharmaceuticals announced a reorganization that would halve its workforce by the end of the third quarter, representing more than 75 jobs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Evotec","company_slug":"evotec","country":null,"city":null,"announced_on":"2024-08-14","effective_on":null,"roles_reported":400,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Evotec announced a global priority-reset program identifying approximately 400 roles for reduction as it sought to restore profitable growth.","sources":"https://www.evotec.com/news/evotec-se-reports-h1-2024-results-challenging-year-priority-reset-for-sustainable-profitable-growth-gaining-momentum-building-on-core-strengths","recorded_on":"2026-10-04"},{"company":"Galera Therapeutics","company_slug":"galera-therapeutics","country":"US","city":null,"announced_on":"2024-08-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"Galera Therapeutics approved a liquidation plan that would reduce the company to a three-person workforce.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Lykos Therapeutics","company_slug":"lykos-therapeutics","country":"US","city":null,"announced_on":"2024-08-15","effective_on":null,"roles_reported":75,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Lykos Therapeutics announced a 75% workforce reduction affecting about 75 people after the FDA rejected its psychedelic-assisted therapy application.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Ansa Biotechnologies","company_slug":"ansa-biotechnologies","country":"US","city":"San Francisco","announced_on":"2024-08-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ansa Biotechnologies laid off a handful of employees, primarily in R&D, as it shifted from an R&D-focused startup toward commercialization.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Aadi Bioscience","company_slug":"aadi-bioscience","country":"US","city":null,"announced_on":"2024-08-20","effective_on":null,"roles_reported":22,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Aadi Bioscience announced a strategic reset after a trial update and approved a workforce reduction of 22 employees, about 32% of total headcount; the company separately described an 80% cut to R&D headcount.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/d859038d8k.htm","recorded_on":"2026-10-04"},{"company":"Bayer","company_slug":"bayer","country":"CH","city":"Basel","announced_on":"2024-08-20","effective_on":null,"roles_reported":150,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bayer announced around 150 job cuts at its Consumer Health international headquarters in Basel, Switzerland.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Emergent BioSolutions","company_slug":"emergent-biosolutions","country":"US","city":"Lansing","announced_on":"2024-08-26","effective_on":null,"roles_reported":70,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Emergent BioSolutions announced a Lansing workforce reduction initially described as fewer than 70 roles; a later company filing reported the completed August plan reduced approximately 70 employees.","sources":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm","recorded_on":"2026-10-04"},{"company":"Tome Biosciences","company_slug":"tome-biosciences","country":"US","city":null,"announced_on":"2024-08-26","effective_on":null,"roles_reported":131,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Tome Biosciences announced layoffs affecting 131 employees as the gene-editing startup sharply reduced its workforce.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Genentech","company_slug":"genentech","country":"US","city":"South San Francisco","announced_on":"2024-08-27","effective_on":null,"roles_reported":93,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Genentech announced another 93 layoffs in South San Francisco, with the cuts set to begin in early October.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"BioMarin Pharmaceutical","company_slug":"biomarin-pharmaceutical","country":null,"city":null,"announced_on":"2024-08-28","effective_on":null,"roles_reported":225,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BioMarin announced a separate workforce reduction of about 225 employees, roughly 7% of its global workforce, as part of an organizational redesign.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Repare Therapeutics","company_slug":"repare-therapeutics","country":null,"city":null,"announced_on":"2024-08-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Repare Therapeutics announced a 25% workforce reduction, focused mainly on its preclinical group, while prioritizing clinical-stage assets.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Rakuten Medical","company_slug":"rakuten-medical","country":null,"city":null,"announced_on":"2024-08-30","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Rakuten Medical confirmed a second undisclosed workforce reduction in 2024.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Astellas","company_slug":"astellas","country":"US","city":"South San Francisco","announced_on":"2024-09-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Astellas announced the closure of its Eccles biomanufacturing facility in South San Francisco, affecting around 100 employees, with at least 17 employees to be laid off.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bionano Genomics","company_slug":"bionano-genomics","country":"US","city":null,"announced_on":"2024-09-04","effective_on":null,"roles_reported":83,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bionano Genomics implemented a second 2024 restructuring that ultimately reduced headcount by approximately 83 employees.","sources":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000063/bngo-20240930.htm","recorded_on":"2026-10-04"},{"company":"ImmunityBio","company_slug":"immunitybio","country":"US","city":null,"announced_on":"2024-09-05","effective_on":null,"roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"ImmunityBio disclosed layoffs affecting 20 employees across several California offices and one Colorado location.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"IN8bio","company_slug":"in8bio","country":"US","city":null,"announced_on":"2024-09-05","effective_on":null,"roles_reported":18,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"IN8bio announced a workforce reduction from 37 to 19 full-time employees as it shifted clinical focus.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Connect Biopharma","company_slug":"connect-biopharma","country":"CN","city":null,"announced_on":"2024-09-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Connect Biopharma announced a significant reduction of its operational presence in China after earlier collaboration and preclinical changes.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Charles River Laboratories","company_slug":"charles-river-laboratories","country":null,"city":null,"announced_on":"2024-09-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"3.0","verification":"Confirmed","cause":"restructuring","summary":"Charles River Laboratories announced a 3% workforce reduction after second-quarter revenue declined.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Cidara Therapeutics","company_slug":"cidara-therapeutics","country":"US","city":null,"announced_on":"2024-09-12","effective_on":null,"roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Cidara Therapeutics announced a workforce reduction of 20 employees, approximately 30% of staff, while focusing resources on CD388.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/cdtx-20240909.htm","recorded_on":"2026-10-04"},{"company":"Oncternal Therapeutics","company_slug":"oncternal-therapeutics","country":"US","city":"San Diego","announced_on":"2024-09-12","effective_on":null,"roles_reported":10,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Oncternal Therapeutics announced a workforce reduction of approximately 10 employees, about 37% of staff, while discontinuing clinical development and exploring strategic alternatives.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/onct-20240911.htm","recorded_on":"2026-10-04"},{"company":"Athira Pharma","company_slug":"athira-pharma","country":"US","city":null,"announced_on":"2024-09-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Athira Pharma announced a 70% workforce reduction after its Alzheimer’s candidate fosgonimeton failed a Phase 2/3 study, as the company pivoted to ATH-1105.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"BioXcel Therapeutics","company_slug":"bioxcel-therapeutics","country":"US","city":null,"announced_on":"2024-09-17","effective_on":null,"roles_reported":15,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BioXcel Therapeutics approved an additional workforce reduction of 15 employees, about 28% of headcount, to extend its cash runway.","sources":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924101176/tm2424352d2_8k.htm","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrenceville","announced_on":"2024-09-20","effective_on":null,"roles_reported":79,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed an additional 79 layoffs in Lawrenceville, New Jersey under its cost-savings program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"bluebird bio","company_slug":"bluebird-bio","country":"US","city":null,"announced_on":"2024-09-24","effective_on":null,"roles_reported":92,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"bluebird bio announced a restructuring that reduced its workforce by 92 employees, approximately 25%, as it focused on its commercial gene-therapy portfolio.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1293971/000129397125000009/R9.htm","recorded_on":"2026-10-04"},{"company":"Fulcrum Therapeutics","company_slug":"fulcrum-therapeutics","country":"US","city":null,"announced_on":"2024-09-24","effective_on":null,"roles_reported":29,"workforce_before":80,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Fulcrum Therapeutics announced a workforce reduction from 80 to 51 full-time employees as it reprioritized R&D activities.","sources":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024109069/fulc-20240924.htm","recorded_on":"2026-10-04"},{"company":"Inventprise","company_slug":"inventprise","country":"US","city":null,"announced_on":"2024-09-30","effective_on":null,"roles_reported":14,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Inventprise confirmed a workforce reduction of around 14 positions, about 7% of staff, after updating its business strategy.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bayer","company_slug":"bayer","country":"US","city":"Whippany","announced_on":"2024-10-01","effective_on":"2024-12-27","roles_reported":57,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bayer disclosed another 57 layoffs at its Whippany, New Jersey headquarters, effective Dec. 27.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Johnson & Johnson","company_slug":"johnson-johnson","country":"US","city":"New Brunswick","announced_on":"2024-10-01","effective_on":null,"roles_reported":231,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Johnson & Johnson disclosed 231 layoffs at its New Brunswick, New Jersey corporate headquarters as part of organizational changes.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"IE","city":null,"announced_on":"2024-10-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer announced proposed manufacturing workforce reductions across three Irish sites, with reporting describing up to 210 positions potentially affected.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Shattuck Labs","company_slug":"shattuck-labs","country":"US","city":null,"announced_on":"2024-10-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"Shattuck Labs announced a 40% workforce reduction after discontinuing a clinical program and refocusing its pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Relay Therapeutics","company_slug":"relay-therapeutics","country":"US","city":"Cambridge","announced_on":"2024-10-03","effective_on":null,"roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Relay Therapeutics announced a workforce reduction of about 30 employees, roughly 10% of staff, as it streamlined operations.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Molecular Templates","company_slug":"molecular-templates","country":"US","city":"Austin","announced_on":"2024-10-04","effective_on":null,"roles_reported":19,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Molecular Templates disclosed a second 2024 reduction in force affecting 19 employees, approximately 60% of staff, while evaluating strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524233039/d884306d8k.htm","recorded_on":"2026-10-04"},{"company":"Black Diamond Therapeutics","company_slug":"black-diamond-therapeutics","country":"US","city":"Cambridge","announced_on":"2024-10-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Black Diamond Therapeutics announced a corporate restructuring that included a reduction in force while deprioritizing BDTX-4933 and focusing resources on BDTX-1535.","sources":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/tm2425668d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Kaléo","company_slug":"kaleo","country":"US","city":null,"announced_on":"2024-10-07","effective_on":null,"roles_reported":58,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Kaléo disclosed a nationwide sales-force reduction affecting 58 employees.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Astellas","company_slug":"astellas","country":"US","city":"Seattle","announced_on":"2024-10-09","effective_on":null,"roles_reported":24,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Astellas eliminated 24 Seattle roles at Universal Cells while transferring another 12 U.S. roles as it expanded the subsidiary in Japan.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Leo Pharma","company_slug":"leo-pharma","country":null,"city":null,"announced_on":"2024-10-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Leo Pharma announced a restructuring that could eliminate or relocate up to 250 roles, with most affected positions based in Denmark.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Turnstone Biologics","company_slug":"turnstone-biologics","country":null,"city":null,"announced_on":"2024-10-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"60.0","verification":"Confirmed","cause":"restructuring","summary":"Turnstone Biologics announced a 60% workforce reduction and leadership changes to concentrate resources on its sole clinical-stage candidate.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Gritstone bio","company_slug":"gritstone-bio","country":"US","city":null,"announced_on":"2024-10-16","effective_on":"2024-11-15","roles_reported":25,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"After filing for Chapter 11, Gritstone bio announced the termination or separation of approximately 25 employees effective Nov. 15.","sources":"https://www.sec.gov/Archives/edgar/data/1656634/000119312524238117/d773987d8k.htm","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"McPherson","announced_on":"2024-10-17","effective_on":null,"roles_reported":80,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer laid off 80 professional and salaried employees at its McPherson, Kansas manufacturing plant while leaving production roles unaffected.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Sage Therapeutics","company_slug":"sage-therapeutics","country":"US","city":"Cambridge","announced_on":"2024-10-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sage Therapeutics announced a strategic reorganization affecting more than 165 employees as it prioritized Zurzuvae commercialization and a narrower development portfolio.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"US","city":null,"announced_on":"2024-10-21","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Takeda disclosed another Massachusetts workforce action affecting 79 positions across Cambridge and Lexington, with the final employment-loss count dependent on redeployment opportunities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"Sanford","announced_on":"2024-10-22","effective_on":null,"roles_reported":75,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Pfizer eliminated another 75 positions at its Sanford, North Carolina site following the earlier Duchenne gene-therapy setback and July reduction.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Spero Therapeutics","company_slug":"spero-therapeutics","country":"US","city":null,"announced_on":"2024-10-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"39.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Spero Therapeutics announced a 39% workforce reduction after its oral antibiotic candidate missed the primary endpoint and showed liver-toxicity concerns in a Phase 2a study.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Compass Pathways","company_slug":"compass-pathways","country":null,"city":null,"announced_on":"2024-10-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Compass Pathways announced a 30% workforce reduction while concentrating resources on its delayed Phase 3 depression program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Matinas BioPharma","company_slug":"matinas-biopharma","country":"US","city":"Bedminster","announced_on":"2024-10-31","effective_on":"2024-10-31","roles_reported":15,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Matinas BioPharma eliminated 15 positions, about 80% of its workforce, after partnership negotiations for its lead asset ended and it ceased product development.","sources":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224043130/ex99-1.htm","recorded_on":"2026-10-04"},{"company":"Sana Biotechnology","company_slug":"sana-biotechnology","country":"US","city":null,"announced_on":"2024-11-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sana Biotechnology announced an undisclosed workforce reduction as it shifted resources from oncology toward autoimmune programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Viracta Therapeutics","company_slug":"viracta-therapeutics","country":"US","city":null,"announced_on":"2024-11-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"42.0","verification":"Confirmed","cause":"restructuring","summary":"Viracta Therapeutics announced another workforce reduction affecting about 42% of its remaining employees to preserve cash for its lymphoma program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Aurinia Pharmaceuticals","company_slug":"aurinia-pharmaceuticals","country":null,"city":null,"announced_on":"2024-11-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"45.0","verification":"Confirmed","cause":"restructuring","summary":"Aurinia Pharmaceuticals announced a 45% workforce reduction as part of a broader organizational reset.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"23andMe","company_slug":"23andme","country":"US","city":null,"announced_on":"2024-11-11","effective_on":null,"roles_reported":223,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"23andMe announced a restructuring that involved 223 employees, approximately 40% of its workforce, while closing substantially all remaining therapeutics operations.","sources":"https://investors.23andme.com/news-releases/news-release-details/23andme-announces-business-restructuring-streamline-operations/ https://www.sec.gov/Archives/edgar/data/1804591/000180459124000059/me-20240930.htm","recorded_on":"2026-10-04"},{"company":"Adaptimmune","company_slug":"adaptimmune","country":null,"city":null,"announced_on":"2024-11-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"33.0","verification":"Confirmed","cause":"restructuring","summary":"Adaptimmune announced a 33% workforce reduction planned for the first quarter of 2025 as part of a multi-year cost-savings program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Foster City","announced_on":"2024-11-13","effective_on":null,"roles_reported":104,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead disclosed 104 layoffs at its Foster City, California headquarters, effective in March 2025, as part of broader resource-alignment changes.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Seattle","announced_on":"2024-11-13","effective_on":"2025-01-17","roles_reported":72,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Gilead announced the closure of its Seattle R&D support office and 72 layoffs beginning Jan. 17, 2025.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Marinus Pharmaceuticals","company_slug":"marinus-pharmaceuticals","country":"US","city":null,"announced_on":"2024-11-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"45.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Marinus Pharmaceuticals announced a 45% workforce reduction after another Phase 3 setback prompted it to stop developing its lead seizure medicine.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Oncternal Therapeutics","company_slug":"oncternal-therapeutics","country":"US","city":null,"announced_on":"2024-11-14","effective_on":"2024-12-02","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Oncternal Therapeutics announced a reduction of all remaining employees, with four employees retained part-time while the company explored strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/onct-20241113.htm","recorded_on":"2026-10-04"},{"company":"Sensei Biotherapeutics","company_slug":"sensei-biotherapeutics","country":"US","city":null,"announced_on":"2024-11-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"46.0","verification":"Confirmed","cause":"restructuring","summary":"Sensei Biotherapeutics announced a 46% workforce reduction and closure of a research site to preserve capital for its lead clinical program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"TFF Pharmaceuticals","company_slug":"tff-pharmaceuticals","country":"US","city":null,"announced_on":"2024-11-14","effective_on":"2024-11-15","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"TFF Pharmaceuticals announced termination of substantially all employees as it moved to wind down operations and pursue dissolution.","sources":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/ea0221102-8k_tffpharma.htm","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"CN","city":null,"announced_on":"2024-11-20","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Merck conducted layoffs in China, largely affecting its diabetes business amid declining sales of several medicines and Gardasil.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Sonata Therapeutics","company_slug":"sonata-therapeutics","country":"US","city":null,"announced_on":"2024-11-21","effective_on":null,"roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sonata Therapeutics laid off about 20 employees while streamlining the organization and changing leadership.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Lexicon Pharmaceuticals","company_slug":"lexicon-pharmaceuticals","country":"US","city":null,"announced_on":"2024-11-22","effective_on":"2024-12-31","roles_reported":null,"workforce_before":null,"share_of_workforce":"60.0","verification":"Confirmed","cause":"restructuring","summary":"Lexicon Pharmaceuticals announced a roughly 60% reduction of its commercial sales team, effective Dec. 31.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrenceville","announced_on":"2024-11-25","effective_on":"2025-02-13","roles_reported":195,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed another Lawrenceville, New Jersey reduction affecting 195 employees, with dismissals beginning Feb. 13, 2025.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Alector","company_slug":"alector","country":"US","city":null,"announced_on":"2024-11-26","effective_on":null,"roles_reported":41,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Alector announced a workforce reduction affecting 41 employees, about 17% of headcount, after its Phase 2 Alzheimer's program failed to slow disease progression.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1653087/000095017025027758/alec-20241231.htm","recorded_on":"2026-10-04"},{"company":"Medigene","company_slug":"medigene","country":"DE","city":null,"announced_on":"2024-11-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"funding","summary":"Medigene announced a 40% workforce reduction and paused plans to move its first asset into the clinic as it conserved cash.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2024-11-26","effective_on":null,"roles_reported":139,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis disclosed 139 layoffs at its East Hanover, New Jersey headquarters, primarily affecting commercial field roles.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Recursion Therapeutics","company_slug":"recursion-therapeutics","country":null,"city":null,"announced_on":"2024-11-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Following completion of its merger with Exscientia, Recursion confirmed layoffs across the combined organization to eliminate redundancies.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Idorsia","company_slug":"idorsia","country":"CH","city":"Allschwil","announced_on":"2024-11-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Idorsia announced a rightsizing initiative centered on R&D and support functions at its Allschwil headquarters.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Kronos Bio","company_slug":"kronos-bio","country":"US","city":null,"announced_on":"2024-11-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"83.0","verification":"Confirmed","cause":"restructuring","summary":"Kronos Bio announced an approximately 83% workforce reduction after discontinuing its remaining clinical asset and beginning a strategic review.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Alligator Bioscience","company_slug":"alligator-bioscience","country":"SE","city":null,"announced_on":"2024-12-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"restructuring","summary":"Alligator Bioscience announced a planned 70% workforce reduction to reduce annual operating costs, subject to employee-representative negotiations.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Vincerx Pharma","company_slug":"vincerx-pharma","country":"US","city":null,"announced_on":"2024-12-04","effective_on":"2024-12-02","roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"restructuring","summary":"Vincerx Pharma announced a roughly 55% workforce reduction and strategic-alternatives process to conserve resources for its VIP943 program.","sources":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524272442/d829648dex991.htm","recorded_on":"2026-10-04"},{"company":"Agenus","company_slug":"agenus","country":"US","city":null,"announced_on":"2024-12-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Agenus announced an organizational restructuring that included an undisclosed number of layoffs while reshaping its operating model.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"AmplifyBio","company_slug":"amplifybio","country":"US","city":"South San Francisco","announced_on":"2024-12-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"AmplifyBio announced closure of its South San Francisco operation and an undisclosed number of layoffs as work shifted to Ohio.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"National Resilience","company_slug":"national-resilience","country":"US","city":"Alachua","announced_on":"2024-12-06","effective_on":"2025-02-03","roles_reported":105,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"National Resilience announced 105 layoffs at its Alachua, Florida manufacturing site as it refocused the facility.","sources":"https://www.fiercepharma.com/pharma/cdmo-resilience-plots-105-layoffs-florida-plant-it-acquired-2021","recorded_on":"2026-10-04"},{"company":"Bavarian Nordic","company_slug":"bavarian-nordic","country":"US","city":"San Diego","announced_on":"2024-12-09","effective_on":"2024-12-13","roles_reported":48,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Bavarian Nordic disclosed closure of its San Diego R&D site, affecting all 48 employees, with the first layoffs effective Dec. 13.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Belharra Therapeutics","company_slug":"belharra-therapeutics","country":"US","city":"San Diego","announced_on":"2024-12-09","effective_on":null,"roles_reported":21,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Belharra Therapeutics announced a 21-person workforce reduction, about 40% of staff, to extend its cash runway amid financing uncertainty.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Carisma Therapeutics","company_slug":"carisma-therapeutics","country":"US","city":"Philadelphia","announced_on":"2024-12-09","effective_on":null,"roles_reported":23,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Carisma Therapeutics announced a second 2024 restructuring that cut 23 full-time employees, about 34% of staff, while discontinuing its sole clinical asset.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Cellectar Biosciences","company_slug":"cellectar-biosciences","country":"US","city":null,"announced_on":"2024-12-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"60.0","verification":"Confirmed","cause":"restructuring","summary":"Cellectar Biosciences announced a 60% workforce reduction while evaluating strategic options for a clinical oncology program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"BenevolentAI","company_slug":"benevolentai","country":null,"city":null,"announced_on":"2024-12-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BenevolentAI announced a significant organizational restructuring that would include layoffs as it returned to a narrower TechBio strategy.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Chroma Medicine","company_slug":"chroma-medicine","country":"US","city":"Boston","announced_on":"2024-12-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Chroma Medicine reduced headcount as part of its merger with Nvelop Therapeutics to form nChroma Bio.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Nvelop Therapeutics","company_slug":"nvelop-therapeutics","country":"US","city":"Boston","announced_on":"2024-12-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Nvelop Therapeutics reduced headcount as part of its merger with Chroma Medicine to form nChroma Bio.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Editas Medicine","company_slug":"editas-medicine","country":"US","city":null,"announced_on":"2024-12-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"65.0","verification":"Confirmed","cause":"restructuring","summary":"Editas Medicine announced a 65% workforce reduction as it returned to preclinical work after failing to secure a partner for its sickle-cell program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Outlook Therapeutics","company_slug":"outlook-therapeutics","country":"US","city":null,"announced_on":"2024-12-13","effective_on":null,"roles_reported":5,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Outlook Therapeutics reduced its workforce by 5 employees, about 23% of headcount, to cut operating expenses and preserve capital.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.sec.gov/Archives/edgar/data/1649989/000110465924128901/tm2431046d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Ring Therapeutics","company_slug":"ring-therapeutics","country":"US","city":null,"announced_on":"2024-12-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ring Therapeutics announced another workforce reduction of just under half of staff alongside a CEO transition.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":null,"city":null,"announced_on":"2024-12-19","effective_on":null,"roles_reported":330,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Novartis announced the closure of MorphoSys sites in Munich and Boston, affecting approximately 330 roles following the acquisition.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024","recorded_on":"2026-10-04"},{"company":"Javara","company_slug":"javara","country":"US","city":null,"announced_on":"2024-12-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Clinical research organization Javara confirmed an operational restructuring that included an undisclosed number of layoffs.","sources":"https://www.biospace.com/job-trends/layoffs-continued-across-biopharma-in-2024","recorded_on":"2026-10-04"},{"company":"Vincerx Pharma","company_slug":"vincerx-pharma","country":"US","city":null,"announced_on":"2024-12-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Vincerx Pharma announced an additional workforce reduction and executive departures while pursuing its proposed strategic merger with Oqory.","sources":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524285929/d875384dex991.htm","recorded_on":"2026-10-04"},{"company":"CytomX Therapeutics","company_slug":"cytomx-therapeutics","country":"US","city":"South San Francisco","announced_on":"2025-01-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"CytomX Therapeutics announced an approximately 40% organizational headcount reduction as it prioritized lead clinical programs and collaboration work.","sources":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525002165/d909597d8k.htm","recorded_on":"2026-10-04"},{"company":"National Resilience","company_slug":"national-resilience","country":"US","city":"Durham","announced_on":"2025-01-06","effective_on":"2025-03-07","roles_reported":120,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"National Resilience filed a WARN notice for 120 permanent layoffs at its Durham gene-therapy manufacturing facility, with terminations beginning March 7.","sources":"https://www.pharmamanufacturing.com/industry-news/news/55259750/national-resilience-to-lay-off-120-employees-at-north-carolina-gene-therapy-site https://www.newsobserver.com/news/business/article298127118.html","recorded_on":"2026-10-04"},{"company":"Cassava Sciences","company_slug":"cassava-sciences","country":null,"city":null,"announced_on":"2025-01-07","effective_on":null,"roles_reported":10,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Cassava Sciences announced a 10-employee workforce reduction after the failure of its Phase 3 RETHINK-ALZ study and related program wind-down.","sources":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/f8k_010725.htm https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/exh_991.htm","recorded_on":"2026-10-04"},{"company":"Galapagos","company_slug":"galapagos","country":null,"city":null,"announced_on":"2025-01-08","effective_on":null,"roles_reported":300,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Galapagos announced a strategic reorganization tied to its planned separation into two companies, anticipating a reduction of approximately 300 positions across Europe.","sources":"https://www.globenewswire.com/news-release/2025/01/08/3005962/0/en/galapagos-to-unlock-shareholder-value-by-declaring-its-intent-to-separate-into-two-publicly-traded-entities.html","recorded_on":"2026-10-04"},{"company":"Scribe Therapeutics","company_slug":"scribe-therapeutics","country":"US","city":null,"announced_on":"2025-01-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Scribe Therapeutics confirmed a workforce reduction of about 20% as it concentrated resources on advancing its genetic-medicine programs toward the clinic.","sources":"https://www.fiercebiotech.com/biotech/scribe-slims-down-workforce-it-readies-cardiometabolic-genetic-medicines-clinic","recorded_on":"2026-10-04"},{"company":"IGM Biosciences","company_slug":"igm-biosciences","country":"US","city":"Mountain View","announced_on":"2025-01-09","effective_on":"2025-03-10","roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"IGM Biosciences halted development of two autoimmune programs after disappointing interim data and announced a 73% workforce reduction; a later WARN notice fixed the Mountain View reduction at 100 employees.","sources":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525004455/d778635d8k.htm https://www.warntracker.com/layoff/igm-biosciences-2025-03-10","recorded_on":"2026-10-04"},{"company":"Intellia Therapeutics","company_slug":"intellia-therapeutics","country":null,"city":null,"announced_on":"2025-01-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"27.0","verification":"Confirmed","cause":"restructuring","summary":"Intellia Therapeutics announced a strategic reorganization expected to reduce its workforce by approximately 27% during 2025.","sources":"https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-anticipated-2025-milestones-and https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/d906527dex991.htm","recorded_on":"2026-10-04"},{"company":"Repare Therapeutics","company_slug":"repare-therapeutics","country":null,"city":null,"announced_on":"2025-01-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Confirmed","cause":"restructuring","summary":"Repare Therapeutics announced planned headcount reductions as part of a January portfolio reprioritization; a February SEC filing later quantified the same reorganization at approximately 75% of the workforce.","sources":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525033718/d859090d8k.htm https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-announces-portfolio-re-prioritization/","recorded_on":"2026-10-04"},{"company":"Velia Therapeutics","company_slug":"velia-therapeutics","country":"US","city":null,"announced_on":"2025-01-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Velia Therapeutics announced that it was winding down operations, affecting an undisclosed number of employees.","sources":"https://www.fiercebiotech.com/biotech/velia-therapeutics-winds-down-stays-loyal-therapeutic-potential-microproteins","recorded_on":"2026-10-04"},{"company":"Barinthus Biotherapeutics","company_slug":"barinthus-biotherapeutics","country":null,"city":null,"announced_on":"2025-01-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"65.0","verification":"Confirmed","cause":"restructuring","summary":"Barinthus Biotherapeutics announced a strategic refocus and an approximately 65% workforce reduction, with most reductions expected in the UK and a planned UK site closure.","sources":"https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-bio-announces-strategic-focus-immunology-and https://investors.barinthusbio.com/node/8966/html","recorded_on":"2026-10-04"},{"company":"Passage Bio","company_slug":"passage-bio","country":"US","city":null,"announced_on":"2025-01-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"restructuring","summary":"Passage Bio announced an approximately 55% workforce reduction as it shifted analytical testing to an outsourced model and reduced operating expenses.","sources":"https://www.sec.gov/Archives/edgar/data/1787297/000110465925002278/tm252728d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Shoreline Biosciences","company_slug":"shoreline-biosciences","country":"US","city":null,"announced_on":"2025-01-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Shoreline Biosciences confirmed an undisclosed workforce reduction tied to changes in work associated with its Kite Pharma collaboration.","sources":"https://www.fiercebiotech.com/biotech/igm-y-mabs-passage-bio-and-more-telegraph-staff-cuts-amid-pipeline-and-business-structure","recorded_on":"2026-10-04"},{"company":"Y-mAbs Therapeutics","company_slug":"y-mabs-therapeutics","country":null,"city":null,"announced_on":"2025-01-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Y-mAbs Therapeutics announced a business-unit realignment expected to reduce its workforce by up to approximately 13%, alongside transfers of some roles between Denmark and the United States.","sources":"https://ir.ymabs.com/news-releases/news-release-details/correcting-replacing-y-mabs-provides-strategic-business-update/","recorded_on":"2026-10-04"},{"company":"Apellis Pharmaceuticals","company_slug":"apellis-pharmaceuticals","country":null,"city":null,"announced_on":"2025-01-13","effective_on":null,"roles_reported":40,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Apellis Pharmaceuticals said it would reduce its ex-U.S. footprint by approximately 40 employees as it prioritized U.S. commercialization of Syfovre.","sources":"https://investors.apellis.com/node/15251 https://investors.apellis.com/node/15261/html","recorded_on":"2026-10-04"},{"company":"Notch Therapeutics","company_slug":"notch-therapeutics","country":null,"city":null,"announced_on":"2025-01-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Notch Therapeutics announced a significant workforce reduction to preserve cash while seeking financing and partnership paths for its cell-therapy programs.","sources":"https://www.linkedin.com/posts/notchtx_the-biotech-market-has-faced-significant-activity-7285814663907360768-G5dt","recorded_on":"2026-10-04"},{"company":"Biogen","company_slug":"biogen","country":null,"city":null,"announced_on":"2025-01-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Biogen confirmed an undisclosed reduction in its research organization as it reprioritized preclinical work and shifted resources toward external opportunities.","sources":"https://www.fiercebiotech.com/biotech/biogen-lays-research-staff-shifts-resources-external-opportunities","recorded_on":"2026-10-04"},{"company":"ImmunityBio","company_slug":"immunitybio","country":"US","city":null,"announced_on":"2025-01-24","effective_on":"2025-03-25","roles_reported":10,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"ImmunityBio filed California WARN notices for 10 permanent layoffs across its El Segundo and Culver City locations, effective March 25, 2025.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"Allakos","company_slug":"allakos","country":"US","city":null,"announced_on":"2025-01-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Allakos discontinued development of its lead program and announced an approximately 75% workforce reduction while evaluating strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/allk-20250127.htm","recorded_on":"2026-10-04"},{"company":"Atara Biotherapeutics","company_slug":"atara-biotherapeutics","country":null,"city":null,"announced_on":"2025-01-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Atara Biotherapeutics announced a workforce reduction affecting approximately 50% of its then-current employees.","sources":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025009225/atra-20250127.htm","recorded_on":"2026-10-04"},{"company":"I-Mab","company_slug":"i-mab","country":null,"city":null,"announced_on":"2025-01-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"27.0","verification":"Confirmed","cause":"restructuring","summary":"I-Mab disclosed an approximately 27% workforce reduction as part of a pipeline and organizational reprioritization.","sources":"https://www.sec.gov/Archives/edgar/data/1778016/000095017025010200/workforce_reduction_1.28.htm","recorded_on":"2026-10-04"},{"company":"Zentalis Pharmaceuticals","company_slug":"zentalis-pharmaceuticals","country":null,"city":null,"announced_on":"2025-01-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"restructuring","summary":"Zentalis Pharmaceuticals announced an approximately 40% workforce reduction as it narrowed development priorities and extended its cash runway.","sources":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/rifpr01282025-forworkivax.htm","recorded_on":"2026-10-04"},{"company":"CARGO Therapeutics","company_slug":"cargo-therapeutics","country":"US","city":"San Carlos","announced_on":"2025-01-29","effective_on":"2025-04-01","roles_reported":81,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"CARGO Therapeutics discontinued its FIRCE-1 Phase 2 study and announced a workforce reduction; a California WARN notice records 81 permanent layoffs in San Carlos.","sources":"https://rss.globenewswire.com/de/news-release/2025/01/29/3017565/0/en/cargo-therapeutics-to-discontinue-firce-1-phase-2-study-of-firi-cel-advances-remaining-programs-while-evaluating-strategic-options.html https://www.sec.gov/Archives/edgar/data/1966494/000119312525015713/d931594d8k.htm https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"Ironwood Pharmaceuticals","company_slug":"ironwood-pharmaceuticals","country":"US","city":null,"announced_on":"2025-01-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Ironwood Pharmaceuticals announced a roughly 50% workforce reduction, primarily affecting field sales, as it concentrated resources on apraglutide and streamlined operations.","sources":"https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Achieves-2024-Financial-Guidance/default.aspx","recorded_on":"2026-10-04"},{"company":"Thermo Fisher Scientific","company_slug":"thermo-fisher-scientific","country":"US","city":null,"announced_on":"2025-01-31","effective_on":"2025-03-30","roles_reported":300,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Thermo Fisher Scientific notified Massachusetts of 300 job cuts across its Cambridge and Plainville viral-vector operations, effective March 30.","sources":"https://www.medtechdive.com/news/Thermo-Fisher-layoffs-Plainville-Cambridge-viral-vector/739556/ https://www.bostonglobe.com/2025/02/03/business/thermo-fisher-layoffs-cambridge-plainville/","recorded_on":"2026-10-04"},{"company":"Omega Therapeutics","company_slug":"omega-therapeutics","country":"US","city":null,"announced_on":"2025-02-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"Omega Therapeutics disclosed a restructuring that could lay off up to 17 employees in connection with a transaction and potential Chapter 11 process.","sources":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/d927659d8k.htm","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2025-02-04","effective_on":"2025-04-24","roles_reported":67,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed a New Jersey WARN round affecting 67 employees in Lawrence Township as its multiyear productivity program continued.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Kyowa Kirin","company_slug":"kyowa-kirin","country":"US","city":"Princeton","announced_on":"2025-02-04","effective_on":"2025-05-01","roles_reported":52,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Kyowa Kirin disclosed a New Jersey WARN round affecting 52 employees at its Princeton North America headquarters, effective May 1.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025","recorded_on":"2026-10-04"},{"company":"Turnstone Biologics","company_slug":"turnstone-biologics","country":"US","city":"San Diego","announced_on":"2025-02-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Turnstone Biologics announced a workforce reduction while discontinuing remaining development work and evaluating strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1764974/000095017025012874/tsbx-ex99_1.htm","recorded_on":"2026-10-04"},{"company":"Frontier Medicines","company_slug":"frontier-medicines","country":"US","city":null,"announced_on":"2025-02-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Frontier Medicines confirmed an undisclosed workforce reduction as it streamlined operations and concentrated resources on priority work.","sources":"https://www.fiercebiotech.com/biotech/layoffs-hit-frontier-medicines-company-streamlines-operations","recorded_on":"2026-10-04"},{"company":"Viracta Therapeutics","company_slug":"viracta-therapeutics","country":"US","city":null,"announced_on":"2025-02-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Viracta Therapeutics announced that it was terminating employees and winding down operations while pursuing remaining strategic options.","sources":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/virx-20250203.htm","recorded_on":"2026-10-04"},{"company":"X4 Pharmaceuticals","company_slug":"x4-pharmaceuticals","country":null,"city":null,"announced_on":"2025-02-06","effective_on":null,"roles_reported":43,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"X4 Pharmaceuticals announced a strategic restructuring that would reduce employee headcount by 43 and close its Vienna facility while concentrating resources on mavorixafor.","sources":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/xfor-20250206.htm","recorded_on":"2026-10-04"},{"company":"Inventiva","company_slug":"inventiva","country":"FR","city":null,"announced_on":"2025-02-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"funding","summary":"Inventiva announced a proposed workforce reduction of approximately 50% as it concentrated resources on lanifibranor and sought to preserve cash.","sources":"https://via.ritzau.dk/pressemeddelelse/14260284/inventiva?lang=en&publisherId=90446","recorded_on":"2026-10-04"},{"company":"Q32 Bio","company_slug":"q32-bio","country":"US","city":null,"announced_on":"2025-02-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Q32 Bio announced a workforce reduction as part of a restructuring that discontinued a clinical program and prioritized remaining assets.","sources":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm","recorded_on":"2026-10-04"},{"company":"Third Harmonic Bio","company_slug":"third-harmonic-bio","country":null,"city":null,"announced_on":"2025-02-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Third Harmonic Bio announced an immediate restructuring that halted non-THB335 research and discovery activities and reduced its workforce by approximately 50% while beginning a strategic-review process.","sources":"https://www.sec.gov/Archives/edgar/data/1923840/000095017025045741/thrd-ex99_1.htm https://www.sec.gov/Archives/edgar/data/1923840/000095017025045736/thrd-20241231.htm","recorded_on":"2026-10-04"},{"company":"Applied DNA Sciences","company_slug":"applied-dna-sciences","country":"US","city":"Stony Brook","announced_on":"2025-02-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Applied DNA Sciences announced that it was exiting its DNA Tagging and Security Products and Services business after completing a workforce reduction of approximately 20% of total headcount.","sources":"https://www.sec.gov/Archives/edgar/data/744452/000110465925012921/tm256524d1_ex99-1.htm","recorded_on":"2026-10-04"},{"company":"Encoded Therapeutics","company_slug":"encoded-therapeutics","country":"US","city":null,"announced_on":"2025-02-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"29.0","verification":"Confirmed","cause":"restructuring","summary":"Encoded Therapeutics announced a 29% workforce reduction as it focused resources on its lead Dravet syndrome gene-therapy program.","sources":"https://encoded.com/encoded-therapeutics-reports-clinical-progress-of-etx101-gene-therapy-for-dravet-syndrome-recaps-2024-corporate-achievements-and-provides-2025-outlook/","recorded_on":"2026-10-04"},{"company":"Kojin Therapeutics","company_slug":"kojin-therapeutics","country":"US","city":"Boston","announced_on":"2025-02-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Kojin Therapeutics announced that it would wind down operations after failing to secure sufficient financing to advance its preclinical programs.","sources":"https://www.linkedin.com/posts/kojin-therapeutics_ferroptosis-celldeath-cellstate-activity-7295989439586058240-jorH","recorded_on":"2026-10-04"},{"company":"Moderna","company_slug":"moderna","country":null,"city":null,"announced_on":"2025-02-13","effective_on":null,"roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Moderna reduced its digital organization by about 50 employees while revamping two digital departments as part of cost-efficiency efforts.","sources":"https://www.fiercepharma.com/pharma/moderna-trims-digital-team-lays-employees-chief-information-officer-departs","recorded_on":"2026-10-04"},{"company":"T2 Biosystems","company_slug":"t2-biosystems","country":"US","city":null,"announced_on":"2025-02-13","effective_on":"2025-02-13","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"T2 Biosystems approved the termination of substantially all employees, effective immediately, as the company ceased operations and later pursued a sale of its assets.","sources":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525027311/d926272d8k.htm https://www.sec.gov/Archives/edgar/data/1492674/000119312525069923/d858678dnt10k.htm","recorded_on":"2026-10-04"},{"company":"Spotlight Therapeutics","company_slug":"spotlight-therapeutics","country":"US","city":"San Francisco","announced_on":"2025-02-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Spotlight Therapeutics' former CEO confirmed that the San Francisco gene-editing company had shut down operations.","sources":"https://www.fiercebiotech.com/biotech/its-curtain-close-spotlight-gene-editing-biotech-shutters","recorded_on":"2026-10-04"},{"company":"LAVA Therapeutics","company_slug":"lava-therapeutics","country":null,"city":null,"announced_on":"2025-02-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"LAVA Therapeutics announced an approximately 30% workforce reduction as part of a restructuring intended to conserve cash and refocus its development portfolio.","sources":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/tm257490d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Ryvu Therapeutics","company_slug":"ryvu-therapeutics","country":"PL","city":null,"announced_on":"2025-02-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Ryvu Therapeutics announced an approximately 30% workforce reduction as it reorganized around development of RVU120 and sought to extend its cash runway.","sources":"https://ryvu.com/2025/02/25/ryvu-therapeutics-announces-strategic-reorganization-to-extend-the-cash-runway-for-the-development-of-rvu120-and-the-preclinical-pipeline/","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Redwood City","announced_on":"2025-02-26","effective_on":"2025-04-22","roles_reported":57,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed 57 job cuts at its Redwood City research site, effective by April 22, as part of its broader cost-savings program.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf https://www.fiercepharma.com/pharma/bristol-myers-billion-dollar-cost-savings-drive-claims-another-223-jobs-nj","recorded_on":"2026-10-04"},{"company":"Eisai","company_slug":"eisai","country":"US","city":null,"announced_on":"2025-02-27","effective_on":null,"roles_reported":121,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Eisai confirmed plans to lay off approximately 121 U.S. employees across commercial, medical and corporate-service functions.","sources":"https://www.fiercepharma.com/pharma/eisai-part-ways-121-employees-amid-new-us-restructuring-effort","recorded_on":"2026-10-04"},{"company":"CRISPR Therapeutics","company_slug":"crispr-therapeutics","country":null,"city":null,"announced_on":"2025-02-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"CRISPR Therapeutics confirmed an undisclosed workforce reduction affecting employees across several functions.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Atara Biotherapeutics","company_slug":"atara-biotherapeutics","country":"US","city":"Newbury Park","announced_on":"2025-03-03","effective_on":"2025-05-02","roles_reported":31,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Atara Biotherapeutics announced a further workforce reduction after discontinuing its CAR-T development programs; a later California WARN notice quantified the affected Newbury Park workforce at 31.","sources":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025030832/atra-20250303.htm https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2025-03-03","effective_on":"2025-05-22","roles_reported":223,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb confirmed a New Jersey WARN round affecting 223 workers in Lawrence Township, with separations beginning May 22 and continuing into August.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://dailyvoice.com/nj/berlin/pharmaceutical-company-laying-off-290-nj-workers-amid-massive-cost-cutting-push/ https://www.fiercepharma.com/pharma/bristol-myers-billion-dollar-cost-savings-drive-claims-another-223-jobs-nj","recorded_on":"2026-10-04"},{"company":"ALX Oncology","company_slug":"alx-oncology","country":"US","city":null,"announced_on":"2025-03-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"ALX Oncology announced an approximately 30% workforce reduction as it focused spending on clinical development of its CD47 program.","sources":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/alxo-20250228.htm","recorded_on":"2026-10-04"},{"company":"Atea Pharmaceuticals","company_slug":"atea-pharmaceuticals","country":null,"city":null,"announced_on":"2025-03-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Atea Pharmaceuticals disclosed that it had reduced its workforce by approximately 25% during the first quarter of 2025 as part of actions to improve infrastructure efficiency and reduce costs.","sources":"https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2024/ https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/d925111dex991.htm","recorded_on":"2026-10-04"},{"company":"Alector","company_slug":"alector","country":null,"city":null,"announced_on":"2025-03-10","effective_on":null,"roles_reported":25,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Alector announced a cost-reduction plan affecting approximately 25 employees as it realigned resources toward its strategic research priorities.","sources":"https://www.sec.gov/Archives/edgar/data/1653087/000119312525050448/d890669d8k.htm https://investors.alector.com/static-files/7cccea25-5100-4130-94eb-ca81c91a6748","recorded_on":"2026-10-04"},{"company":"Cepheid","company_slug":"cepheid","country":"US","city":null,"announced_on":"2025-03-12","effective_on":"2025-05-12","roles_reported":167,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Cepheid filed a same-day California workforce action affecting 167 employees across 14 sites in five cities, with layoffs effective May 12, 2025.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"GRO Biosciences","company_slug":"gro-biosciences","country":"US","city":null,"announced_on":"2025-03-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"GRO Biosciences confirmed an undisclosed reduction of research staff as part of a restructuring and strategic-alternatives process.","sources":"https://www.fiercebiotech.com/biotech/george-church-spinout-grobio-explores-strategic-alternatives-months-after-top-vc-backed","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"San Diego","announced_on":"2025-03-13","effective_on":"2025-06-27","roles_reported":35,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Novartis filed California WARN notices covering 35 positions at its Campus Point operation in San Diego as part of a permanent site closure.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf https://www.warntracker.com/layoff/novartis-pharmaceuticals-2025-06-27","recorded_on":"2026-10-04"},{"company":"Sutro Biopharma","company_slug":"sutro-biopharma","country":"US","city":null,"announced_on":"2025-03-13","effective_on":"2025-08-01","roles_reported":65,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Sutro Biopharma announced a major restructuring after deprioritizing further development of luvelta; later WARN records quantified 65 affected positions across San Carlos and South San Francisco.","sources":"https://ir.sutrobio.com/financials/sec-filings/content/0000950170-25-038879/stro-ex99_2.htm https://www.warntracker.com/layoff/sutro-biopharma-2025-08-01","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"US","city":"Riverside","announced_on":"2025-03-14","effective_on":"2025-05-16","roles_reported":163,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Merck confirmed phased layoffs affecting approximately 163 workers as it continued the multiyear wind-down of its Cherokee manufacturing plant in Riverside, Pennsylvania.","sources":"https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices?os=os https://finance.yahoo.com/news/layoffs-begin-may-merck-phases-035900729.html","recorded_on":"2026-10-04"},{"company":"Apriori Bio","company_slug":"apriori-bio","country":null,"city":null,"announced_on":"2025-03-17","effective_on":null,"roles_reported":15,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Apriori Bio confirmed a 15-employee workforce reduction as it shifted from platform-building toward pipeline development.","sources":"https://www.fiercebiotech.com/biotech/flagship-backed-apriori-bio-deducts-15-employees-shifts-focus-pipeline-development","recorded_on":"2026-10-04"},{"company":"CARGO Therapeutics","company_slug":"cargo-therapeutics","country":"US","city":"San Carlos","announced_on":"2025-03-18","effective_on":"2025-05-19","roles_reported":84,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"CARGO Therapeutics announced a further wind-down and approximately 90% workforce reduction; a separate California WARN notice records 84 permanent job losses.","sources":"https://www.sec.gov/Archives/edgar/data/1966494/000119312525056674/d835509dex991.htm https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"Empress Therapeutics","company_slug":"empress-therapeutics","country":null,"city":null,"announced_on":"2025-03-18","effective_on":null,"roles_reported":23,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Empress Therapeutics confirmed a 23-person workforce reduction as it focused resources on moving its small-molecule programs toward the clinic.","sources":"https://www.fiercebiotech.com/biotech/flagships-empress-lays-53-staffers-push-get-science-clinic","recorded_on":"2026-10-04"},{"company":"HC Bioscience","company_slug":"hc-bioscience","country":"US","city":null,"announced_on":"2025-03-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"HC Bioscience shut down after reviewing preclinical results for its tRNA program, with the company declining to disclose how many employees were affected.","sources":"https://www.fiercebiotech.com/biotech/arch-backed-hc-bioscience-closes-doors-after-seeing-early-data-trna-asset","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2025-03-18","effective_on":"2025-06-13","roles_reported":427,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis disclosed a New Jersey WARN round affecting 427 U.S. employees reporting to its East Hanover headquarters as it reworked its cardiovascular commercialization model.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/novartis-plots-427-layoffs-nj-looming-entresto-patent-cliff-sparks-cardio-marketing-refresh","recorded_on":"2026-10-04"},{"company":"Pyxis Oncology","company_slug":"pyxis-oncology","country":"US","city":"Boston","announced_on":"2025-03-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Pyxis Oncology announced an approximately 20% workforce reduction as it narrowed its pipeline and concentrated resources on its lead oncology candidate.","sources":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/pyxs-20250318.htm","recorded_on":"2026-10-04"},{"company":"TC BioPharm","company_slug":"tc-biopharm","country":"GB","city":"Edinburgh","announced_on":"2025-03-18","effective_on":null,"roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"TC BioPharm announced an approximately 20-employee workforce reduction as it outsourced production and other functions.","sources":"https://www.prnewswire.com/news-releases/tcbp-announces-outsourcing-initiatives-reducing-burn-rate-and-overhead-302403910.html","recorded_on":"2026-10-04"},{"company":"bit.bio","company_slug":"bitbio","country":"GB","city":"Cambridge","announced_on":"2025-03-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"bit.bio announced a 25% workforce reduction as it shifted its focus from therapeutics toward biomedical tools and cell products.","sources":"https://www.fiercebiotech.com/biotech/uk-cell-therapy-biotech-lays-25-staff-turns-tool-development-over-therapeutics","recorded_on":"2026-10-04"},{"company":"Elevation Oncology","company_slug":"elevation-oncology","country":null,"city":null,"announced_on":"2025-03-20","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Elevation Oncology discontinued EO-3021 after updated clinical data and announced an approximately 70% workforce reduction while evaluating strategic options.","sources":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/tm259617d1_ex99-1.htm","recorded_on":"2026-10-04"},{"company":"Vaxart","company_slug":"vaxart","country":"US","city":"South San Francisco","announced_on":"2025-03-21","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"10.0","verification":"Confirmed","cause":null,"summary":"Vaxart announced a 10% workforce reduction after U.S. government action halted work on a COVID-19 vaccine trial.","sources":"https://www.fiercebiotech.com/biotech/vaxart-lays-10-staff-after-hhs-unexpectedly-demands-halt-covid-vaccine-trial","recorded_on":"2026-10-04"},{"company":"Lyndra Therapeutics","company_slug":"lyndra-therapeutics","country":"US","city":"Watertown","announced_on":"2025-03-25","effective_on":"2025-03-26","roles_reported":60,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Lyndra Therapeutics began winding down operations after it was unable to secure financing needed for its next clinical stage, with 60 employees set to be laid off.","sources":"https://www.bizjournals.com/boston/news/2025/03/25/lyndra-therapeutics-is-winding-down-operations.html https://www.fiercebiotech.com/biotech/langer-spin-out-lyndra-therapeutics-begins-winding-down-operations-lays-staff","recorded_on":"2026-10-04"},{"company":"ElevateBio","company_slug":"elevatebio","country":"US","city":null,"announced_on":"2025-03-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"17.0","verification":"Confirmed","cause":"restructuring","summary":"ElevateBio confirmed a 17% workforce reduction as part of an organizational adjustment intended to support long-term operations and scale.","sources":"https://www.fiercebiotech.com/biotech/despite-raising-1b-over-past-5-years-elevatebio-lets-go-17-workforce","recorded_on":"2026-10-04"},{"company":"Nkarta","company_slug":"nkarta","country":null,"city":null,"announced_on":"2025-03-26","effective_on":null,"roles_reported":53,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Nkarta announced a reduction in force of 53 positions while focusing resources on its autoimmune NK-cell therapy programs.","sources":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/nktx-20250326.htm https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/nktx-ex99_1.htm","recorded_on":"2026-10-04"},{"company":"Arbutus Biopharma","company_slug":"arbutus-biopharma","country":null,"city":null,"announced_on":"2025-03-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"57.0","verification":"Confirmed","cause":"restructuring","summary":"Arbutus Biopharma announced a 57% workforce reduction as it narrowed operations to a core team supporting its hepatitis B clinical program.","sources":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001760/exh_991.htm","recorded_on":"2026-10-04"},{"company":"BioAtla","company_slug":"bioatla","country":"US","city":"San Diego","announced_on":"2025-03-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"BioAtla announced an approximately 30% workforce reduction to streamline its cost structure while prioritizing selected development programs and partnering efforts.","sources":"https://www.sec.gov/Archives/edgar/data/1826892/000095017025046065/bcab-20250327.htm","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Foster City","announced_on":"2025-03-27","effective_on":"2025-05-27","roles_reported":149,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead filed a California WARN notice for 149 permanent layoffs at its Foster City headquarters, effective May 27.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf https://www.warntracker.com/layoff/gilead-sciences-2025-05-27","recorded_on":"2026-10-04"},{"company":"Roche Molecular Systems","company_slug":"roche-molecular-systems","country":"US","city":"Santa Clara","announced_on":"2025-03-27","effective_on":"2025-05-28","roles_reported":108,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Roche Molecular Systems filed a California WARN notice for 108 permanent layoffs at its Santa Clara diagnostics operation, effective May 28.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf https://www.warntracker.com/layoff/roche-molecular-systems-2025-05-28","recorded_on":"2026-10-04"},{"company":"Carisma Therapeutics","company_slug":"carisma-therapeutics","country":null,"city":null,"announced_on":"2025-03-31","effective_on":"2025-03-31","roles_reported":37,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Carisma Therapeutics reduced its workforce by 37 employees as part of a cash-preservation plan while pursuing strategic alternatives and preparing an orderly wind-down.","sources":"https://www.sec.gov/Archives/edgar/data/1485003/000162828025015673/carm-20241231.htm https://www.prnewswire.com/news-releases/carisma-therapeutics-provides-corporate-updates-302416072.html","recorded_on":"2026-10-04"},{"company":"Inspirna","company_slug":"inspirna","country":"US","city":null,"announced_on":"2025-03-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Inspirna's leadership announced that the cancer biotech was winding down operations and that employees would be entering the job market.","sources":"https://www.fiercebiotech.com/biotech/cancer-biotech-inspirna-winding-down-its-odyssey-microrna-comes-end","recorded_on":"2026-10-04"},{"company":"LifeMine Therapeutics","company_slug":"lifemine-therapeutics","country":"US","city":null,"announced_on":"2025-03-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"LifeMine Therapeutics confirmed workforce reductions and consolidation of operations as it concentrated resources on clinical development of its lead program.","sources":"https://www.fiercebiotech.com/biotech/lifemine-therapeutics-lays-staff-pivots-away-rd-drill-lead-asset-clinic","recorded_on":"2026-10-04"},{"company":"Lyell Immunopharma","company_slug":"lyell-immunopharma","country":"US","city":"Los Angeles","announced_on":"2025-04-01","effective_on":null,"roles_reported":73,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Lyell Immunopharma announced closure of the West Hills manufacturing facility acquired with ImmPACT Bio and a related workforce reduction of approximately 73 employees.","sources":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525070521/d920617d8k.htm https://www.sec.gov/Archives/edgar/data/1806952/000162828025025135/lyel-20250331.htm","recorded_on":"2026-10-04"},{"company":"Sail Biomedicines","company_slug":"sail-biomedicines","country":null,"city":null,"announced_on":"2025-04-01","effective_on":null,"roles_reported":12,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sail Biomedicines confirmed a 12-person workforce reduction following a review of its organizational structure.","sources":"https://www.fiercebiotech.com/biotech/flagship-backed-sail-biomedicines-lays-staff-following-review-organizational-structure","recorded_on":"2026-10-04"},{"company":"Oncodesign Precision Medicine","company_slug":"oncodesign-precision-medicine","country":"FR","city":null,"announced_on":"2025-04-02","effective_on":null,"roles_reported":5,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Oncodesign Precision Medicine disclosed a cost-cutting plan that included five employee redundancies implemented in January 2025 after the Servier collaboration ended.","sources":"https://www.oncodesign.com/wp-content/uploads/2025/04/PR_OPM_FYR2024_EN_02042025_vf.pdf","recorded_on":"2026-10-04"},{"company":"Philips Respironics","company_slug":"philips-respironics","country":"US","city":"Mount Pleasant","announced_on":"2025-04-02","effective_on":"2025-05-23","roles_reported":14,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Philips Respironics disclosed a 14-person layoff at its Mount Pleasant, Pennsylvania facility after eliminating a shift, with separations beginning May 23, 2025.","sources":"https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices?os=os https://www.post-gazette.com/business/career-workplace/2025/04/02/philips-respironics-layoffs-westmoreland-county/stories/202504020097","recorded_on":"2026-10-04"},{"company":"Spark Therapeutics","company_slug":"spark-therapeutics","country":"US","city":"Philadelphia","announced_on":"2025-04-03","effective_on":null,"roles_reported":337,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Spark Therapeutics confirmed that 337 employees would be laid off as Roche reorganized the gene-therapy subsidiary.","sources":"https://www.inquirer.com/health/spark-therapeutics-roche-layoffs-philadelphia-20250403.html https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices?os=os","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"San Diego","announced_on":"2025-04-04","effective_on":"2025-06-02","roles_reported":56,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer filed a California WARN notice for 56 permanent layoffs at its San Diego research operation, effective June 2.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.fiercebiotech.com/biotech/pfizer-shakes-rd-presence-san-diego-255m-site-sale-56-layoffs","recorded_on":"2026-10-04"},{"company":"Relay Therapeutics","company_slug":"relay-therapeutics","country":null,"city":null,"announced_on":"2025-04-04","effective_on":null,"roles_reported":70,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Relay Therapeutics announced a workforce reduction of approximately 70 people as it streamlined operations and concentrated spending on its key clinical programs.","sources":"https://www.linkedin.com/posts/relay-therapeutics-inc._today-we-shared-with-the-relay-therapeutics-activity-7313968624677908480-Gprh https://www.fiercebiotech.com/biotech/relay-therapeutics-sheds-70-staffers-drive-forward-clinical-programs","recorded_on":"2026-10-04"},{"company":"Tango Therapeutics","company_slug":"tango-therapeutics","country":"US","city":"Boston","announced_on":"2025-04-07","effective_on":null,"roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Tango Therapeutics laid off approximately 30 employees while reducing preclinical R&D spending to extend its cash runway and focus resources on clinical PRMT5 programs.","sources":"https://www.biopharmadive.com/news/tango-therapeutics-layoffs-cancer-biotech/744678/","recorded_on":"2026-10-04"},{"company":"Vincerx Pharma","company_slug":"vincerx-pharma","country":null,"city":null,"announced_on":"2025-04-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Vincerx Pharma announced that management would begin winding down the company after its latest proposed merger collapsed, while seeking to monetize or out-license remaining assets.","sources":"https://www.fiercebiotech.com/biotech/vincerxs-final-merger-attempt-collapses-leaving-adc-biotech-wind-down","recorded_on":"2026-10-04"},{"company":"Opthea","company_slug":"opthea","country":null,"city":null,"announced_on":"2025-04-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Opthea announced major workforce reductions after its COAST and ShORe Phase 3 trials missed their primary endpoints, initially targeting approximately 65% of staff.","sources":"https://www.sec.gov/Archives/edgar/data/1815620/000095017025052661/opt-ex99_1.htm https://www.sec.gov/Archives/edgar/data/1815620/000119312525202743/opt-20250630.htm","recorded_on":"2026-10-04"},{"company":"Organon","company_slug":"organon","country":"US","city":"Jersey City","announced_on":"2025-04-10","effective_on":"2025-04-30","roles_reported":93,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Organon disclosed a 93-position reduction in Jersey City as part of efforts to optimize its internal operations.","sources":"https://njbiz.com/organon-plans-93-layoffs-in-jersey-city-in-latest-cuts/ https://nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf","recorded_on":"2026-10-04"},{"company":"Third Harmonic Bio","company_slug":"third-harmonic-bio","country":null,"city":null,"announced_on":"2025-04-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Third Harmonic Bio approved a plan of liquidation and dissolution and began an orderly wind-down after its earlier February restructuring and strategic review.","sources":"https://www.sec.gov/Archives/edgar/data/1923840/000119312525079594/d891311dex991.htm","recorded_on":"2026-10-04"},{"company":"Mural Oncology","company_slug":"mural-oncology","country":null,"city":null,"announced_on":"2025-04-15","effective_on":null,"roles_reported":104,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Mural Oncology announced the discontinuation of all clinical development of nemvaleukin alfa and a workforce reduction of approximately 104 positions.","sources":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/d940480d8k.htm https://www.globenewswire.com/news-release/2025/04/15/3061678/0/en/Mural-Oncology-Announces-Plans-to-Explore-Strategic-Alternatives.html https://www.warntracker.com/layoff/mural-oncology-2025-06-14","recorded_on":"2026-10-04"},{"company":"Actavis Laboratories","company_slug":"actavis-laboratories","country":"US","city":"Salt Lake City","announced_on":"2025-04-18","effective_on":null,"roles_reported":78,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Actavis Laboratories filed a Utah WARN notice covering 78 workers in Salt Lake City.","sources":"https://jobs.utah.gov/employer/business/warnnotices.html","recorded_on":"2026-10-04"},{"company":"Tempest Therapeutics","company_slug":"tempest-therapeutics","country":"US","city":"Brisbane","announced_on":"2025-04-18","effective_on":"2025-04-30","roles_reported":21,"workforce_before":26,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Tempest Therapeutics adopted a plan to conserve capital while exploring strategic alternatives, reducing its workforce by 21 of 26 full-time employees effective April 30.","sources":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525085773/d792758d8k.htm https://www.sec.gov/Archives/edgar/data/1544227/000095017025106558/tpst-20250630.htm","recorded_on":"2026-10-04"},{"company":"Spruce Biosciences","company_slug":"spruce-biosciences","country":null,"city":null,"announced_on":"2025-04-21","effective_on":"2025-04-21","roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"restructuring","summary":"Spruce Biosciences announced an immediately effective workforce reduction of 55% while prioritizing development of tralesinidase alfa.","sources":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025058863/sprb-20250421.htm","recorded_on":"2026-10-04"},{"company":"Ono Pharma USA","company_slug":"ono-pharma-usa","country":"US","city":"Cambridge","announced_on":"2025-04-22","effective_on":"2025-06-30","roles_reported":83,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Ono Pharma USA filed a Massachusetts WARN notice covering 83 workers in Cambridge, with the layoffs scheduled to take effect June 30.","sources":"https://warnscan.com/index.php/notice/ono-pharma-usa-incthecompany-or-opus-ma-2025-04-22","recorded_on":"2026-10-04"},{"company":"Caribou Biosciences","company_slug":"caribou-biosciences","country":"US","city":null,"announced_on":"2025-04-24","effective_on":null,"roles_reported":47,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Caribou Biosciences announced a strategic pipeline-prioritization restructuring that would eliminate 47 employees, about 32% of its workforce, while focusing resources on its lead oncology programs.","sources":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/crbu-20250424.htm","recorded_on":"2026-10-04"},{"company":"Octagon Therapeutics","company_slug":"octagon-therapeutics","country":null,"city":null,"announced_on":"2025-04-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Octagon Therapeutics decided to wind down after deprioritizing its lead B-cell program and concluding that unresolved biology left the company without a viable path forward.","sources":"https://www.linkedin.com/posts/isaacstoner_the-board-and-i-have-made-the-difficult-decision-activity-7322629609747824641-Nr12","recorded_on":"2026-10-04"},{"company":"Arvinas","company_slug":"arvinas","country":"US","city":null,"announced_on":"2025-04-30","effective_on":"2025-06-29","roles_reported":131,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Arvinas announced a companywide restructuring that would eliminate 131 jobs, including 92 in Connecticut, as it streamlined operations and advanced its portfolio.","sources":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/arvn-20250430.htm https://www.newstimes.com/business/article/arvinas-layoffs-connecticut-new-haven-biotech-20305124.php","recorded_on":"2026-10-04"},{"company":"Entrada Therapeutics","company_slug":"entrada-therapeutics","country":"US","city":null,"announced_on":"2025-04-30","effective_on":"2025-05-02","roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Entrada Therapeutics announced focused workforce reductions in selected research areas expected to reduce its workforce by approximately 20% while prioritizing DMD clinical programs.","sources":"https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Lisata Therapeutics","company_slug":"lisata-therapeutics","country":"US","city":null,"announced_on":"2025-04-30","effective_on":null,"roles_reported":4,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Lisata Therapeutics eliminated four R&D roles as several clinical trials concluded; the company said it was not planning further cuts at that time.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Pliant Therapeutics","company_slug":"pliant-therapeutics","country":"US","city":"South San Francisco","announced_on":"2025-05-01","effective_on":null,"roles_reported":69,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pliant Therapeutics announced an approximately 45% workforce reduction; California WARN data records 69 permanent layoffs at its South San Francisco site.","sources":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/d949809d8k.htm https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Libertyville","announced_on":"2025-05-02","effective_on":"2025-07-01","roles_reported":133,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Bristol Myers Squibb announced that it would cease viral-vector manufacturing at its Libertyville, Illinois site, with a WARN-derived count of 133 affected workers.","sources":"https://www.fiercepharma.com/manufacturing/bms-calls-it-quits-former-novartis-plant-shifting-viral-vector-production-cell https://www.warntracker.com/layoff/bristol-myers-squibb-2025-07-01","recorded_on":"2026-10-04"},{"company":"Unity Biotechnology","company_slug":"unity-biotechnology","country":"US","city":null,"announced_on":"2025-05-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Unity Biotechnology approved a cost-preservation plan following full ASPIRE study data, implementing a reduction in force affecting all employees while retaining some personnel as consultants.","sources":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/ubx-20250502.htm","recorded_on":"2026-10-04"},{"company":"Biomea Fusion","company_slug":"biomea-fusion","country":"US","city":"San Carlos","announced_on":"2025-05-05","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"35.0","verification":"Confirmed","cause":"restructuring","summary":"Biomea Fusion implemented a strategic realignment including an approximately 35% workforce reduction and consolidation of its remaining workforce at its San Carlos research facility.","sources":"https://www.sec.gov/Archives/edgar/data/1840439/000095017025063523/bmea-ex99_1.htm","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2025-05-05","effective_on":"2025-05-09","roles_reported":516,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed another Lawrence Township WARN round affecting 516 workers as its expanded productivity program moved forward.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/bristol-myers-charts-500-more-layoffs-nj-following-expanded-cost-savings-drive https://njbiz.com/bristol-myers-squibb-layoffs-nj/","recorded_on":"2026-10-04"},{"company":"Mammoth Biosciences","company_slug":"mammoth-biosciences","country":"US","city":null,"announced_on":"2025-05-05","effective_on":null,"roles_reported":24,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Mammoth Biosciences confirmed a 24-person workforce reduction as part of a strategic alignment intended to focus the organization on internal programs, partnerships and research.","sources":"https://www.fiercebiotech.com/biotech/unity-shrinks-its-workforce-it-searches-strategic-path-forward-while-mammoth-cuts-24","recorded_on":"2026-10-04"},{"company":"Mersana Therapeutics","company_slug":"mersana-therapeutics","country":null,"city":null,"announced_on":"2025-05-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"55.0","verification":"Confirmed","cause":"restructuring","summary":"Mersana Therapeutics announced a strategic restructuring and reprioritization plan expected to reduce its workforce by approximately 55% across functions.","sources":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/tm2514089d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Korro Bio","company_slug":"korro-bio","country":"US","city":"Cambridge","announced_on":"2025-05-07","effective_on":null,"roles_reported":21,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Korro Bio streamlined its organization in May 2025; a later SEC filing fixed the reduction at 21 positions, or 19% of the workforce.","sources":"https://ir.korrobio.com/news-releases/news-release-details/korro-reports-first-quarter-2025-financial-results-and-provides https://www.sec.gov/Archives/edgar/data/1703647/000095017025106912/krro-20250630.htm","recorded_on":"2026-10-04"},{"company":"10x Genomics","company_slug":"10x-genomics","country":"US","city":"Pleasanton","announced_on":"2025-05-08","effective_on":"2025-07-07","roles_reported":93,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"10x Genomics disclosed an approximately 8% global workforce reduction; California WARN records identify 93 employees laid off at its Pleasanton headquarters as the California component of that action.","sources":"https://www.sec.gov/Archives/edgar/data/1770787/000177078725000031/txg-20250506.htm https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"IGM Biosciences","company_slug":"igm-biosciences","country":"US","city":"Mountain View","announced_on":"2025-05-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"80.0","verification":"Confirmed","cause":"funding","summary":"IGM Biosciences disclosed an additional reduction of approximately 80% of its remaining workforce and closure of most lab and office facilities after Sanofi terminated its collaboration.","sources":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525116071/d60800d8k.htm","recorded_on":"2026-10-04"},{"company":"insitro","company_slug":"insitro","country":"US","city":"South San Francisco","announced_on":"2025-05-08","effective_on":null,"roles_reported":63,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"insitro announced a 22% workforce reduction; California WARN data records 63 permanent layoffs at its South San Francisco site.","sources":"https://www.linkedin.com/posts/insitro_today-we-shared-with-our-team-of-insitrocytes-activity-7326282288529293313-Do66 https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-2024-to-06-30-2025.pdf","recorded_on":"2026-10-04"},{"company":"Rallybio","company_slug":"rallybio","country":"US","city":null,"announced_on":"2025-05-08","effective_on":null,"roles_reported":9,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Rallybio announced a nine-position workforce reduction, about 40% of its staff, as it narrowed spending and concentrated resources on its remaining development priorities.","sources":"https://investors.rallybio.com/news-releases/news-release-details/rallybio-reports-first-quarter-2025-financial-results-and","recorded_on":"2026-10-04"},{"company":"Shape Therapeutics","company_slug":"shape-therapeutics","country":null,"city":null,"announced_on":"2025-05-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Shape Therapeutics confirmed a workforce reduction as part of a broader shift in pipeline and organizational priorities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Vor Biopharma","company_slug":"vor-biopharma","country":"US","city":"Cambridge","announced_on":"2025-05-08","effective_on":null,"roles_reported":154,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Vor Biopharma announced the wind-down of its clinical and manufacturing operations and a workforce reduction later fixed at 154 full-time employees, about 99% of its then-current workforce.","sources":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/d924194d8k.htm https://www.sec.gov/Archives/edgar/data/1817229/000095017025107276/vor-20250630.htm","recorded_on":"2026-10-04"},{"company":"Atara Biotherapeutics","company_slug":"atara-biotherapeutics","country":null,"city":null,"announced_on":"2025-05-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Atara Biotherapeutics announced another workforce reduction affecting approximately 30% of its then-current employees while retaining personnel needed for its remaining strategic priorities.","sources":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025069198/atra-20250512.htm","recorded_on":"2026-10-04"},{"company":"Lexeo Therapeutics","company_slug":"lexeo-therapeutics","country":"US","city":"New York","announced_on":"2025-05-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"15.0","verification":"Confirmed","cause":"restructuring","summary":"Lexeo Therapeutics disclosed that an April capital-redeployment plan included a limited reduction in force affecting approximately 15% of employees as it focused resources on lead cardiac gene-therapy programs.","sources":"https://ir.lexeotx.com/node/8001/html","recorded_on":"2026-10-04"},{"company":"NGM Bio","company_slug":"ngm-bio","country":"US","city":null,"announced_on":"2025-05-12","effective_on":"2025-06-30","roles_reported":85,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"NGM Bio said a strategic pivot would eliminate 85 positions, including nearly all research roles, with the reduction taking effect June 30.","sources":"https://www.fiercebiotech.com/biotech/ngm-bio-slims-down-strategic-pivot-cutting-75-staff-and-halting-mid-stage-liver-disease","recorded_on":"2026-10-04"},{"company":"Allogene Therapeutics","company_slug":"allogene-therapeutics","country":null,"city":null,"announced_on":"2025-05-13","effective_on":null,"roles_reported":61,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Allogene Therapeutics reduced manufacturing and related functions while reprioritizing resources toward clinical programs; a later annual filing states that 61 employees were affected.","sources":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000064/allo-20250331.htm https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm","recorded_on":"2026-10-04"},{"company":"Kyverna Therapeutics","company_slug":"kyverna-therapeutics","country":null,"city":null,"announced_on":"2025-05-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"16.0","verification":"Confirmed","cause":"restructuring","summary":"Kyverna Therapeutics disclosed that it had reduced its workforce by approximately 16% during the first quarter of 2025 as part of organizational changes.","sources":"https://www.sec.gov/Archives/edgar/data/1994702/000095017025070286/kytx-ex99_1.htm","recorded_on":"2026-10-04"},{"company":"Leap Therapeutics","company_slug":"leap-therapeutics","country":"US","city":null,"announced_on":"2025-05-13","effective_on":"2025-05-06","roles_reported":13,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Leap Therapeutics disclosed a restructuring that cut 13 full-time employees as it reduced cash burn and prioritized its lead development programs.","sources":"https://www.sec.gov/Archives/edgar/data/1509745/000141057825001204/lptx-20250331x10q.htm","recorded_on":"2026-10-04"},{"company":"RA Ventures","company_slug":"ra-ventures","country":null,"city":null,"announced_on":"2025-05-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":null,"summary":"STAT reported layoffs at RA Capital’s company-creation incubator RA Ventures, based on people familiar with the matter.","sources":"https://www.statnews.com/2025/05/13/ra-capital-incubator-raven-layoffs/","recorded_on":"2026-10-04"},{"company":"Prime Medicine","company_slug":"prime-medicine","country":"US","city":null,"announced_on":"2025-05-19","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Prime Medicine announced a strategic restructuring, deprioritizing its CGD programs and reducing organizational headcount by approximately 25% to lower cash needs.","sources":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/d863812dex992.htm","recorded_on":"2026-10-04"},{"company":"Schrödinger","company_slug":"schrodinger","country":null,"city":null,"announced_on":"2025-05-20","effective_on":null,"roles_reported":60,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Schrödinger disclosed a restructuring expected to reduce headcount by approximately 60 employees, about 7% of its workforce, alongside focused cost reductions.","sources":"https://www.sec.gov/Archives/edgar/data/1490978/000119312525122461/d50434d8k.htm","recorded_on":"2026-10-04"},{"company":"Allergan Aesthetics","company_slug":"allergan-aesthetics","country":"US","city":"Irvine","announced_on":"2025-05-21","effective_on":"2025-07-22","roles_reported":202,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Allergan Aesthetics filed a California WARN notice for 202 layoffs tied to its Irvine operation, effective July 22.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.fiercepharma.com/pharma/abbvies-allergan-aesthetics-business-tightens-202-layoffs-california","recorded_on":"2026-10-04"},{"company":"Eikon Therapeutics","company_slug":"eikon-therapeutics","country":"US","city":"Millbrae","announced_on":"2025-05-21","effective_on":"2025-07-21","roles_reported":55,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Eikon Therapeutics filed a California WARN notice for 55 permanent layoffs in Millbrae as part of a corporate reorganization to sharpen operational focus and improve cash runway.","sources":"https://www.warntracker.com/layoff/eikon-therapeutics-2025-07-21 https://www.sec.gov/Archives/edgar/data/1861123/000119312526349185/eikn-20260630.htm","recorded_on":"2026-10-04"},{"company":"Boundless Bio","company_slug":"boundless-bio","country":null,"city":null,"announced_on":"2025-05-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Boundless Bio announced a workforce reduction of approximately one-third as part of a portfolio-prioritization plan.","sources":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025076911/bold-20250523.htm","recorded_on":"2026-10-04"},{"company":"iTeos Therapeutics","company_slug":"iteos-therapeutics","country":null,"city":null,"announced_on":"2025-05-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"iTeos Therapeutics announced that it intended to wind down clinical and operational activities and pursue a plan of dissolution.","sources":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/itos-ex99_1.htm","recorded_on":"2026-10-04"},{"company":"Genentech","company_slug":"genentech","country":"US","city":"South San Francisco","announced_on":"2025-05-29","effective_on":"2025-07-14","roles_reported":143,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Genentech filed a California WARN notice for 143 positions associated with its South San Francisco headquarters, effective July 14.","sources":"https://www.warntracker.com/layoff/genentech-2025-07-14 https://www.fiercebiotech.com/biotech/genentech-lays-143-workers-south-san-francisco-site","recorded_on":"2026-10-04"},{"company":"Keros Therapeutics","company_slug":"keros-therapeutics","country":"US","city":null,"announced_on":"2025-05-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"45.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Keros Therapeutics announced a corporate restructuring and approximately 45% workforce reduction after discontinuing development of cibotercept in pulmonary arterial hypertension.","sources":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/kros-20250528.htm https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-tropos-topline-data-and-corporate","recorded_on":"2026-10-04"},{"company":"Stealth BioTherapeutics","company_slug":"stealth-biotherapeutics","country":null,"city":null,"announced_on":"2025-05-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Stealth BioTherapeutics announced a roughly 30% workforce reduction after the FDA rejected its elamipretide application, as the company moved to conserve cash.","sources":"https://www.fiercebiotech.com/biotech/stealth-bombs-fda-receiving-rejection-twice-delayed-filing-and-laying-staff","recorded_on":"2026-10-04"},{"company":"Prothena Biosciences","company_slug":"prothena-biosciences","country":"US","city":"Brisbane","announced_on":"2025-06-02","effective_on":"2025-08-01","roles_reported":91,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Following the failed Phase 3 AFFIRM-AL trial, Prothena filed a California WARN notice for 91 Brisbane employees; the company later announced a broader approximately 63% workforce reduction.","sources":"https://ir.prothena.com/investors/press-releases/news-details/2025/Prothena-Announces-Phase-3-AFFIRM-AL-Clinical-Trial-for-Birtamimab-in-Patients-with-AL-Amyloidosis-Did-Not-Meet-Primary-Endpoint/default.aspx https://www.warntracker.com/layoff/prothena-biosciences-2025-08-01 https://ir.prothena.com/investors/press-releases/news-details/2025/Prothena-Announces-Corporate-Restructuring/default.aspx","recorded_on":"2026-10-04"},{"company":"Plexium","company_slug":"plexium","country":null,"city":null,"announced_on":"2025-06-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Plexium confirmed layoffs and a resource realignment intended to support its protein-degrader pipeline.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"RAPT Therapeutics","company_slug":"rapt-therapeutics","country":null,"city":null,"announced_on":"2025-06-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"RAPT Therapeutics confirmed another reduction in force as it continued restructuring after setbacks to its lead development program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Vertex Pharmaceuticals","company_slug":"vertex-pharmaceuticals","country":"US","city":"Providence","announced_on":"2025-06-06","effective_on":"2025-08-05","roles_reported":125,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Vertex filed a Rhode Island WARN notice for 125 layoffs as it consolidated its Providence campus after discontinuing the VX-264 diabetes program.","sources":"https://www.warntracker.com/company/vertex-pharmaceuticals https://www.fiercebiotech.com/biotech/vertex-slims-its-rhode-island-campus-lays-125-staffers-after-ditching-failed-diabetes-cell","recorded_on":"2026-10-04"},{"company":"Molecular Partners","company_slug":"molecular-partners","country":null,"city":null,"announced_on":"2025-06-10","effective_on":null,"roles_reported":34,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Molecular Partners announced a workforce restructuring in June 2025; a later SEC restructuring disclosure established that 34 positions were ultimately impacted.","sources":"https://www.sec.gov/Archives/edgar/data/1745114/000174511425000022/a20250610molecularpartners.htm https://www.sec.gov/Archives/edgar/data/1745114/000174511426000028/R19.htm","recorded_on":"2026-10-04"},{"company":"Recursion Pharmaceuticals","company_slug":"recursion-pharmaceuticals","country":null,"city":null,"announced_on":"2025-06-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Recursion Pharmaceuticals announced an approximately 20% workforce reduction as part of a streamlined post-integration operating strategy intended to extend its cash runway.","sources":"https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/d80288d8k.htm","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Oceanside","announced_on":"2025-06-11","effective_on":"2025-08-15","roles_reported":36,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead filed a California WARN notice for 36 Oceanside layoffs after abandoning an expansion plan and co-locating biologics teams elsewhere in California.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.fiercebiotech.com/biotech/gilead-lays-36-people-after-axing-california-expansion-plan","recorded_on":"2026-10-04"},{"company":"ADC Therapeutics","company_slug":"adc-therapeutics","country":null,"city":null,"announced_on":"2025-06-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"ADC Therapeutics disclosed a global restructuring expected to reduce its workforce by approximately 30% and close its U.K. research-and-development site.","sources":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325007282/dp230070_8k.htm","recorded_on":"2026-10-04"},{"company":"BioNTech","company_slug":"biontech","country":"US","city":"Gaithersburg","announced_on":"2025-06-13","effective_on":"2025-08-09","roles_reported":63,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"BioNTech filed a Maryland WARN notice for 63 layoffs at its Gaithersburg cell-therapy operation after ending development of BNT211 in a testicular-cancer setting and winding down manufacturing there.","sources":"https://www.labor.maryland.gov/employment/warn2025.shtml https://www.fiercebiotech.com/manufacturing/biontech-wind-down-cell-therapy-manufacturing-maryland-lay-63-it-ends-development-car","recorded_on":"2026-10-04"},{"company":"Scorpion Therapeutics","company_slug":"scorpion-therapeutics","country":null,"city":null,"announced_on":"2025-06-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Scorpion Therapeutics reduced staffing as operations were reorganized around the sale of its remaining development assets to Eli Lilly and the launch of Antares Therapeutics.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Teva Pharmaceuticals","company_slug":"teva-pharmaceuticals","country":"US","city":"Salt Lake City","announced_on":"2025-06-20","effective_on":null,"roles_reported":54,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Teva Pharmaceuticals filed a Utah WARN notice covering 54 workers in Salt Lake City.","sources":"https://jobs.utah.gov/employer/business/warnnotices.html","recorded_on":"2026-10-04"},{"company":"Leap Therapeutics","company_slug":"leap-therapeutics","country":null,"city":null,"announced_on":"2025-06-23","effective_on":"2025-06-30","roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Confirmed","cause":"funding","summary":"Leap Therapeutics announced an additional workforce reduction affecting approximately 75% of its then-current workforce as it sought to preserve cash and evaluate strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925061385/tm2518612d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Kenvue","company_slug":"kenvue","country":"US","city":"Summit","announced_on":"2025-06-24","effective_on":"2025-10-10","roles_reported":69,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Kenvue disclosed plans to eliminate 69 positions at its Summit, New Jersey headquarters, with separations scheduled between October 10 and December 19, 2025.","sources":"https://njbiz.com/kenvue-layoffs-new-summit-hq-2025/ https://nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf","recorded_on":"2026-10-04"},{"company":"BlueRock Therapeutics","company_slug":"bluerock-therapeutics","country":null,"city":null,"announced_on":"2025-06-25","effective_on":null,"roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BlueRock Therapeutics confirmed 50 layoffs across its sites while shutting its Cambridge research labs and focusing on priority cell-therapy programs.","sources":"https://www.fiercebiotech.com/biotech/bayer-owned-bluerock-lays-50-employees-shuts-cambridge-research-labs","recorded_on":"2026-10-04"},{"company":"Genentech","company_slug":"genentech","country":"US","city":"South San Francisco","announced_on":"2025-06-26","effective_on":"2025-08-18","roles_reported":141,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Genentech filed a California WARN notice covering 141 layoffs effective August 18, 2025; the record did not appear in the state's public listing until February 2026 because of a reporting-system delay.","sources":"https://www.warntracker.com/layoff/genentech-2025-08-18 https://www.fiercebiotech.com/biotech/genentech-cut-least-489-jobs-last-year-new-disclosure-reveals","recorded_on":"2026-10-04"},{"company":"Sage Therapeutics","company_slug":"sage-therapeutics","country":"US","city":"Cambridge","announced_on":"2025-06-26","effective_on":"2025-08-22","roles_reported":338,"workforce_before":338,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Sage Therapeutics filed a Massachusetts WARN notice for all 338 remaining employees after announcing its planned acquisition by Supernus Pharmaceuticals.","sources":"https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn-layoff-and-closure-updates https://www.statnews.com/2025/06/30/sage-therapeutics-cuts-supernus/ https://www.biospace.com/business/sage-sacks-entire-staff-after-supernus-buyout","recorded_on":"2026-10-04"},{"company":"Applied DNA Sciences","company_slug":"applied-dna-sciences","country":"US","city":"Stony Brook","announced_on":"2025-06-30","effective_on":"2025-06-27","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Applied DNA Sciences announced a strategic restructuring focused on synthetic DNA manufacturing, including an approximately 27% workforce reduction and the closure of Applied DNA Clinical Labs.","sources":"https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/tm2519488d1_8k.htm https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/tm2519488d1_ex99-1.htm","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2025-06-30","effective_on":"2025-09-25","roles_reported":68,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed a fourth 2025 New Jersey WARN round affecting 68 positions in Lawrence Township, with separations extending into January 2026.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://njbiz.com/bristol-myers-squibb-2025-nj-layoffs-lawrenceville/","recorded_on":"2026-10-04"},{"company":"4D Molecular Therapeutics","company_slug":"4d-molecular-therapeutics","country":"US","city":null,"announced_on":"2025-07-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"4D Molecular Therapeutics announced a workforce reduction of approximately 25% of current and planned roles as it prioritized late-stage development of 4D-150 and 4D-710.","sources":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025092964/fdmt-20250627.htm","recorded_on":"2026-10-04"},{"company":"Eurofins Lancaster Laboratories Professional Scientific Services","company_slug":"eurofins-lancaster-laboratories-professional-scientific-services","country":"US","city":"Frederick","announced_on":"2025-07-03","effective_on":"2025-09-03","roles_reported":25,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Eurofins Lancaster Laboratories Professional Scientific Services filed a Maryland mass-layoff notice affecting 25 employees in Frederick.","sources":"https://www.labor.maryland.gov/employment/warn2025.shtml","recorded_on":"2026-10-04"},{"company":"Century Therapeutics","company_slug":"century-therapeutics","country":"US","city":"Philadelphia","announced_on":"2025-07-07","effective_on":"2025-07-11","roles_reported":72,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Century Therapeutics announced a major workforce reduction; Pennsylvania's WARN record identifies 72 affected employees at its Philadelphia site.","sources":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/tm2519717d1_8k.htm https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices?os=os","recorded_on":"2026-10-04"},{"company":"CSL","company_slug":"csl","country":null,"city":null,"announced_on":"2025-07-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"CSL confirmed a global R&D reorganization that would consolidate internal research around six hub sites and reduce the size of its R&D workforce.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Jasper Therapeutics","company_slug":"jasper-therapeutics","country":null,"city":null,"announced_on":"2025-07-09","effective_on":"2025-07-08","roles_reported":22,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Jasper Therapeutics announced a corporate reorganization to extend its cash runway and focus on briquilimab programs, later reporting that the workforce reduction represented 22 employees.","sources":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/ea024839401ex99-1_jasper.htm https://www.sec.gov/Archives/edgar/data/1788028/000121390025107884/ea0263643-10q_jasper.htm https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/ea0282128-10k_jasper.htm","recorded_on":"2026-10-04"},{"company":"Pacira BioSciences","company_slug":"pacira-biosciences","country":"US","city":"San Diego","announced_on":"2025-07-09","effective_on":"2025-09-07","roles_reported":71,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pacira instituted a reduction in force affecting 71 employees at its San Diego Science Center Campus as it decommissioned an older EXPAREL manufacturing suite.","sources":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000093/pcrx-20250709.htm https://californiawarn.com/companies/pacira-biosciences","recorded_on":"2026-10-04"},{"company":"Karyopharm Therapeutics","company_slug":"karyopharm-therapeutics","country":null,"city":null,"announced_on":"2025-07-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Karyopharm Therapeutics announced a further workforce reduction of approximately 20% as part of ongoing operating-expense management.","sources":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025095167/kpti-20250711.htm","recorded_on":"2026-10-04"},{"company":"Azurity Pharmaceuticals","company_slug":"azurity-pharmaceuticals","country":"US","city":"Wilmington","announced_on":"2025-07-14","effective_on":"2025-09-12","roles_reported":75,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Azurity Pharmaceuticals announced plans to close its Wilmington, Massachusetts manufacturing facility, eliminating approximately 75 positions beginning in September 2025.","sources":"https://www.fiercepharma.com/manufacturing/formulation-specialist-azurity-will-lay-75-amid-plans-sunset-massachusetts-production https://warnscan.com/notice/azurity-pharmaceuticals-inc-ma-2025-07-08","recorded_on":"2026-10-04"},{"company":"GSK","company_slug":"gsk","country":null,"city":null,"announced_on":"2025-07-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"GSK confirmed a very limited workforce reduction within its global R&D organization as it adjusted resources across research and development.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Ventus Therapeutics","company_slug":"ventus-therapeutics","country":null,"city":null,"announced_on":"2025-07-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ventus Therapeutics confirmed a workforce recalibration while prioritizing development resources for two phase 2 programs and selected discovery capabilities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Genentech","company_slug":"genentech","country":"US","city":"South San Francisco","announced_on":"2025-07-16","effective_on":"2025-09-15","roles_reported":87,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Genentech filed a California WARN notice for 87 permanent layoffs at its South San Francisco headquarters, effective September 15.","sources":"https://www.warntracker.com/layoff/genentech-2025-09-15 https://www.fiercebiotech.com/biotech/genentech-eliminates-87-jobs-another-round-layoffs-its-south-san-francisco-campus","recorded_on":"2026-10-04"},{"company":"Sarepta Therapeutics","company_slug":"sarepta-therapeutics","country":null,"city":null,"announced_on":"2025-07-16","effective_on":null,"roles_reported":500,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sarepta announced a strategic restructuring and pipeline-prioritization plan including an approximately 500-employee workforce reduction.","sources":"https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-strategic-restructuring-and","recorded_on":"2026-10-04"},{"company":"GSK","company_slug":"gsk","country":"US","city":"Cambridge","announced_on":"2025-07-18","effective_on":"2025-10-04","roles_reported":150,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"GSK disclosed plans to eliminate 150 Cambridge positions as manufacturing work moves out of its Binney Street site and the facility transitions to an R&D-only operation.","sources":"https://www.bizjournals.com/boston/news/2025/07/18/gsk-to-cut-150-jobs-in-cambridge.html https://www.fiercepharma.com/manufacturing/gsk-telegraphs-150-layoffs-amid-plan-transfer-manufacturing-cambridge-site","recorded_on":"2026-10-04"},{"company":"HOOKIPA Pharma","company_slug":"hookipa-pharma","country":null,"city":null,"announced_on":"2025-07-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"HOOKIPA Pharma announced plans to delist, sell key program assets and proceed toward dissolution and liquidation, retaining only employees needed to wind up the company.","sources":"https://www.sec.gov/Archives/edgar/data/1760542/000110465925069029/tm2521167d1_ex99-1.htm https://www.sec.gov/Archives/edgar/data/1760542/000110465925069029/tm2521167d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Sail Biomedicines","company_slug":"sail-biomedicines","country":null,"city":null,"announced_on":"2025-07-18","effective_on":null,"roles_reported":36,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sail Biomedicines confirmed a second 2025 workforce reduction, affecting about 36 employees as it concentrated resources on immunology and in-vivo CAR-T work.","sources":"https://www.fiercebiotech.com/biotech/flagship-pioneerings-sail-biomedicines-sends-staff-packing-second-time-year","recorded_on":"2026-10-04"},{"company":"Fujifilm Cellular Dynamics","company_slug":"fujifilm-cellular-dynamics","country":"US","city":"Madison","announced_on":"2025-07-21","effective_on":null,"roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Fujifilm Cellular Dynamics cut 30 positions at its Madison, Wisconsin operations as part of a restructuring intended to deploy resources more efficiently.","sources":"https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025","recorded_on":"2026-10-04"},{"company":"Adicet Bio","company_slug":"adicet-bio","country":null,"city":null,"announced_on":"2025-07-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Adicet Bio publicly disclosed an approximately 30% workforce reduction tied to strategic pipeline prioritization and discontinuation of its ADI-270 program.","sources":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/acet-20250722.htm","recorded_on":"2026-10-04"},{"company":"Generate:Biomedicines","company_slug":"generate-biomedicines","country":null,"city":null,"announced_on":"2025-07-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"10.0","verification":"Confirmed","cause":"restructuring","summary":"Generate:Biomedicines confirmed that it eliminated about 10% of roles while rebalancing staffing toward skills aligned with its advancing portfolio.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Rocket Pharmaceuticals","company_slug":"rocket-pharmaceuticals","country":null,"city":null,"announced_on":"2025-07-23","effective_on":null,"roles_reported":80,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Rocket Pharmaceuticals began a strategic reorganization and pipeline prioritization expected to eliminate approximately 80 positions.","sources":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125026946/ef20052517_8k.htm https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm","recorded_on":"2026-10-04"},{"company":"Tessera Therapeutics","company_slug":"tessera-therapeutics","country":null,"city":null,"announced_on":"2025-07-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"17.0","verification":"Confirmed","cause":"restructuring","summary":"Tessera Therapeutics confirmed a 17% workforce reduction as it rebalanced staffing for its transition toward clinical development.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Adaptimmune Therapeutics","company_slug":"adaptimmune-therapeutics","country":null,"city":null,"announced_on":"2025-07-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"62.0","verification":"Confirmed","cause":"restructuring","summary":"Adaptimmune announced a restructuring following its asset transaction with US WorldMeds, planning to reduce its remaining workforce by approximately 62%.","sources":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925071009/tm2521829d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Moderna","company_slug":"moderna","country":null,"city":null,"announced_on":"2025-07-31","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"10.0","verification":"Confirmed","cause":"restructuring","summary":"Moderna announced an approximately 10% global workforce reduction as part of a broader plan to lower operating expenses and align its cost structure with current business conditions.","sources":"https://www.modernatx.com/media-center/all-media/blogs/aligning-cost-structure-to-deliver-pipeline https://investors.modernatx.com/statements-perspectives/moderna-announces-an-organizational-restructuring","recorded_on":"2026-10-04"},{"company":"Poseida Therapeutics","company_slug":"poseida-therapeutics","country":"US","city":"San Diego","announced_on":"2025-07-31","effective_on":"2025-10-01","roles_reported":52,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Poseida Therapeutics filed a California WARN notice affecting 52 workers in San Diego following its acquisition by Roche.","sources":"https://californiawarn.com/companies/poseida-therapeutics https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"BioNTech","company_slug":"biontech","country":"US","city":null,"announced_on":"2025-08-05","effective_on":null,"roles_reported":90,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BioNTech confirmed a further 90 U.S. layoffs across Cambridge and Gaithersburg as part of a strategic pipeline and organizational alignment.","sources":"https://www.labor.maryland.gov/employment/warn2025.shtml https://www.fiercebiotech.com/biotech/biontech-cuts-90-more-us-jobs-drugmaker-hones-pipeline-focus https://www.biospace.com/business/biontech-cuts-90-jobs-amid-strategic-alignment","recorded_on":"2026-10-04"},{"company":"Alltrna","company_slug":"alltrna","country":"US","city":null,"announced_on":"2025-08-06","effective_on":null,"roles_reported":8,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Alltrna laid off eight employees as it slimmed its team while advancing its first engineered tRNA therapy toward the clinic.","sources":"https://www.fiercebiotech.com/biotech/flagship-pioneerings-alltrna-sheds-staff-after-getting-new-ceo","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Oceanside","announced_on":"2025-08-06","effective_on":"2025-10-10","roles_reported":5,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead filed a California WARN notice for five layoffs at its Oceanside operation, effective October 10.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.warntracker.com/layoff/gilead-sciences-2025-10-10","recorded_on":"2026-10-04"},{"company":"Iovance Biotherapeutics","company_slug":"iovance-biotherapeutics","country":null,"city":null,"announced_on":"2025-08-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Iovance Biotherapeutics confirmed a strategic restructuring affecting fewer than 20% of employees and contractors to extend its cash runway.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Precision BioSciences","company_slug":"precision-biosciences","country":null,"city":null,"announced_on":"2025-08-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Precision BioSciences disclosed an operating-efficiency program that included an undisclosed workforce reduction and reduced early-research spending.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Dewpoint Therapeutics","company_slug":"dewpoint-therapeutics","country":null,"city":null,"announced_on":"2025-08-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"restructuring","summary":"Dewpoint Therapeutics cut around 70% of its workforce while consolidating global operations in Boston and narrowing its development portfolio.","sources":"https://www.statnews.com/2025/08/07/dewpoint-therapeutics-layoffs/","recorded_on":"2026-10-04"},{"company":"Bicycle Therapeutics","company_slug":"bicycle-therapeutics","country":null,"city":null,"announced_on":"2025-08-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Bicycle Therapeutics announced cost-reduction initiatives centered on a workforce reduction of approximately 25% of its current and planned workforce.","sources":"https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-reports-recent-business-progress-and-3 https://www.sec.gov/Archives/edgar/data/1761612/000110465925104010/bcyc-20250930x10q.htm","recorded_on":"2026-10-04"},{"company":"TriLink BioTechnologies","company_slug":"trilink-biotechnologies","country":"US","city":"San Diego","announced_on":"2025-08-08","effective_on":"2025-10-06","roles_reported":90,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"TriLink BioTechnologies' San Diego workforce reduction affected 90 employees across four sites as parent Maravai implemented a broader restructuring.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-25-to-6-30-26.pdf https://www.sec.gov/Archives/edgar/data/1823239/000182323925000105/mrvi-20250807.htm","recorded_on":"2026-10-04"},{"company":"Tune Therapeutics","company_slug":"tune-therapeutics","country":null,"city":null,"announced_on":"2025-08-08","effective_on":null,"roles_reported":17,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Tune Therapeutics cut 17 positions, about one quarter of its workforce, after a strategic review of research priorities under its new chief executive.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025 https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025","recorded_on":"2026-10-04"},{"company":"Absci","company_slug":"absci","country":null,"city":null,"announced_on":"2025-08-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Absci confirmed an organizational realignment that eliminated a small number of roles as the company sharpened focus on priority AI, clinical-development and research programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"NextRNA Therapeutics","company_slug":"nextrna-therapeutics","country":"US","city":null,"announced_on":"2025-08-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":"funding","summary":"NextRNA Therapeutics was reported to be winding down operations after running low on cash.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Fate Therapeutics","company_slug":"fate-therapeutics","country":null,"city":null,"announced_on":"2025-08-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"12.0","verification":"Confirmed","cause":"restructuring","summary":"Fate Therapeutics announced a reduction in force affecting approximately 12% of its workforce as part of a tactical operating plan to reduce costs and extend funding.","sources":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/d452012d8k.htm","recorded_on":"2026-10-04"},{"company":"Generation Bio","company_slug":"generation-bio","country":null,"city":null,"announced_on":"2025-08-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"90.0","verification":"Confirmed","cause":"restructuring","summary":"Generation Bio announced a phased strategic restructuring expected to reduce its workforce by approximately 90% while it explored strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1733294/000155837025011226/gbio-20250630x10q.htm","recorded_on":"2026-10-04"},{"company":"ORIC Pharmaceuticals","company_slug":"oric-pharmaceuticals","country":null,"city":null,"announced_on":"2025-08-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"ORIC Pharmaceuticals announced a strategic pipeline prioritization that included an approximately 20% workforce reduction and elimination of its discovery research group.","sources":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/oric-20250812.htm","recorded_on":"2026-10-04"},{"company":"Abata Therapeutics","company_slug":"abata-therapeutics","country":"US","city":null,"announced_on":"2025-08-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":"funding","summary":"Abata Therapeutics was reported to be shutting down after difficulties raising additional financing.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Bausch Health US","company_slug":"bausch-health-us","country":"US","city":"Petaluma","announced_on":"2025-08-13","effective_on":"2025-08-13","roles_reported":49,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Bausch Health US filed a California WARN notice for a permanent closure affecting 49 employees at its Petaluma site.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn-report-for-7-1-25-to-6-30-26.pdf","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"US","city":"Rahway","announced_on":"2025-08-13","effective_on":"2025-11-14","roles_reported":58,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Merck disclosed a New Jersey WARN round affecting 58 employees at its Rahway headquarters, effective November 14, as the company began implementing its broader cost-reduction plan.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/merck-begins-8-workforce-purge-laying-58-its-new-jersey-hq","recorded_on":"2026-10-04"},{"company":"Vedanta Biosciences","company_slug":"vedanta-biosciences","country":null,"city":null,"announced_on":"2025-08-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Rumoured","cause":"pipeline_setback","summary":"Vedanta Biosciences was reported to be laying off 20% of staff after a phase 2 ulcerative-colitis study failed and the company shifted focus to its C. difficile program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"CSL","company_slug":"csl","country":null,"city":null,"announced_on":"2025-08-18","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"CSL announced a broader transformation program expected to produce a net headcount reduction of up to 15% of its employee base.","sources":"https://newsroom.csl.com/2025-08-18-CSL-announces-rise-in-full-year-net-profit","recorded_on":"2026-10-04"},{"company":"Catalent Maryland","company_slug":"catalent-maryland","country":"US","city":null,"announced_on":"2025-08-20","effective_on":"2025-10-18","roles_reported":353,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Catalent Maryland filed a mass-layoff notice covering 353 employees across Harmans, Baltimore and Hanover, with layoffs effective October 18, 2025.","sources":"https://www.labor.maryland.gov/employment/warn2025.shtml","recorded_on":"2026-10-04"},{"company":"Arena BioWorks","company_slug":"arena-bioworks","country":"US","city":"Cambridge","announced_on":"2025-08-22","effective_on":null,"roles_reported":22,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Arena BioWorks cut 22 roles, roughly 30% of its workforce, while deprioritizing cell and gene therapy work and reorganizing its research portfolio.","sources":"https://www.fiercebiotech.com/biotech/arena-bioworks-19-months-after-splashy-launch-lays-30-its-staff","recorded_on":"2026-10-04"},{"company":"LB Pharmaceuticals","company_slug":"lb-pharmaceuticals","country":"US","city":"New York","announced_on":"2025-08-22","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"LB Pharmaceuticals publicly disclosed that it had begun a reduction in force on May 6 affecting several employees, including its former CFO and former CSO.","sources":"https://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080ds1.htm","recorded_on":"2026-10-04"},{"company":"Appia Bio","company_slug":"appia-bio","country":"US","city":null,"announced_on":"2025-08-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":"funding","summary":"Appia Bio was reported to have ceased operations after running out of cash while preparing an IND filing for its cell-therapy programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"US","city":"Bothell","announced_on":"2025-08-25","effective_on":"2025-08-25","roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer filed a Washington WARN notice affecting 100 employees at the former Seagen operation in Bothell.","sources":"https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database https://www.fiercepharma.com/pharma/pfizer-lays-100-former-seagen-hq-seattle-area","recorded_on":"2026-10-04"},{"company":"Vaxxas","company_slug":"vaxxas","country":"AU","city":null,"announced_on":"2025-08-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"10.0","verification":"Rumoured","cause":null,"summary":"Vaxxas was reported to have reduced its workforce by about 10% alongside leadership changes.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Indivior","company_slug":"indivior","country":null,"city":null,"announced_on":"2025-08-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Indivior disclosed headcount reductions as part of the first major initiative under its Action Agenda to simplify the organization and reduce operating expenses.","sources":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000064/indv-20250826.htm","recorded_on":"2026-10-04"},{"company":"Exelixis","company_slug":"exelixis","country":"US","city":null,"announced_on":"2025-08-28","effective_on":null,"roles_reported":130,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Exelixis confirmed a 130-person workforce reduction while winding down its King of Prussia, Pennsylvania site and consolidating operations around Alameda, California.","sources":"https://www.inquirer.com/health/exelixis-biotech-layoffs-king-of-prussia-20250828.html https://www.fiercepharma.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing","recorded_on":"2026-10-04"},{"company":"BioLife Plasma Services","company_slug":"biolife-plasma-services","country":"US","city":"Riverdale","announced_on":"2025-09-02","effective_on":"2025-08-25","roles_reported":26,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"BioLife Plasma Services filed a Maryland plant-closure notice affecting 26 employees at its Riverdale location.","sources":"https://www.labor.maryland.gov/employment/warn2025.shtml","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2025-09-02","effective_on":"2025-11-28","roles_reported":58,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis announced a 58-position reduction in its U.S. medical-affairs organization centered on East Hanover, New Jersey.","sources":"https://www.fiercepharma.com/pharma/novartis-plots-58-layoffs-new-jersey-amid-reviews-operations-us-hq https://nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf","recorded_on":"2026-10-04"},{"company":"AC Immune","company_slug":"ac-immune","country":null,"city":null,"announced_on":"2025-09-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"AC Immune announced operational efficiencies and a workforce reduction of around 30% following a strategic review of its pipeline investments.","sources":"https://www.sec.gov/Archives/edgar/data/1651625/000095010325011258/dp233965_6k.htm","recorded_on":"2026-10-04"},{"company":"Lundbeck","company_slug":"lundbeck","country":null,"city":null,"announced_on":"2025-09-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Lundbeck announced a transition of operations in 27 markets to partners affecting 602 employees, while saying most displaced staff were expected to have opportunities to join those partners.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"GB","city":"London","announced_on":"2025-09-10","effective_on":null,"roles_reported":125,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Merck announced it would end early drug-discovery research in the U.K., vacate existing London R&D sites and eliminate 125 scientific jobs.","sources":"https://www.theguardian.com/business/2025/sep/10/us-drugmaker-merck-scraps-1bn-london-research-centre-and-cuts-125-science-jobs https://www.bloomberg.com/news/articles/2025-09-10/merck-scraps-plans-for-1-billion-london-hub-in-fresh-blow-to-uk","recorded_on":"2026-10-04"},{"company":"Novo Nordisk","company_slug":"novo-nordisk","country":null,"city":null,"announced_on":"2025-09-10","effective_on":null,"roles_reported":9000,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novo Nordisk announced a company-wide transformation intended to reduce approximately 9,000 roles globally, including about 5,000 in Denmark, to simplify the organization and redirect resources.","sources":"https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?gsid=1e021c77-c110-4e0d-a4e2-aa6a0e69dd26&id=916424 https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Revvity","company_slug":"revvity","country":"US","city":"Boston","announced_on":"2025-09-10","effective_on":"2026-06-01","roles_reported":29,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Revvity announced the permanent closure of its Boston facility; a final amended WARN notice later established that 29 employees would actually experience employment loss after 47 of 76 impacted employees accepted transfers.","sources":"https://www.mass.gov/doc/revvity-inc-boston-03-24-2026-updated-warn-notice/download https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn-layoff-and-closure-updates","recorded_on":"2026-10-04"},{"company":"Rising Pharmaceuticals","company_slug":"rising-pharmaceuticals","country":"US","city":"Decatur","announced_on":"2025-09-15","effective_on":"2025-11-15","roles_reported":86,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Rising Pharmaceuticals disclosed the closure of its two Decatur, Illinois facilities, with a state WARN record listing 86 affected workers and layoffs beginning Nov. 15.","sources":"https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025 https://www.wandtv.com/news/rising-pharmaceuticals-shuts-down-decatur-operations-after-2-years/article_0bcd63a8-d4d7-4dbc-ad45-761ef16423c8.html","recorded_on":"2026-10-04"},{"company":"Arsenal Biosciences","company_slug":"arsenal-biosciences","country":"US","city":"South San Francisco","announced_on":"2025-09-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"Arsenal Biosciences confirmed an approximately 50% workforce reduction as it restructured around its clinical-stage cell-therapy programs.","sources":"https://www.fiercebiotech.com/biotech/arsenalbio-lays-50-staff-it-turns-away-early-stage-research","recorded_on":"2026-10-04"},{"company":"Arvinas","company_slug":"arvinas","country":"US","city":null,"announced_on":"2025-09-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"15.0","verification":"Confirmed","cause":"restructuring","summary":"Arvinas announced a second 2025 workforce reduction of approximately 15%, focused mainly on roles tied to vepdegestrant commercialization.","sources":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvn-20250917.htm","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2025-09-17","effective_on":"2025-12-11","roles_reported":282,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed another Lawrence Township reduction affecting 282 positions, with separations scheduled across several dates beginning in December 2025.","sources":"https://www.fiercepharma.com/pharma/new-jersey-novo-nordisk-cuts-263-workers-while-bms-slashes-282 https://nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf","recorded_on":"2026-10-04"},{"company":"Innate Pharma","company_slug":"innate-pharma","country":"FR","city":null,"announced_on":"2025-09-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Innate Pharma announced plans to streamline its organization, with staffing expected to decrease by about 30% including attrition, while prioritizing higher-value clinical assets.","sources":"https://www.innate-pharma.com/media/all-press-releases/innate-pharma-reports-first-half-2025-business-update-and-financial-results","recorded_on":"2026-10-04"},{"company":"X4 Pharmaceuticals","company_slug":"x4-pharmaceuticals","country":null,"city":null,"announced_on":"2025-09-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"50.0","verification":"Confirmed","cause":"restructuring","summary":"X4 Pharmaceuticals announced an additional restructuring that would reduce its workforce by approximately 50% to focus resources on completing the 4WARD phase 3 trial.","sources":"https://www.sec.gov/Archives/edgar/data/1501697/000150169725000021/xfor-20250915.htm https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-restructuring-business-operations/","recorded_on":"2026-10-04"},{"company":"MaxCyte","company_slug":"maxcyte","country":"US","city":"Rockville","announced_on":"2025-09-22","effective_on":"2025-11-21","roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"MaxCyte announced a broader workforce restructuring; a Maryland WARN notice identifies 20 affected employees at its Rockville headquarters.","sources":"https://www.sec.gov/Archives/edgar/data/1287098/000110465925092162/mxct-20250922x8k.htm https://www.labor.maryland.gov/employment/warn2025.shtml","recorded_on":"2026-10-04"},{"company":"Rome Therapeutics","company_slug":"rome-therapeutics","country":"US","city":"Boston","announced_on":"2025-09-23","effective_on":null,"roles_reported":null,"workforce_before":14,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Rome Therapeutics confirmed plans to reduce its 14-person workforce, go fully virtual and explore strategic alternatives amid difficult market conditions.","sources":"https://www.fiercebiotech.com/biotech/big-pharma-backed-rome-therapeutics-nears-end-road-planned-layoffs-and-strategic-review","recorded_on":"2026-10-04"},{"company":"Seres Therapeutics","company_slug":"seres-therapeutics","country":null,"city":null,"announced_on":"2025-09-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"funding","summary":"Seres Therapeutics announced cost-reduction actions including an approximately 25% workforce reduction to extend its cash runway while seeking capital and other resources for SER-155.","sources":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525230118/d63317d8k.htm https://ir.serestherapeutics.com/node/12666 https://www.sec.gov/Archives/edgar/data/1609809/000119312525266011/mcrb-20250930.htm","recorded_on":"2026-10-04"},{"company":"Heidelberg Pharma","company_slug":"heidelberg-pharma","country":"DE","city":"Ladenburg","announced_on":"2025-09-25","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Confirmed","cause":"funding","summary":"Heidelberg Pharma announced plans to reduce its workforce by approximately 75% after a delayed $70 million milestone payment forced a major cost-reduction program and pipeline focus.","sources":"https://heidelberg-pharma.com/en/press-investors/announcements/press-releases-and-ad-hoc-announcements/ah-heidelberg-pharma-significantly-reduces-operating-costs-and-focuses-on-lead-adc-candidate-hdp-101-due-to-delayed-milestone-payment","recorded_on":"2026-10-04"},{"company":"Biogen","company_slug":"biogen","country":null,"city":null,"announced_on":"2025-09-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Biogen confirmed layoffs affecting a small number of employees as it ended all AAV-based gene-therapy work and reassigned most of the team.","sources":"https://www.fiercebiotech.com/biotech/biogen-officially-ends-all-aav-gene-therapy-work-prompting-team-restructure","recorded_on":"2026-10-04"},{"company":"GSK","company_slug":"gsk","country":"US","city":"San Francisco","announced_on":"2025-09-29","effective_on":"2025-09-29","roles_reported":8,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"GSK disclosed a separate eight-person workforce reduction at its San Francisco site, effective Sept. 29.","sources":"https://www.warntracker.com/layoff/gsk-plc-2025-09-29 https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025","recorded_on":"2026-10-04"},{"company":"IO Biotech","company_slug":"io-biotech","country":null,"city":null,"announced_on":"2025-09-29","effective_on":null,"roles_reported":34,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"IO Biotech announced a restructuring that reduced its global workforce by 34 people while conserving capital and refocusing development resources.","sources":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525221704/d940102d8k.htm https://www.sec.gov/Archives/edgar/data/1865494/000119312525281820/iobt-20250930.htm","recorded_on":"2026-10-04"},{"company":"KALA BIO","company_slug":"kala-bio","country":"US","city":null,"announced_on":"2025-09-29","effective_on":null,"roles_reported":19,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"KALA BIO announced an approximately 19-person workforce reduction after its Phase 2b CHASE trial failed its primary and key secondary endpoints and the company stopped development of KPI-012.","sources":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925094125/tm2527340d1_8k.htm https://www.sec.gov/Archives/edgar/data/1479419/000110465925113927/kala-20250930x10q.htm","recorded_on":"2026-10-04"},{"company":"Sutro Biopharma","company_slug":"sutro-biopharma","country":"US","city":null,"announced_on":"2025-09-29","effective_on":"2025-09-30","roles_reported":54,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sutro Biopharma announced a further restructuring and filed California WARN notices covering 54 positions across South San Francisco, San Carlos and a remote California role.","sources":"https://ir.sutrobio.com/financials/sec-filings/content/0001193125-25-223434/stro-20250929.htm https://www.warntracker.com/layoff/sutro-biopharma-2025-09-30","recorded_on":"2026-10-04"},{"company":"Theriva Biologics","company_slug":"theriva-biologics","country":null,"city":null,"announced_on":"2025-09-30","effective_on":"2025-09-30","roles_reported":7,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Theriva Biologics implemented a seven-employee workforce reduction, equal to about 32% of its global workforce, while resizing operations around business development and VCN-01 clinical planning.","sources":"https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/tm2527561d1_8k.htm https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm","recorded_on":"2026-10-04"},{"company":"Bolt Biotherapeutics","company_slug":"bolt-biotherapeutics","country":"US","city":null,"announced_on":"2025-10-01","effective_on":null,"roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Bolt Biotherapeutics implemented an approximately 20-person workforce reduction, about half of its staff, to conserve capital and extend its cash runway into 2027.","sources":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525228293/bolt-20251001.htm https://www.globenewswire.com/news-release/2025/10/01/3159924/0/en/bolt-biotherapeutics-provides-update-on-bdc-4182-and-extends-cash-runway-into-2027.html","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"US","city":"Cambridge","announced_on":"2025-10-01","effective_on":"2026-01-01","roles_reported":137,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Takeda filed a Massachusetts WARN notice for up to 137 Massachusetts positions as it discontinued its cell-therapy efforts, with separations beginning in January 2026.","sources":"https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn-layoff-and-closure-updates https://www.bostonglobe.com/2025/10/04/business/takeda-layoffs-massachusetts-biopharma/","recorded_on":"2026-10-04"},{"company":"Vifor Pharma","company_slug":"vifor-pharma","country":"US","city":null,"announced_on":"2025-10-01","effective_on":"2025-12-01","roles_reported":55,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Vifor Pharma filed a Pennsylvania WARN notice covering 55 layoffs effective December 1, 2025, as CSL reorganized Vifor's field-based teams.","sources":"https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices https://www.fiercepharma.com/pharma/vifor-cut-55-jobs-pa-parent-company-csl-pushes-ahead-downsizing-savings-campaign","recorded_on":"2026-10-04"},{"company":"Applied DNA Sciences","company_slug":"applied-dna-sciences","country":"US","city":"Stony Brook","announced_on":"2025-10-06","effective_on":"2025-09-30","roles_reported":16,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Applied DNA Sciences disclosed a further restructuring that reduced its workforce by 16 employees, approximately 60% of its September 30 workforce.","sources":"https://www.sec.gov/Archives/edgar/data/744452/000110465925097097/tm2528084d1_8k.htm","recorded_on":"2026-10-04"},{"company":"Atara Biotherapeutics","company_slug":"atara-biotherapeutics","country":null,"city":null,"announced_on":"2025-10-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"29.0","verification":"Confirmed","cause":"restructuring","summary":"Atara Biotherapeutics announced a further workforce reduction affecting approximately 29% of its current employees while retaining a small team for remaining priorities.","sources":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525232117/d802811d8k.htm","recorded_on":"2026-10-04"},{"company":"Mythic Therapeutics","company_slug":"mythic-therapeutics","country":null,"city":null,"announced_on":"2025-10-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Mythic Therapeutics confirmed an unspecified workforce reduction while refocusing the business around its lead MYTX-011 program; the company later entered a wind-down and asset-sale process.","sources":"https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025 https://www.fiercebiotech.com/biotech/oncology-biotech-mythic-and-former-fundraising-heavy-weight-areteia-wind-down","recorded_on":"2026-10-04"},{"company":"Pharming Group","company_slug":"pharming","country":"NL","city":null,"announced_on":"2025-10-06","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Pharming Group announced an organizational restructuring including a 20% net reduction in non-commercial and non-medical headcount, primarily at its Netherlands headquarters.","sources":"https://www.pharming.com/our-news/pharming-group-provides-update-on-previously-announced-g-and-a-expense-reduction-plan","recorded_on":"2026-10-04"},{"company":"Ascidian Therapeutics","company_slug":"ascidian-therapeutics","country":null,"city":null,"announced_on":"2025-10-09","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ascidian Therapeutics confirmed that it had conducted a modest reduction in force over the summer while refocusing on its lead clinical and most promising preclinical programs.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"Kezar Life Sciences","company_slug":"kezar-life-sciences","country":null,"city":null,"announced_on":"2025-10-17","effective_on":"2025-11-06","roles_reported":31,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Kezar Life Sciences moved toward a major workforce reduction after failing to align with the FDA on a registrational path for zetomipzomib; the subsequently implemented plan cut approximately 31 employees.","sources":"https://www.fiercebiotech.com/biotech/kezar-plans-layoffs-after-fda-cancels-meeting-discuss-next-trial https://www.sec.gov/Archives/edgar/data/1645666/000162828025050671/kzr-20251106.htm https://kezarlifesciences.gcs-web.com/news-releases/news-release-details/kezar-life-sciences-reports-third-quarter-2025-financial-results","recorded_on":"2026-10-04"},{"company":"Alector","company_slug":"alector","country":"US","city":"South San Francisco","announced_on":"2025-10-21","effective_on":"2025-12-22","roles_reported":75,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Alector filed a California WARN notice for 75 layoffs after its GSK-partnered latozinemab Phase 3 study failed, triggering a major workforce reduction.","sources":"https://www.warntracker.com/company/alector https://www.sfgate.com/tech/article/alector-biotech-lays-off-half-21118936.php","recorded_on":"2026-10-04"},{"company":"Galapagos","company_slug":"galapagos","country":null,"city":null,"announced_on":"2025-10-21","effective_on":null,"roles_reported":365,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Galapagos announced its intention to wind down its cell-therapy business after failing to secure a viable buyer, a plan affecting approximately 365 employees and five sites across Europe, the United States and China.","sources":"https://www.sec.gov/Archives/edgar/data/1421876/000117184325006542/exh_991.htm https://www.globenewswire.com/news-release/2026/1/5/3213177/0/en/galapagos-announces-board-decision-to-initiate-wind-down-of-cell-therapy-activities.html","recorded_on":"2026-10-04"},{"company":"Merck KGaA","company_slug":"merck-kgaa","country":"IE","city":"Arklow","announced_on":"2025-10-22","effective_on":null,"roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Merck KGaA announced plans to close its Arklow, Ireland API production plant by the end of 2028, affecting approximately 100 jobs.","sources":"https://www.irishtimes.com/business/2025/10/22/merck-to-close-arklow-plant-with-loss-of-100-jobs/ https://www.rte.ie/news/business/2025/1022/1539956-merck-life-science-plant-in-arklow-to-close/","recorded_on":"2026-10-04"},{"company":"Genentech","company_slug":"genentech","country":"US","city":"South San Francisco","announced_on":"2025-10-24","effective_on":"2025-11-28","roles_reported":118,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Genentech filed another California WARN notice for 118 layoffs at its South San Francisco headquarters, effective November 28.","sources":"https://www.warntracker.com/layoff/genentech-2025-11-28 https://www.fiercebiotech.com/biotech/genentech-says-goodbye-118-employees-third-hq-layoff-round-year","recorded_on":"2026-10-04"},{"company":"Ferring Pharmaceuticals","company_slug":"ferring-pharmaceuticals","country":"US","city":"Parsippany","announced_on":"2025-10-27","effective_on":"2026-01-23","roles_reported":64,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ferring Pharmaceuticals disclosed that 64 positions in Parsippany, New Jersey would be eliminated as part of its broader global operating-model changes.","sources":"https://njbiz.com/ferring-layoffs-parsippany-global-job-cuts/ https://nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf","recorded_on":"2026-10-04"},{"company":"Sensei Biotherapeutics","company_slug":"sensei-biotherapeutics","country":"US","city":null,"announced_on":"2025-10-30","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"65.0","verification":"Confirmed","cause":"restructuring","summary":"Sensei Biotherapeutics announced a strategic review and workforce reduction after discontinuing solnerstotug; a later filing said the reduction was approximately 65% of the workforce.","sources":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm","recorded_on":"2026-10-04"},{"company":"Respironics, Inc.","company_slug":"respironics","country":"US","city":null,"announced_on":"2025-10-31","effective_on":"2025-12-31","roles_reported":196,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Respironics disclosed a 196-person layoff across three Westmoreland County, Pennsylvania facilities, with separations beginning December 31, 2025 and continuing through June 2026.","sources":"https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices?os=os https://www.bizjournals.com/pittsburgh/news/2025/10/31/philips-respironics-layoffs-westmoreland-county.html https://www.wtae.com/article/respironics-layoffs-pennsylvania/69223072","recorded_on":"2026-10-04"},{"company":"Inventprise","company_slug":"inventprise","country":"US","city":null,"announced_on":"2025-11-01","effective_on":"2025-12-31","roles_reported":76,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Inventprise filed for a 76-person workforce reduction affecting its Seattle-area operations and remote employees, with the first separations scheduled for December 31, 2025.","sources":"https://www.geekwire.com/2025/filing-seattle-area-vaccine-company-inventprise-laying-off-76-employees/ https://warnscan.com/notice/inventprise-inc-wa-2025-10-30-1","recorded_on":"2026-10-04"},{"company":"TScan Therapeutics","company_slug":"tscan-therapeutics","country":"US","city":"Waltham","announced_on":"2025-11-03","effective_on":"2025-11-03","roles_reported":66,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"TScan Therapeutics prioritized its heme program and implemented a workforce reduction of 66 employees, approximately 30% of its workforce.","sources":"https://www.sec.gov/Archives/edgar/data/1783328/000119312525261612/d873161d8k.htm https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-reaches-agreement-fda-pivotal-study-design","recorded_on":"2026-10-04"},{"company":"Arena BioWorks","company_slug":"arena-bioworks","country":"US","city":"Cambridge","announced_on":"2025-11-04","effective_on":null,"roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Arena BioWorks announced a full shutdown less than three months after an earlier reduction, with approximately 50 remaining staff expected to be laid off.","sources":"https://www.statnews.com/2025/11/04/arena-bioworks-research-institute-shuts-down/ https://www.fiercebiotech.com/biotech/billionaire-backed-arena-bioworks-shutters-less-2-years-after-launch-cites-biotech-macro","recorded_on":"2026-10-04"},{"company":"Catalent Maryland","company_slug":"catalent-maryland","country":"US","city":null,"announced_on":"2025-11-06","effective_on":"2026-01-05","roles_reported":77,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Catalent Maryland filed a second 2025 mass-layoff notice covering 77 employees across Harmans, Baltimore and Hanover, effective January 5, 2026.","sources":"https://www.labor.maryland.gov/employment/warn2025.shtml","recorded_on":"2026-10-04"},{"company":"AbbVie","company_slug":"abbvie","country":"US","city":null,"announced_on":"2025-11-10","effective_on":"2026-01-09","roles_reported":59,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"AbbVie filed simultaneous California WARN notices covering 59 workers across Dublin, Livermore and Pleasanton, with layoffs effective January 9, 2026.","sources":"https://www.warntracker.com/company/abbvie","recorded_on":"2026-10-04"},{"company":"Charles River Laboratories","company_slug":"charles-river-laboratories","country":"US","city":"Wilmington","announced_on":"2025-11-10","effective_on":"2026-01-09","roles_reported":71,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Charles River Laboratories notified Massachusetts of a partial closure at its Wilmington site; an amended notice increased the affected count from 68 to 71, with separations beginning January 9, 2026.","sources":"https://www.mass.gov/doc/charles-river-laboratories-inc-11-10-2025-warn-notices/download https://www.mass.gov/doc/charles-river-laboratories-inc-12-16-2025-updated-warn-notices/download https://www.mass.gov/doc/charles-river-laboratories-inc-03-25-2026-wilmington-ma-updated-warn-notice/download","recorded_on":"2026-10-04"},{"company":"Ironwood Pharmaceuticals","company_slug":"ironwood-pharmaceuticals","country":null,"city":null,"announced_on":"2025-11-10","effective_on":null,"roles_reported":10,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Ironwood Pharmaceuticals disclosed that it had eliminated 10 positions supporting apraglutide commercialization during August 2025 after development timelines were delayed.","sources":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925108795/R19.htm https://www.sec.gov/Archives/edgar/data/1446847/000110465926020489/R22.htm","recorded_on":"2026-10-04"},{"company":"Metagenomi","company_slug":"metagenomi","country":null,"city":null,"announced_on":"2025-11-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"25.0","verification":"Confirmed","cause":"restructuring","summary":"Metagenomi announced strategic pipeline prioritization and an organizational restructuring that reduced its workforce by 25%.","sources":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/mgx-ex99_1.htm","recorded_on":"2026-10-04"},{"company":"AbbVie","company_slug":"abbvie","country":"US","city":null,"announced_on":"2025-11-12","effective_on":null,"roles_reported":100,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":"restructuring","summary":"STAT reported that AbbVie was ending its long-running Calico collaboration and that about 100 employees associated with the work were set to lose their jobs.","sources":"https://www.statnews.com/2025/11/12/abbvie-calico-layoffs/","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Oceanside","announced_on":"2025-11-12","effective_on":"2026-01-16","roles_reported":17,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead filed another California WARN notice for 17 layoffs at its Oceanside operation, effective January 16, 2026.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.warntracker.com/layoff/gilead-sciences-2026-01-16","recorded_on":"2026-10-04"},{"company":"Korro Bio","company_slug":"korro-bio","country":"US","city":"Cambridge","announced_on":"2025-11-12","effective_on":"2025-11-12","roles_reported":null,"workforce_before":null,"share_of_workforce":"34.0","verification":"Confirmed","cause":"funding","summary":"Korro Bio implemented a second 2025 restructuring, reducing its workforce by approximately 34% to extend its cash runway after the earlier May reduction.","sources":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/krro-20251107.htm","recorded_on":"2026-10-04"},{"company":"nChroma Bio","company_slug":"nchroma-bio","country":"US","city":"Boston","announced_on":"2025-11-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"nChroma Bio confirmed layoffs as it reorganized research around its lead hepatitis program and deprioritized virus-like-particle work.","sources":"https://www.fiercebiotech.com/biotech/genetic-medicine-outfit-nchroma-sheds-staff-research-reorganization","recorded_on":"2026-10-04"},{"company":"Ventus Therapeutics","company_slug":"ventus-therapeutics","country":null,"city":null,"announced_on":"2025-11-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ventus Therapeutics confirmed a second 2025 workforce adjustment intended to align staffing with the company's current development priorities.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025","recorded_on":"2026-10-04"},{"company":"BIOLYST Scientific","company_slug":"biolyst-scientific","country":"US","city":"Hatfield","announced_on":"2025-11-14","effective_on":"2026-01-12","roles_reported":76,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"BIOLYST Scientific announced the closure of its Hatfield, Pennsylvania facility, affecting 76 workers, with separations beginning January 12, 2026.","sources":"https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices?os=os https://www.bizjournals.com/philadelphia/news/2025/11/14/biolyst-scientific-hatfield-layoffs-closing.html","recorded_on":"2026-10-04"},{"company":"Blueprint Medicines","company_slug":"blueprint-medicines","country":"US","city":"Cambridge","announced_on":"2025-11-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Following Sanofi's acquisition of Blueprint Medicines, the companies conducted a portfolio review that resulted in an undisclosed number of Blueprint employees being notified of layoffs.","sources":"https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025","recorded_on":"2026-10-04"},{"company":"Nxera Pharma","company_slug":"nxera-pharma","country":null,"city":null,"announced_on":"2025-11-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"15.0","verification":"Confirmed","cause":"restructuring","summary":"Nxera Pharma announced a 15% workforce reduction across roles in the United Kingdom and Japan while reprioritizing its pipeline and streamlining leadership.","sources":"https://www.fiercebiotech.com/biotech/nxera-lays-15-staff-and-prioritizes-pipeline-profitability-push","recorded_on":"2026-10-04"},{"company":"Actavis Laboratories","company_slug":"actavis-laboratories","country":"US","city":"Salt Lake City","announced_on":"2025-11-18","effective_on":null,"roles_reported":205,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Actavis Laboratories filed a second 2025 Utah WARN notice covering 205 workers in Salt Lake City.","sources":"https://jobs.utah.gov/employer/business/warnnotices.html","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"US","city":"Rahway","announced_on":"2025-11-18","effective_on":"2026-02-20","roles_reported":204,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Merck disclosed another Rahway, New Jersey workforce reduction affecting 204 employees, with terminations scheduled across several dates from February through May 2026.","sources":"https://nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://www.biospace.com/job-trends/biopharmas-continued-staff-cuts-in-2025","recorded_on":"2026-10-04"},{"company":"Applied Therapeutics","company_slug":"applied-therapeutics","country":"US","city":null,"announced_on":"2025-11-20","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"46.0","verification":"Confirmed","cause":"funding","summary":"Applied Therapeutics initiated a strategic-alternatives review and announced an approximately 46% workforce reduction alongside cash-conservation measures.","sources":"https://www.sec.gov/Archives/edgar/data/1697532/000119312525288900/aplt-20251120.htm","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2025-11-20","effective_on":"2026-02-12","roles_reported":110,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed a further Lawrence Township workforce reduction affecting 110 positions, with separations scheduled for February and March 2026.","sources":"https://njbiz.com/merck-bms-nj-layoffs/ https://nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf","recorded_on":"2026-10-04"},{"company":"Ensoma","company_slug":"ensoma","country":"US","city":"Boston","announced_on":"2025-11-20","effective_on":null,"roles_reported":37,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ensoma confirmed a 37-person workforce reduction as it shifted resources from platform optimization toward clinical development and immuno-oncology programs.","sources":"https://www.fiercebiotech.com/biotech/ensoma-halves-workforce-after-transitioning-genetic-medicine-clinic","recorded_on":"2026-10-04"},{"company":"Nurix Therapeutics","company_slug":"nurix-therapeutics","country":"US","city":null,"announced_on":"2025-11-21","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Nurix Therapeutics confirmed a small targeted workforce reduction intended to align resources with strategic priorities while continuing its clinical and research programs.","sources":"https://www.fiercebiotech.com/biotech/nurix-trims-workforce-pivotal-trial-lead-btk-degrader-kicks","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"CH","city":"Stein","announced_on":"2025-11-25","effective_on":null,"roles_reported":550,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis announced planned changes to Swiss manufacturing that could eliminate approximately 550 permanent positions by the end of 2027, subject to consultation.","sources":"https://www.novartis.com/ch-de/news/media-releases/novartis-passt-produktionsaktivitaeten-der-schweiz-und-investiert-innovative-herstelltechnologien","recorded_on":"2026-10-04"},{"company":"Valneva","company_slug":"valneva","country":"FR","city":"Nantes","announced_on":"2025-11-26","effective_on":null,"roles_reported":30,"workforce_before":39,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Valneva announced closure of its Nantes site as it consolidated French operations in Lyon and R&D in Vienna; 30 of 39 positions at Nantes were slated for elimination.","sources":"https://www.globenewswire.com/news-release/2025/11/26/3195261/0/en/valneva-to-further-consolidate-its-operations-in-france.html https://www.fiercebiotech.com/biotech/vaccine-focused-valneva-shutters-site-efforts-consolidate-rd-eliminating-30-roles","recorded_on":"2026-10-04"},{"company":"Intercept Pharmaceuticals","company_slug":"intercept-pharmaceuticals","country":"US","city":"Morristown","announced_on":"2025-12-01","effective_on":"2026-02-28","roles_reported":146,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Intercept Pharmaceuticals filed a New Jersey WARN notice for 146 layoffs in Morristown after the withdrawal of Ocaliva and a series of regulatory setbacks.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2025_WARN_Notice_Archive.pdf https://warnscan.com/notice/intercept-pharmaceuticals-nj-2025-12-01-1 https://www.fiercepharma.com/pharma/intercept-heels-ocaliva-withdrawal-restructures-146-layoffs","recorded_on":"2026-10-04"},{"company":"Adare Pharmaceuticals","company_slug":"adare-pharmaceuticals","country":"US","city":"Philadelphia","announced_on":"2025-12-08","effective_on":"2026-03-01","roles_reported":137,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Adare Pharmaceuticals announced the closure of its Philadelphia production facility, affecting 137 employees beginning March 1, 2026.","sources":"https://www.pa.gov/agencies/dli/programs-services/workforce-development-home/warn-requirements/warn-notices https://www.bizjournals.com/philadelphia/news/2025/12/08/adare-pharma-solutions-plant-closing-layoffs.html","recorded_on":"2026-10-04"},{"company":"BiomX","company_slug":"biomx","country":null,"city":null,"announced_on":"2025-12-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"BiomX announced a significant workforce reduction alongside discontinuing the BX004 cystic-fibrosis program after a safety review and while evaluating strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1739174/000121390025118969/ea0268807-8k_biomx.htm https://www.globenewswire.com/news-release/2025/12/08/3201429/0/en/biomx-announces-discontinuation-of-phase-2b-bx004-trial-following-internal-review.html","recorded_on":"2026-10-04"},{"company":"Pfizer","company_slug":"pfizer","country":"CH","city":null,"announced_on":"2025-12-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Pfizer confirmed workforce reductions in Switzerland as part of its global cost-saving program; reporting said the Swiss workforce was expected to fall from about 300 to roughly 70.","sources":"https://www.fiercepharma.com/pharma/pfizers-cost-cutting-drive-reaches-switzerland-where-company-plans-lay-hundreds-year-end","recorded_on":"2026-10-04"},{"company":"Areteia Therapeutics","company_slug":"areteia-therapeutics","country":null,"city":null,"announced_on":"2025-12-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":"pipeline_setback","summary":"Endpoints News reported that Areteia Therapeutics was shutting down after a benefit-risk assessment led to termination of key asthma studies.","sources":"https://www.fiercebiotech.com/biotech/oncology-biotech-mythic-and-former-fundraising-heavy-weight-areteia-wind-down","recorded_on":"2026-10-04"},{"company":"Geron","company_slug":"geron","country":"US","city":null,"announced_on":"2025-12-16","effective_on":"2025-12-16","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Geron publicly disclosed implementation of a strategic restructuring expected to reduce its workforce by approximately one-third.","sources":"https://www.sec.gov/Archives/edgar/data/886744/000088674425000074/gern-20251210.htm","recorded_on":"2026-10-04"},{"company":"Mythic Therapeutics","company_slug":"mythic-therapeutics","country":"US","city":null,"announced_on":"2025-12-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Mythic Therapeutics confirmed that it was winding down and selling assets after an earlier fall layoff round, creating a distinct closure-stage workforce event.","sources":"https://www.fiercebiotech.com/biotech/oncology-biotech-mythic-and-former-fundraising-heavy-weight-areteia-wind-down","recorded_on":"2026-10-04"},{"company":"Voyager Therapeutics","company_slug":"voyager-therapeutics","country":"US","city":null,"announced_on":"2025-12-17","effective_on":null,"roles_reported":30,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Voyager Therapeutics laid off 30 employees after Novartis returned rights to two discovery-stage programs in their collaboration.","sources":"https://www.fiercebiotech.com/biotech/voyager-jettisons-30-employees-novartis-hands-back-rights-2-programs https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/vygr-20251231x10k.htm","recorded_on":"2026-10-04"},{"company":"Nido Biosciences","company_slug":"nido-biosciences","country":null,"city":null,"announced_on":"2026-01-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Nido Biosciences announced that it would close operations in early 2026 after its Phase 2 NIDO-361 study produced disappointing results and the program was discontinued.","sources":"https://www.linkedin.com/posts/nido-biosciences_a-note-from-our-ceo-jeremy-p-springhorn-activity-7410417862449790976-DMaf https://www.fiercebiotech.com/biotech/neuro-biotech-nido-closes-after-phase-2-study-fails-move-needle-rare-disease","recorded_on":"2026-10-04"},{"company":"Labcorp","company_slug":"labcorp","country":"US","city":"Ann Arbor","announced_on":"2026-01-07","effective_on":"2026-03-09","roles_reported":76,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Labcorp filed notice of the permanent closure of its Ann Arbor early-development facility, with 76 affected jobs scheduled to end between March 9 and June 14, 2026.","sources":"https://www.michigan.gov/leo/-/media/Project/Websites/leo/Documents/WD-DATA_PUBLIC_WARN_NOTICES4/2026/2026-01-07_WARN-Notice_Labcorp-Ann-Arbor.pdf https://www.cbsnews.com/detroit/news/labcorp-to-close-an-ann-arbor-facility-lay-off-76-employees/","recorded_on":"2026-10-04"},{"company":"Tessera Therapeutics","company_slug":"tessera-therapeutics","country":"US","city":"Somerville","announced_on":"2026-01-07","effective_on":"2026-03-08","roles_reported":90,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Tessera Therapeutics filed a WARN notice for a permanent layoff of 90 employees reporting to its Somerville headquarters, beginning March 8.","sources":"https://www.mass.gov/doc/tessera-therapeutics-inc-01-07-2026-warn-notice/download https://www.fiercebiotech.com/biotech/flagship-founded-tessera-plans-lay-90-employees-march","recorded_on":"2026-10-04"},{"company":"InflaRx","company_slug":"inflarx","country":null,"city":null,"announced_on":"2026-01-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"InflaRx announced an approximately 30% workforce reduction as part of a strategic refocusing intended to reduce spending and concentrate resources on izicopan.","sources":"https://www.sec.gov/Archives/edgar/data/1708688/000114036126000715/ef20062541_6k.htm https://www.sec.gov/Archives/edgar/data/1708688/000114036126000715/ef20062541_ex99-1.htm https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026","recorded_on":"2026-10-04"},{"company":"Rampart Bioscience","company_slug":"rampart-bioscience","country":null,"city":null,"announced_on":"2026-01-08","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":null,"summary":"Endpoints News reported that Rampart Bioscience had shut down after pursuing non-viral gene-therapy technology.","sources":"https://endpoints.news/secretive-rampart-bioscience-closes-after-pursuing-non-viral-gene-therapy/ https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026","recorded_on":"2026-10-04"},{"company":"Thermo Fisher Scientific","company_slug":"thermo-fisher-scientific","country":"US","city":"Asheville","announced_on":"2026-01-08","effective_on":null,"roles_reported":423,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Thermo Fisher announced a permanent closure of its Asheville-area manufacturing facility in North Carolina; the current state WARN summary lists 423 affected workers.","sources":"https://www.commerce.nc.gov/data-tools-reports/labor-market-data-tools/workforce-warn-reports/report-workforce-warn-summary-list-2026 https://www.newsobserver.com/news/business/article314324046.html https://828newsnow.com/news/228822-thermo-fisher-to-end-operations-at-weaverville-site/","recorded_on":"2026-10-04"},{"company":"Lyra Therapeutics","company_slug":"lyra-therapeutics","country":"US","city":"Watertown","announced_on":"2026-01-12","effective_on":null,"roles_reported":28,"workforce_before":28,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Lyra Therapeutics suspended further development of LYR-210 and announced a workforce reduction affecting all 28 remaining employees while preserving capital and pursuing strategic alternatives.","sources":"https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-provides-corporate-update/ https://www.sec.gov/Archives/edgar/data/1327273/000119312526009772/d27712d8k.htm https://www.fiercebiotech.com/biotech/lyra-ditches-sole-rhinosinusitis-asset-lays-all-employees","recorded_on":"2026-10-04"},{"company":"EMD Serono","company_slug":"emd-serono","country":"US","city":"Durham","announced_on":"2026-01-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"EMD Serono confirmed an undisclosed reduction in its Durham, North Carolina research team as it streamlined research operations after Merck KGaA's acquisition of SpringWorks Therapeutics.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026 https://www.pharmalive.com/gilead-continues-california-cuts-with-34-laid-off-and-more-pharma-payoffs/","recorded_on":"2026-10-04"},{"company":"Sonoma Biotherapeutics","company_slug":"sonoma-biotherapeutics","country":"US","city":null,"announced_on":"2026-01-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Sonoma Biotherapeutics confirmed a companywide workforce reduction affecting roles across functions in South San Francisco, Seattle and remotely as it aligned resources around its highest-priority clinical program.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026 https://endpoints.news/treg-biotech-sonoma-sheds-staff-after-getting-new-ceo/","recorded_on":"2026-10-04"},{"company":"Curia Global","company_slug":"curia-global","country":"US","city":"Burlington","announced_on":"2026-01-14","effective_on":"2026-03-10","roles_reported":81,"workforce_before":81,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Curia Global announced the permanent closure of its Burlington, Massachusetts drug-product development and manufacturing facility, eliminating approximately 81 positions.","sources":"https://www.mass.gov/doc/curia-global-inc-burlington-ma-01-14-2026-warn-notice/download https://www.fiercepharma.com/manufacturing/curia-plant-shutdown-massachusetts-forces-lay-81","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":"US","city":null,"announced_on":"2026-01-14","effective_on":null,"roles_reported":243,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Takeda disclosed the elimination of 243 U.S. field positions as it reorganized its neuroscience commercial organization ahead of the approaching loss of exclusivity for Trintellix.","sources":"https://www.mass.gov/doc/takeda-pharmaceuticals-america-inc-cambridge-ma-01-15-2026-warn-notice/download https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix","recorded_on":"2026-10-04"},{"company":"Vedanta Biosciences","company_slug":"vedanta-biosciences","country":null,"city":null,"announced_on":"2026-01-16","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Vedanta Biosciences confirmed a significant headcount reduction as it concentrated resources on the Phase 3 VE303 program for recurrent C. difficile infection.","sources":"https://www.biospace.com/job-trends/vedanta-significantly-reduces-staff-focuses-on-phase-iii-study-of-c-diff-drug https://www.fiercebiotech.com/biotech/vedanta-significantly-reduces-headcount-fund-lead-bacteria-cocktail-program","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"Oceanside","announced_on":"2026-01-21","effective_on":"2026-03-27","roles_reported":34,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead filed a California WARN notice for 34 permanent layoffs in Oceanside, effective March 27.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.warntracker.com/layoff/gilead-sciences-2026-03-27","recorded_on":"2026-10-04"},{"company":"Thermo Fisher Scientific","company_slug":"thermo-fisher-scientific","country":"US","city":"Franklin","announced_on":"2026-01-23","effective_on":"2026-12-31","roles_reported":80,"workforce_before":200,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Thermo Fisher disclosed plans to close its Franklin, Massachusetts facility; an initial WARN notice listed 103 affected employees, but the company later clarified that 80 workers would be laid off while other employees were reassigned, relocated or able to pursue internal roles.","sources":"https://www.mass.gov/doc/thermo-fisher-scientific-franklin-ma-01-26-2026-warn-notice/download https://www.boston.com/news/business/2026/02/02/thermo-fisher-closing-franklin-site/ https://www.bostonglobe.com/2026/02/02/business/thermo-fisher-layoff-franklin-plant/","recorded_on":"2026-10-04"},{"company":"Bitterroot Bio","company_slug":"bitterroot-bio","country":null,"city":null,"announced_on":"2026-01-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bitterroot Bio began a restructuring that would affect departing CEO Pavan Cheruvu and many other team members as the company shifted its focus back toward discovery biology and translational research.","sources":"https://www.linkedin.com/posts/pavan-cheruvu-117b5310a_after-nearly-4-years-as-ceo-at-bitterroot-activity-7422713135414976512-fP46 https://www.biospace.com/biospace-layoff-tracker","recorded_on":"2026-10-04"},{"company":"IO Biotech","company_slug":"io-biotech","country":null,"city":null,"announced_on":"2026-01-30","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"IO Biotech announced a significant global workforce reduction as part of cost-containment measures while evaluating strategic alternatives.","sources":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/d13704d8k.htm https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/d13704dex991.htm","recorded_on":"2026-10-04"},{"company":"Charles River Laboratories","company_slug":"charles-river-laboratories","country":"US","city":"Hanover","announced_on":"2026-02-02","effective_on":"2026-03-23","roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Charles River Laboratories filed a Maryland WARN notice for a 20-person plant closure at its Hanover facility, effective March 23.","sources":"https://www.labor.maryland.gov/employment/warn.shtml https://labor.maryland.gov/employment/pdf/warn-log-2026.pdf?=v5","recorded_on":"2026-10-04"},{"company":"GSK","company_slug":"gsk","country":null,"city":null,"announced_on":"2026-02-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"GSK confirmed an R&D reorganization expected initially to affect fewer than 50 U.K. workers and fewer than 70 U.S. workers, with no more than 350 jobs potentially affected in total.","sources":"https://www.fiercebiotech.com/biotech/gsk-plans-lay-350-rd-workers-across-us-uk https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026","recorded_on":"2026-10-04"},{"company":"Seres Therapeutics","company_slug":"seres-therapeutics","country":null,"city":null,"announced_on":"2026-02-12","effective_on":null,"roles_reported":21,"workforce_before":66,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Seres Therapeutics announced cost-reduction actions including an approximately 30% workforce reduction while pausing additional investment in its planned SER-155 Phase 2 study and prioritizing earlier-stage programs.","sources":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-provides-program-and-corporate-updates-and-prioritizes https://ir.serestherapeutics.com/static-files/c16ba0b8-df53-4b01-b373-fe7407fa363f https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm","recorded_on":"2026-10-04"},{"company":"Ultragenyx Pharmaceutical","company_slug":"ultragenyx-pharmaceutical","country":null,"city":null,"announced_on":"2026-02-12","effective_on":null,"roles_reported":130,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ultragenyx announced a strategic restructuring that includes a 10% workforce reduction affecting approximately 130 employees across the company.","sources":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-20260212.htm https://ir.ultragenyx.com/node/18386/pdf https://www.fiercebiotech.com/biotech/ultragenyx-lays-10-workforce-wake-phase-3-brittle-bone-trial-fails","recorded_on":"2026-10-04"},{"company":"Integra LifeSciences","company_slug":"integra-lifesciences","country":"US","city":"Princeton","announced_on":"2026-02-13","effective_on":"2026-05-01","roles_reported":65,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Integra LifeSciences disclosed organizational changes affecting 65 employees at its Princeton site, with separations scheduled across May and June.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercebiotech.com/medtech/integra-lifesciences-cuts-roles-65-staffers-impacted-princeton-site","recorded_on":"2026-10-04"},{"company":"Concerto Biosciences","company_slug":"concerto-biosciences","country":null,"city":null,"announced_on":"2026-02-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Concerto Biosciences confirmed that it reorganized and reduced its team while shifting new discovery and development work toward consumer products and applications.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026 https://www.biospace.com/biospace-layoff-tracker","recorded_on":"2026-10-04"},{"company":"Catalent Maryland","company_slug":"catalent-maryland","country":"US","city":null,"announced_on":"2026-02-19","effective_on":"2026-04-19","roles_reported":96,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Catalent Maryland filed same-day WARN notices covering 96 permanent layoffs across its Harmans and Baltimore locations, effective April 19.","sources":"https://labor.maryland.gov/employment/warn.shtml https://labor.maryland.gov/employment/pdf/warn-log-2026.pdf?=v5","recorded_on":"2026-10-04"},{"company":"Tourmaline Bio","company_slug":"tourmaline-bio","country":"US","city":"New York","announced_on":"2026-02-19","effective_on":"2026-05-29","roles_reported":60,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Tourmaline Bio closed its New York headquarters after its acquisition by Novartis, with a New York WARN notice listing 60 affected employees.","sources":"https://dol.ny.gov/warn-dashboard https://www.biospace.com/biospace-layoff-tracker","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2026-02-23","effective_on":"2026-05-21","roles_reported":247,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed a New Jersey WARN round affecting 247 employees tied to its Lawrence Township operations, with separations phased through the end of 2026.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://njbiz.com/bristol-myers-squibb-nj-layoffs-cost-cutting/","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"US","city":"Durham","announced_on":"2026-02-24","effective_on":"2026-05-01","roles_reported":154,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Merck filed permanent layoff notices affecting 154 employees at two Durham sites as it moved to end Gardasil production at the Old Oxford Road facility.","sources":"https://www.commerce.nc.gov/data-tools-reports/labor-market-data-tools/workforce-warn-reports/report-workforce-warn-summary-list-2026 https://www.newsobserver.com/news/business/article314863916.html https://businessnc.com/merck-lays-off-154-workers-in-durham-as-use-of-its-hpv-vaccine-declines/","recorded_on":"2026-10-04"},{"company":"Viatris","company_slug":"viatris","country":null,"city":null,"announced_on":"2026-02-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Viatris announced an enterprise-wide restructuring expected to reduce its global workforce by up to approximately 10% over roughly three years.","sources":"https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/vtrs-20260223.htm https://newsroom.viatris.com/2026-02-26-Viatris-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm","recorded_on":"2026-10-04"},{"company":"Disc Medicine","company_slug":"disc-medicine","country":null,"city":null,"announced_on":"2026-02-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Disc Medicine disclosed a workforce reduction of approximately 20% after receiving a complete response letter for bitopertin, as it narrowed spending and priorities.","sources":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526082855/iron-20260226.htm https://www.fiercebiotech.com/biotech/disc-lays-20-employees-it-steadies-ship-after-fda-rejection-rare-disease-drug","recorded_on":"2026-10-04"},{"company":"BioAtla","company_slug":"bioatla","country":"US","city":"San Diego","announced_on":"2026-03-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"70.0","verification":"Confirmed","cause":"restructuring","summary":"BioAtla announced a restructuring alongside a formal strategic-options process, including a workforce reduction of approximately 70%.","sources":"https://www.sec.gov/Archives/edgar/data/1826892/000153949726000812/n5620_8k.htm https://www.sec.gov/Archives/edgar/data/1826892/000153949726000812/exh99_1.htm https://www.fiercebiotech.com/biotech/bioatla-lays-70-workforce-seeks-buyers-antibodies","recorded_on":"2026-10-04"},{"company":"EveryOne Medicines","company_slug":"everyone-medicines","country":null,"city":null,"announced_on":"2026-03-03","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Rumoured","cause":null,"summary":"Endpoints News reported that individualized-therapy startup EveryOne Medicines would close, with an unknown number of workers affected.","sources":"https://endpoints.news/everyone-medicines-shuts-down-ending-custom-cure-venture-that-banked-on-new-fda-pathway/ https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026","recorded_on":"2026-10-04"},{"company":"Theravance Biopharma","company_slug":"theravance-biopharma","country":null,"city":null,"announced_on":"2026-03-03","effective_on":null,"roles_reported":null,"workforce_before":90,"share_of_workforce":"50.0","verification":"Confirmed","cause":"pipeline_setback","summary":"After the Phase 3 CYPRESS study missed its primary endpoint, Theravance announced a restructuring expected to affect approximately 50% of its workforce and wind down R&D.","sources":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/tm267846d1_8k.htm https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-reports-phase-3-cypress-study-did-not-meet https://www.sec.gov/Archives/edgar/data/1583107/000110465926056760/tbph-20260331x10q.htm","recorded_on":"2026-10-04"},{"company":"Alltrna","company_slug":"alltrna","country":null,"city":null,"announced_on":"2026-03-06","effective_on":null,"roles_reported":19,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Alltrna confirmed a 19-person workforce reduction as it reorganized ahead of moving its first engineered tRNA drug candidate toward the clinic.","sources":"https://www.fiercebiotech.com/biotech/alltrna-undergoes-third-layoff-round-entering-clinic-cutting-35-jobs","recorded_on":"2026-10-04"},{"company":"Vertex Pharmaceuticals","company_slug":"vertex-pharmaceuticals","country":"US","city":null,"announced_on":"2026-03-06","effective_on":null,"roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Vertex Pharmaceuticals confirmed the elimination of about 20 roles in Massachusetts as part of a functional reorganization.","sources":"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026 https://www.biospace.com/biospace-layoff-tracker","recorded_on":"2026-10-04"},{"company":"Horizon Therapeutics","company_slug":"horizon-therapeutics","country":"US","city":"Rockville","announced_on":"2026-03-09","effective_on":"2026-05-08","roles_reported":22,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Horizon Therapeutics, an Amgen subsidiary, filed a Maryland mass-layoff notice for 22 employees at its Rockville research and development location.","sources":"https://labor.maryland.gov/employment/warn.shtml https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026","recorded_on":"2026-10-04"},{"company":"Evotec","company_slug":"evotec","country":null,"city":null,"announced_on":"2026-03-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Evotec announced the Horizon transformation program, including a global workforce adjustment affecting up to 800 positions and a reduction of its site footprint from 14 to 10 locations over two years.","sources":"https://www.evotec.com/news/evotec-announces-horizon-next-inflection-in-its-strategic-transformation-to-accelerate-growth-and-promote-agility https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026","recorded_on":"2026-10-04"},{"company":"f5 Therapeutics","company_slug":"f5-therapeutics","country":null,"city":null,"announced_on":"2026-03-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"f5 Therapeutics' founder and CEO announced that the company would wind down after six years, describing a prolonged period of exceptionally weak funding for early-stage biotech.","sources":"https://www.linkedin.com/posts/garytravischoy_closing-a-company-you-poured-your-heart-into-activity-7436772813304135681-KnBB https://www.fiercebiotech.com/biotech/molecular-glue-biotech-shutters-after-brutal-last-few-years-early-stage-companies","recorded_on":"2026-10-04"},{"company":"Vistagen Therapeutics","company_slug":"vistagen-therapeutics","country":null,"city":null,"announced_on":"2026-03-11","effective_on":"2026-03-05","roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Vistagen disclosed a workforce reduction of approximately 20% as part of measures intended to conserve cash and align resources with its remaining development priorities.","sources":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/vtgn-20260305.htm https://www.fiercebiotech.com/biotech/vistagen-reduces-workforce-20-after-phase-3-failure","recorded_on":"2026-10-04"},{"company":"INOVIO Pharmaceuticals","company_slug":"inovio-pharmaceuticals","country":null,"city":null,"announced_on":"2026-03-12","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"INOVIO said it eliminated roles that did not directly support its primary goal of advancing INO-3107 toward U.S. approval.","sources":"https://ir.inovio.com/news/news-details/2026/INOVIO-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Business-Highlights/default.aspx https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-20260312.htm https://www.fiercebiotech.com/biotech/inovio-trims-team-trouble-brews-fda-rare-disease-candidate","recorded_on":"2026-10-04"},{"company":"Bicycle Therapeutics","company_slug":"bicycle-therapeutics","country":null,"city":null,"announced_on":"2026-03-17","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"30.0","verification":"Confirmed","cause":"restructuring","summary":"Bicycle Therapeutics announced a strategic reprioritization and a proposed workforce reduction of approximately 30%, intended to focus resources on next-generation programs.","sources":"https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-reports-recent-business-progress-and-5 https://investors.bicycletherapeutics.com/static-files/f70663fa-3b90-4060-af78-47ec822f2e47 https://www.fiercebiotech.com/biotech/bicycle-pumps-brakes-lead-program-deflates-headcount-30","recorded_on":"2026-10-04"},{"company":"Gossamer Bio","company_slug":"gossamer-bio","country":null,"city":null,"announced_on":"2026-03-17","effective_on":null,"roles_reported":73,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Gossamer Bio implemented a workforce reduction after the Phase 3 PROSERA study failed to meet its primary endpoint, while shifting resources toward remaining programs and strategic priorities.","sources":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000018/goss-20260317xexx991.htm https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/R23.htm https://www.sec.gov/Archives/edgar/data/1728117/000172811726000032/goss-20260331.htm","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":"San Mateo","announced_on":"2026-03-25","effective_on":"2026-05-29","roles_reported":51,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Gilead filed a California WARN notice for 51 permanent layoffs in San Mateo, effective May 29.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.warntracker.com/layoff/gilead-sciences-2026-05-29","recorded_on":"2026-10-04"},{"company":"Takeda","company_slug":"takeda","country":null,"city":null,"announced_on":"2026-03-25","effective_on":null,"roles_reported":4500,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Takeda launched the next phase of a global transformation program that the company later quantified as approximately 4,500 job reductions during fiscal 2026.","sources":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000100/form6k_032526.htm https://www.mass.gov/doc/takeda-pharmaceuticals-usa-inc-cambridge-ma-03-25-2026-warn-notice/download https://www.reuters.com/legal/litigation/takeda-cut-about-4500-jobs-fiscal-2026-it-steps-up-restructuring-2026-05-13/","recorded_on":"2026-10-04"},{"company":"Iterum Therapeutics","company_slug":"iterum-therapeutics","country":null,"city":null,"announced_on":"2026-03-27","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"Iterum Therapeutics filed a petition in Ireland to wind up the company and entered provisional liquidation after concluding that it had no reasonable alternative strategic transaction available.","sources":"https://www.sec.gov/Archives/edgar/data/1659323/000119312526127785/itrm-20260327.htm https://www.sec.gov/Archives/edgar/data/1659323/000119312526127785/itrm-ex99_1.htm","recorded_on":"2026-10-04"},{"company":"Novo Nordisk","company_slug":"novo-nordisk","country":"US","city":"Bloomington","announced_on":"2026-03-30","effective_on":null,"roles_reported":400,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Novo Nordisk confirmed an approximately 400-position workforce reduction at its Bloomington manufacturing site, with about 1,400 employees expected to remain.","sources":"https://bloomingtonian.com/2026/03/30/more-than-400-layoffs-planned-at-novo-nordisk-bloomington-site/ https://bloomingtonian.com/2026/04/01/novo-nordisk-confirms-bloomington-layoffs-city-says-support-resources-will-be-offered/","recorded_on":"2026-10-04"},{"company":"IO Biotech","company_slug":"io-biotech","country":null,"city":null,"announced_on":"2026-03-31","effective_on":"2026-03-31","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"IO Biotech ceased operations and filed for Chapter 7 bankruptcy, terminating its remaining workforce and management as the company entered liquidation.","sources":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/d87973d8k.htm https://www.fiercebiotech.com/biotech/after-reeling-fda-refusal-io-biotech-surrenders-bankruptcy","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2026-03-31","effective_on":"2026-06-26","roles_reported":114,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis disclosed a first 2026 East Hanover workforce reduction affecting 114 employees, with separations beginning June 26 and continuing through November.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.biospace.com/biospace-layoff-tracker","recorded_on":"2026-10-04"},{"company":"BioNTech","company_slug":"biontech","country":"SG","city":"Singapore","announced_on":"2026-04-01","effective_on":null,"roles_reported":85,"workforce_before":85,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"BioNTech announced that it would close its Tuas manufacturing plant by the end of February 2027, affecting the site's 85 employees.","sources":"https://www.straitstimes.com/business/biontech-to-wind-up-singapore-vaccine-manufacturing-plant-in-early-2027 https://www.channelnewsasia.com/singapore/biontech-close-tuas-covid-vaccine-manufacturing-plant-february-2027-6033291","recorded_on":"2026-10-04"},{"company":"Astellas US Holding","company_slug":"astellas-us-holding","country":"US","city":"Seattle","announced_on":"2026-04-10","effective_on":"2026-07-01","roles_reported":50,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Astellas filed a Washington WARN notice covering 50 workers as it moved to close the Seattle site inherited through its acquisition of Universal Cells.","sources":"https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database https://www.fiercebiotech.com/biotech/astellas-close-stem-cell-units-seattle-site-layoffs-incoming","recorded_on":"2026-10-04"},{"company":"Replimune Group","company_slug":"replimune","country":"US","city":"Woburn","announced_on":"2026-04-10","effective_on":"2026-04-13","roles_reported":63,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"After the FDA issued a second complete response letter for RP1, Replimune initiated an initial workforce reduction affecting 63 commercial positions.","sources":"https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn-layoff-and-closure-updates https://www.sec.gov/Archives/edgar/data/1737953/000110465926042141/tm2611633d1_8k.htm https://www.fiercebiotech.com/biotech/replimune-sheds-60-staff-after-fda-rejection-vows-continue-operations","recorded_on":"2026-10-04"},{"company":"Click Therapeutics","company_slug":"click-therapeutics","country":null,"city":null,"announced_on":"2026-04-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"27.0","verification":"Confirmed","cause":"restructuring","summary":"Click Therapeutics reduced its workforce as it retooled the organization for a shift from R&D toward commercialization; trade press reported a 27% reduction while the company confirmed the layoffs without disclosing a fixed count.","sources":"https://endpoints.news/click-therapeutics-cuts-27-of-workforce-after-50m-raise/ https://www.fiercebiotech.com/medtech/click-hits-cut-workforce-after-commercial-deal-changeup","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Lawrence Township","announced_on":"2026-04-17","effective_on":"2026-07-16","roles_reported":206,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed another New Jersey WARN round affecting 206 employees tied to Lawrence Township, with separations scheduled from July through December.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://njbiz.com/bristol-myers-squibb-206-more-layoffs-new-jersey/","recorded_on":"2026-10-04"},{"company":"Replimune Group","company_slug":"replimune","country":"US","city":null,"announced_on":"2026-04-17","effective_on":null,"roles_reported":161,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Replimune expanded its post-FDA restructuring with an additional 161 layoffs across Woburn and Framingham, including its manufacturing operation.","sources":"https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn-layoff-and-closure-updates https://www.warntracker.com/layoff/replimune-2026-04-17 https://www.fiercebiotech.com/biotech/replimune-sheds-60-staff-after-fda-rejection-vows-continue-operations","recorded_on":"2026-10-04"},{"company":"Passage Bio","company_slug":"passage-bio","country":"US","city":null,"announced_on":"2026-04-28","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Confirmed","cause":"restructuring","summary":"Passage Bio announced a restructuring plan to reduce operating expenses by cutting approximately 75% of its workforce.","sources":"https://www.sec.gov/Archives/edgar/data/1787297/000110465926049755/tm2612859d1_8k.htm https://www.fiercebiotech.com/biotech/blocked-fda-passage-cuts-headcount-75","recorded_on":"2026-10-04"},{"company":"Autolus Therapeutics","company_slug":"autolus-therapeutics","country":null,"city":null,"announced_on":"2026-04-29","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"13.0","verification":"Confirmed","cause":"restructuring","summary":"Autolus Therapeutics announced a restructuring that included an approximately 13% workforce reduction as it adjusted its operating plan and resource allocation.","sources":"https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/d113906d8k.htm https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/d113906dex991.htm","recorded_on":"2026-10-04"},{"company":"Gilead Sciences","company_slug":"gilead-sciences","country":"US","city":null,"announced_on":"2026-04-30","effective_on":"2026-06-30","roles_reported":192,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Gilead filed WARN notices for 192 roles across Arcellx sites in Redwood City and Rockville shortly after completing its acquisition of the cell-therapy company.","sources":"https://labor.maryland.gov/employment/warn.shtml https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://www.fiercebiotech.com/biotech/after-arcellx-buyout-close-gilead-trims-108-jobs-car-t-biotechs-redwood-city-outpost","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2026-05-04","effective_on":"2026-07-24","roles_reported":60,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis disclosed a separate East Hanover round affecting 60 employees as it adjusted U.S. oncology, rheumatology, dermatology and neuroscience field sales teams.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/after-march-cuts-novartis-trims-another-60-roles-us-headquarters","recorded_on":"2026-10-04"},{"company":"BioNTech","company_slug":"biontech","country":"DE","city":null,"announced_on":"2026-05-05","effective_on":null,"roles_reported":1800,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"BioNTech announced plans to exit manufacturing operations at several sites; after the buyer search failed, the closures of Idar-Oberstein, Marburg and Tübingen were confirmed, affecting approximately 1,800 employees.","sources":"https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2026/05/biontech-announces-first-quarter-2026-financial-results.html https://www.sec.gov/Archives/edgar/data/1776985/000177698526000031/form6-kq12026quarterlyrepo.htm https://www.tagesschau.de/wirtschaft/unternehmen/biontech-standorte-schliessung-100.html","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"DE","city":"Wehr","announced_on":"2026-05-05","effective_on":null,"roles_reported":220,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Novartis announced plans to close its Wehr production site by the end of 2028, a move expected to eliminate approximately 220 jobs.","sources":"https://www.novartis.com/de-de/medien/pressemitteilungen/novartis-plant-schliessung-des-produktionsstandorts-wehr https://www.reuters.com/business/world-at-work/novartis-cut-220-jobs-it-closes-german-site-2026-05-05/","recorded_on":"2026-10-04"},{"company":"Amicus Therapeutics","company_slug":"amicus-therapeutics","country":"US","city":"Princeton","announced_on":"2026-05-12","effective_on":"2026-08-07","roles_reported":58,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Amicus Therapeutics disclosed 58 job cuts at its Princeton headquarters following its acquisition by BioMarin, with separations scheduled from August through October.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/biomarin-consolidates-staff-amicus-hq-after-closing-48b-deal-rare-disease-peer","recorded_on":"2026-10-04"},{"company":"Valneva","company_slug":"valneva","country":null,"city":null,"announced_on":"2026-05-13","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Valneva announced a further global restructuring intended to streamline operations, including a workforce reduction stated as a range of 10% to 15%.","sources":"https://valneva.gcs-web.com/static-files/c64ed960-3eef-4083-91a5-2f9943ac3e8c https://www.globenewswire.com/news-release/2026/5/13/3293636/0/en/Valneva-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Updates.html https://www.sec.gov/Archives/edgar/data/1836564/000162828026056525/valn-20260630.htm","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2026-05-22","effective_on":"2026-08-21","roles_reported":76,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis disclosed a third East Hanover workforce reduction affecting 76 employees, including roles in its biomedical research organization.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/novartis-unleash-another-76-cuts-nj-while-abbvie-plots-85-layoffs-ca","recorded_on":"2026-10-04"},{"company":"Johnson & Johnson","company_slug":"johnson-johnson","country":"US","city":"New Brunswick","announced_on":"2026-05-29","effective_on":"2026-08-21","roles_reported":56,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Johnson & Johnson confirmed 56 position eliminations in New Jersey, primarily tied to New Brunswick, as it prepared to separate its orthopedics business.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://njbiz.com/jnj-cutting-jobs-new-brunswick-hq/","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"US","city":"Rahway","announced_on":"2026-06-02","effective_on":"2026-09-04","roles_reported":88,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Merck disclosed a WARN round affecting 88 employees at its Rahway headquarters, effective September 4, as part of its multiyear optimization program.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/merck-shrinks-headcount-88-nj-3b-cost-cutting-scheme-rolls","recorded_on":"2026-10-04"},{"company":"Fulcrum Therapeutics","company_slug":"fulcrum-therapeutics","country":null,"city":null,"announced_on":"2026-06-04","effective_on":null,"roles_reported":48,"workforce_before":57,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Fulcrum Therapeutics disclosed an approximately 85% workforce reduction after discontinuing its lead clinical program and beginning a strategic review.","sources":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/fulc-20260531.htm https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-discontinuation-pociredir-and","recorded_on":"2026-10-04"},{"company":"Teva Pharmaceutical Industries","company_slug":"teva-pharmaceutical-industries","country":"IL","city":"Neot Hovav","announced_on":"2026-06-10","effective_on":null,"roles_reported":250,"workforce_before":650,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Teva's TAPI active-pharmaceutical-ingredients business announced plans to eliminate about 250 jobs in Israel over two years as it restructures the unit and continues evaluating a possible sale.","sources":"https://en.globes.co.il/en/article-teva-to-lay-off-250-in-api-division-in-israel-1001545492 https://www.calcalistech.com/ctechnews/article/rywmg6u11zx https://www.fiercepharma.com/manufacturing/teva-lay-250-api-unit-search-new-owner-drags-report","recorded_on":"2026-10-04"},{"company":"enGene","company_slug":"engene","country":"US","city":null,"announced_on":"2026-06-15","effective_on":null,"roles_reported":29,"workforce_before":65,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"enGene's U.S. subsidiary selected 29 of its 65 employees for termination as part of the June 2026 strategic restructuring.","sources":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-20260613.htm https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-ex99_1.htm https://www.sec.gov/Archives/edgar/data/1980845/000119312526384383/engn-ex10_5.htm","recorded_on":"2026-10-04"},{"company":"Neumora Therapeutics","company_slug":"neumora-therapeutics","country":null,"city":null,"announced_on":"2026-06-15","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"35.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Neumora Therapeutics announced an approximately 35% workforce reduction after late-stage studies of navacaprant failed, while reprioritizing its development portfolio.","sources":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192d8k.htm https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192dex991.htm https://www.fiercebiotech.com/biotech/neumora-lay-35-staff-after-navacaprant-goes-0-3-phase-3-depression-studies","recorded_on":"2026-10-04"},{"company":"Boundless Bio","company_slug":"boundless-bio","country":null,"city":null,"announced_on":"2026-06-23","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"75.0","verification":"Confirmed","cause":"merger","summary":"Boundless Bio announced a workforce reduction of approximately 75% in connection with its merger agreement with Serapha Bio.","sources":"https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/d159021d8k.htm https://investors.boundlessbio.com/news-releases/news-release-details/boundless-bio-and-serapha-bio-announce-merger-agreement-and-230 https://boundlessbio.gcs-web.com/node/7856/html","recorded_on":"2026-10-04"},{"company":"Sangamo Therapeutics","company_slug":"sangamo-therapeutics","country":"US","city":null,"announced_on":"2026-06-23","effective_on":null,"roles_reported":51,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"insolvency","summary":"Sangamo Therapeutics disclosed a restructuring eliminating approximately 51 U.S. roles while filing for Chapter 11 bankruptcy and pursuing asset sales.","sources":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm https://www.fiercebiotech.com/biotech/sangamo-puts-substantially-all-assets-sale-bankruptcy-lines-lilly-and-astellas-buyers","recorded_on":"2026-10-04"},{"company":"ADC Therapeutics","company_slug":"adc-therapeutics","country":null,"city":null,"announced_on":"2026-06-24","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"17.0","verification":"Confirmed","cause":"restructuring","summary":"ADC Therapeutics announced a global restructuring that included an approximately 17% workforce reduction as it streamlined operations and focused spending.","sources":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_8k.htm https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_ex9901.htm","recorded_on":"2026-10-04"},{"company":"Biogen","company_slug":"biogen","country":null,"city":null,"announced_on":"2026-06-26","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"After acquiring Apellis Pharmaceuticals, Biogen paused or terminated most legacy Apellis research programs and eliminated a small number of research roles during the integration.","sources":"https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-scales-back-apellis-programs-trims-research-roles-after-56-billion-buyout-2026-06-26/ https://www.fiercebiotech.com/biotech/biogen-ends-apellis-research-programs-cuts-small-number-roles-after-56b-buyout","recorded_on":"2026-10-04"},{"company":"Genentech","company_slug":"genentech","country":"US","city":"South San Francisco","announced_on":"2026-06-26","effective_on":"2026-07-29","roles_reported":103,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Genentech filed a California WARN notice for 103 permanent layoffs, while the company said the eliminations formed part of restructuring across its early-development organization and other areas.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn_report1.xlsx https://www.fiercebiotech.com/biotech/genentech-sees-103-roles-impacted-gred-rethink-pens-490m-breast-cancer-collab https://www.sfchronicle.com/tech/article/genentech-layoffs-south-san-francisco-22330978.php","recorded_on":"2026-10-04"},{"company":"BioCryst Pharmaceuticals","company_slug":"biocryst-pharmaceuticals","country":"US","city":"Hoover","announced_on":"2026-06-29","effective_on":"2026-10-07","roles_reported":47,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"BioCryst announced that it will discontinue its internal discovery programs and close its Discovery Center of Excellence in Birmingham, Alabama by the end of 2026, affecting employees at the facility.","sources":"https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/f8k_062926.htm https://ir.biocryst.com/news-releases/news-release-details/biocryst-sharpens-scientific-focus-external-innovation-wind-down https://workforce.alabama.gov/warn-list/","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"US","city":"East Hanover","announced_on":"2026-07-07","effective_on":"2026-10-02","roles_reported":322,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novartis disclosed a fourth 2026 East Hanover workforce reduction affecting 322 employees as it changed field sales, patient support and marketing organizations.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/novartis-dismisses-322-more-its-us-headquarters-nj","recorded_on":"2026-10-04"},{"company":"DesigneRX Pharmaceuticals","company_slug":"designerx-pharmaceuticals","country":"US","city":"Vacaville","announced_on":"2026-07-20","effective_on":"2026-09-21","roles_reported":25,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"DesigneRX Pharmaceuticals filed a California WARN notice for 25 permanent layoffs at its Vacaville facility, effective September 21.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn_report1.xlsx https://californiawarn.com/companies/designerx-pharmaceuticals","recorded_on":"2026-10-04"},{"company":"Clinuvel Pharmaceuticals","company_slug":"clinuvel-pharmaceuticals","country":null,"city":null,"announced_on":"2026-07-23","effective_on":"2027-01-01","roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Clinuvel Pharmaceuticals announced a strategic reorganization effective January 1, 2027, including a global workforce reduction stated as approximately 10% to 20%.","sources":"https://www.sec.gov/Archives/edgar/data/1290877/000149315226034387/form6-k.htm https://www.sec.gov/Archives/edgar/data/1290877/000149315226034387/ex99-1.htm","recorded_on":"2026-10-04"},{"company":"Amgen","company_slug":"amgen","country":null,"city":null,"announced_on":"2026-07-24","effective_on":null,"roles_reported":40,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Amgen confirmed that around 40 employees were laid off as part of organizational changes intended to better align operations with strategic objectives.","sources":"https://www.fiercebiotech.com/biotech/amgen-sheds-around-40-staffers-struggles-pile-tavneos-pipeline","recorded_on":"2026-10-04"},{"company":"Lisata Therapeutics","company_slug":"lisata-therapeutics","country":null,"city":null,"announced_on":"2026-08-04","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"72.0","verification":"Confirmed","cause":"merger","summary":"Lisata Therapeutics announced an approximately 72% workforce reduction after termination of its proposed merger, while pursuing strategic alternatives and preserving cash.","sources":"https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-provides-update-following-termination-merger https://www.fiercebiotech.com/biotech/lisata-lays-72-staffers-sues-kuva-after-merger-falls-apart","recorded_on":"2026-10-04"},{"company":"Emergent BioSolutions","company_slug":"emergent-biosolutions","country":null,"city":null,"announced_on":"2026-08-05","effective_on":null,"roles_reported":93,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Emergent BioSolutions announced a restructuring that would reduce its current workforce by approximately 93 employees across the company and eliminate 21 additional vacant positions.","sources":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/ebs-20260805.htm https://investors.emergentbiosolutions.com/news/news-details/2026/Emergent-BioSolutions-Reports-Second-Quarter-2026-Financial-Results/default.aspx","recorded_on":"2026-10-04"},{"company":"aTyr Pharma","company_slug":"atyr-pharma","country":null,"city":null,"announced_on":"2026-08-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"60.0","verification":"Confirmed","cause":"restructuring","summary":"aTyr Pharma announced an approximately 60% workforce reduction as part of a restructuring and program-prioritization plan.","sources":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-quarter-2026-results-program https://www.fiercebiotech.com/biotech/atyr-lays-60-workforce-fund-2nd-attempt-phase-3-success-lung-disease-drug","recorded_on":"2026-10-04"},{"company":"Blueprint Medicines","company_slug":"blueprint-medicines","country":"US","city":"Cambridge","announced_on":"2026-08-07","effective_on":"2026-10-09","roles_reported":229,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"merger","summary":"Blueprint Medicines, now part of Sanofi, filed a Massachusetts WARN notice affecting 229 employees as Sanofi integrated the acquired company and consolidated Cambridge operations.","sources":"https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn https://www.nbcboston.com/boston-business-journal/mass-life-sciences-company-laying-off-200-workers-after-9-1b-acquisition/3998150/ https://www.fiercepharma.com/pharma/sanofi-lay-229-blueprint-medicines-staff-close-cambridge-offices-following-acquisition","recorded_on":"2026-10-04"},{"company":"Ensoma","company_slug":"ensoma","country":"US","city":"Boston","announced_on":"2026-08-07","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Ensoma confirmed a second workforce reduction while concentrating resources on EN-374 and pausing other preclinical programs.","sources":"https://www.fiercebiotech.com/biotech/ensoma-sheds-more-staff-pauses-preclinical-programs-home-lead-gene-therapy https://www.biospace.com/biospace-layoff-tracker","recorded_on":"2026-10-04"},{"company":"Arpeggio Biosciences","company_slug":"arpeggio-biosciences","country":null,"city":null,"announced_on":"2026-08-10","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Arpeggio Biosciences' CEO announced that the company was winding down after its lead NRF2 degrader program could not separate efficacy from an off-target liability.","sources":"https://www.linkedin.com/posts/joeyazofeifa_last-month-we-made-the-difficult-decision-activity-7491593869428514818-x5_g https://www.fiercebiotech.com/biotech/arpeggio-plays-final-chord-biotech-disbands-poor-prospects-nrf2-program","recorded_on":"2026-10-04"},{"company":"Aura Biosciences","company_slug":"aura-biosciences","country":"US","city":"Boston","announced_on":"2026-08-11","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"20.0","verification":"Confirmed","cause":"restructuring","summary":"Aura Biosciences announced an organizational realignment focused on ocular oncology, including a workforce reduction of approximately 20%.","sources":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-20260811.htm https://www.sec.gov/Archives/edgar/data/1501796/000119312526343429/aura-20260630.htm https://www.fiercebiotech.com/biotech/aura-lays-20-staff-rejigs-c-suite-amid-rd-refocusing","recorded_on":"2026-10-04"},{"company":"EMD Serono Research Development Institute","company_slug":"emd-serono-research-development-institute","country":"US","city":"Billerica","announced_on":"2026-08-12","effective_on":"2026-10-16","roles_reported":20,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"EMD Serono filed a Massachusetts WARN notice for 20 layoffs at its Billerica research site, with the positions scheduled to be eliminated beginning in October.","sources":"https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn https://fiercebiotech.dev.qtxquartz.com/biotech/merck-kgaa-lays-20-staffers-latest-blow-us-research-team https://www.nbcboston.com/boston-business-journal/major-biopharma-company-cuts-20-jobs-at-massachusetts-rd-site/3999271/","recorded_on":"2026-10-04"},{"company":"Kolon TissueGene","company_slug":"kolon-tissuegene","country":"US","city":"Rockville","announced_on":"2026-08-14","effective_on":"2026-08-31","roles_reported":37,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"pipeline_setback","summary":"Kolon TissueGene filed a Maryland mass-layoff notice for 37 employees at its Rockville site, effective August 31, after a late-stage clinical setback prompted a corporate realignment.","sources":"https://labor.maryland.gov/employment/warn.shtml https://www.fiercebiotech.com/biotech/kolon-tissuegene-layoffs-follow-phase-3-setback","recorded_on":"2026-10-04"},{"company":"Cellares","company_slug":"cellares","country":"US","city":null,"announced_on":"2026-08-21","effective_on":"2026-10-20","roles_reported":168,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":null,"summary":"Cellares reduced staffing across its South San Francisco headquarters and Bridgewater, New Jersey smart factory after Bristol Myers Squibb ended a major cell-therapy manufacturing partnership.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn_report1.xlsx https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.pharmamanufacturing.com/production/automation-control/article/55405768/cellares-defends-its-cell-shuttle-platform-after-bristol-myers-squibb-ends-partnership","recorded_on":"2026-10-04"},{"company":"PDS Biotechnology","company_slug":"pds-biotechnology","country":null,"city":null,"announced_on":"2026-08-25","effective_on":"2026-08-21","roles_reported":null,"workforce_before":null,"share_of_workforce":"36.0","verification":"Confirmed","cause":"restructuring","summary":"PDS Biotechnology disclosed a reduction in force affecting approximately 36% of its workforce as it concentrated resources on PDS0301.","sources":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126034320/ef20081077_8k.htm https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/134-2026-news/1040-pds-biotech-announces-strategic-refocus-prioritizing-pds03012026-08-11-075038","recorded_on":"2026-10-04"},{"company":"Arsenal Biosciences","company_slug":"arsenal-biosciences","country":"US","city":"South San Francisco","announced_on":"2026-08-31","effective_on":null,"roles_reported":99,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Arsenal Biosciences announced a strategic pivot toward in vivo CAR-T and laid off 99 employees across teams, functions and locations.","sources":"https://www.globenewswire.com/news-release/2026/08/31/3353670/0/en/arsenalbio-announces-new-focus-on-in-vivo-car-t-programs-to-leverage-investment-in-t-cell-engineering.html https://www.fiercebiotech.com/biotech/arsenalbio-sheds-most-staff-pivot-vivo-car-t","recorded_on":"2026-10-04"},{"company":"ArsenalBio","company_slug":"arsenalbio","country":"US","city":null,"announced_on":"2026-08-31","effective_on":null,"roles_reported":99,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"ArsenalBio announced a strategic shift toward in-vivo CAR-T programs and a substantial workforce reduction; a company spokesperson confirmed 99 roles across its teams and locations.","sources":"https://arsenalbio.com/2026/08/31/arsenalbio-announces-new-focus-on-in-vivo-car-t-programs-to-leverage-investment-in-t-cell-engineering/ https://www.fiercebiotech.com/biotech/arsenalbio-sheds-most-staff-pivot-vivo-car-t https://www.biospace.com/job-trends/august-biopharma-layoffs-impact-just-over-500-down-90-year-over-year","recorded_on":"2026-10-04"},{"company":"TELA Bio","company_slug":"tela-bio","country":null,"city":null,"announced_on":"2026-08-31","effective_on":null,"roles_reported":41,"workforce_before":201,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"TELA Bio announced a targeted workforce reduction of approximately 20% as part of a broader cost-reduction initiative intended to lower operating expenses and preserve capital.","sources":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926103548/tm2624299d1_8k.htm https://www.sec.gov/Archives/edgar/data/1561921/000110465926103548/tm2624299d1_ex99-1.htm","recorded_on":"2026-10-04"},{"company":"Novartis","company_slug":"novartis","country":"CH","city":"Basel","announced_on":"2026-09-02","effective_on":null,"roles_reported":130,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"Novartis said planned changes at its Kleinbasel operations could affect around 130 jobs as it relocates laboratory activities and plans to stop small-volume biologics production there.","sources":"https://www.novartis.com/ch-de/news/media-releases/novartis-informiert-ueber-den-geplanten-uebergang-von-aktivitaeten-im-kleinbasel https://www.reuters.com/business/world-at-work/novartis-could-cut-about-130-jobs-basel-site-relocation-2026-09-02/ https://www.fiercepharma.com/pharma/novartis-telegraphs-130-job-cuts-amid-biologics-rethink-switzerland","recorded_on":"2026-10-04"},{"company":"TScan Therapeutics","company_slug":"tscan-therapeutics","country":"US","city":"Waltham","announced_on":"2026-09-02","effective_on":"2026-11-02","roles_reported":96,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"TScan Therapeutics announced a strategic reorganization eliminating approximately 75% of its workforce while focusing resources on in-vivo programs and conserving capital.","sources":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/d309786d8k.htm https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-announces-strategic-reorganization-focus-vivo https://www.mass.gov/info-details/worker-adjustment-and-retraining-notification-act-warn","recorded_on":"2026-10-04"},{"company":"Merck","company_slug":"merck","country":"US","city":"Rahway","announced_on":"2026-09-08","effective_on":"2026-12-11","roles_reported":54,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Merck disclosed another Rahway WARN round affecting 54 employees, with separations on December 11 and January 4.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://njbiz.com/merck-54-jobs-rahway-nj-layoffs/","recorded_on":"2026-10-04"},{"company":"GSK","company_slug":"gsk","country":"DE","city":"Dresden","announced_on":"2026-09-10","effective_on":null,"roles_reported":650,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"GSK announced plans to close its Dresden vaccine manufacturing site and consolidate influenza-vaccine production in Canada, affecting approximately 650 employees.","sources":"https://www.pharmadeutschland.de/newsroom/news/gsk-will-impfstoffwerk-dresden-schliessen/ https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-shut-vaccine-factory-germany-putting-641-jobs-risk-2026-09-11/ https://www.biospace.com/business/gsk-lays-off-650-staffers-amid-closure-of-german-vaccine-manufacturing-site?trk=public_post_comment-text","recorded_on":"2026-10-04"},{"company":"DesigneRX Pharmaceuticals","company_slug":"designerx-pharmaceuticals","country":"US","city":"Vacaville","announced_on":"2026-09-14","effective_on":"2026-11-15","roles_reported":7,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"site_closure","summary":"DesigneRX Pharmaceuticals filed a second California WARN notice for a permanent closure affecting 7 additional positions at its Vacaville site, effective November 15.","sources":"https://edd.ca.gov/siteassets/files/jobs_and_training/warn/warn_report1.xlsx https://www.layofftracker.us/layoff-tracker/designerx-pharmaceuticals-vacaville-ca-nov-2026-layoffs/17PxiT","recorded_on":"2026-10-04"},{"company":"Sionna Therapeutics","company_slug":"sionna-therapeutics","country":"US","city":"Waltham","announced_on":"2026-09-14","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"46.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Sionna Therapeutics publicly announced a 46% workforce reduction while refocusing resources on its SION-451 plus SION-2222 program after disappointing SION-719 results.","sources":"https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638d8k.htm https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638dex991.htm https://www.fiercebiotech.com/biotech/sionna-lays-46-workforce-strategic-shift-after-cystic-fibrosis-trial-fail","recorded_on":"2026-10-04"},{"company":"Johnson & Johnson Services","company_slug":"johnson-johnson-services","country":"US","city":"New Brunswick","announced_on":"2026-09-21","effective_on":"2026-12-18","roles_reported":87,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Johnson & Johnson Services disclosed a separate New Brunswick WARN round affecting 87 employees, effective December 18.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://nj-explorer.s3.us-west-2.amazonaws.com/nj-layoff-notices/index.html https://www.biospace.com/biospace-layoff-tracker","recorded_on":"2026-10-04"},{"company":"Bristol Myers Squibb","company_slug":"bristol-myers-squibb","country":"US","city":"Princeton","announced_on":"2026-09-22","effective_on":"2026-12-17","roles_reported":265,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Bristol Myers Squibb disclosed a third New Jersey WARN round in 2026, affecting 265 employees tied to its Princeton headquarters from December 2026 through May 2027.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/bristol-myers-cuts-another-265-jobs-tied-new-jersey-headquarters","recorded_on":"2026-10-04"},{"company":"Adagio Medical Holdings","company_slug":"adagio-medical","country":"US","city":"Laguna Hills","announced_on":"2026-09-23","effective_on":"2026-09-23","roles_reported":25,"workforce_before":43,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Adagio Medical Holdings adopted a cost-reduction plan while exploring strategic alternatives, cutting 25 of its 43 full-time employees effective September 23, 2026.","sources":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926109821/adgm-20260923x8k.htm https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-strategic-review-process-maximize","recorded_on":"2026-10-04"},{"company":"BioMarin Pharmaceutical","company_slug":"biomarin-pharmaceutical","country":"US","city":"Novato","announced_on":"2026-09-24","effective_on":"2026-12-04","roles_reported":117,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"BioMarin filed a California WARN notice for 117 permanent layoffs at its Novato site as part of a consolidation of its local and global footprint.","sources":"https://edd.ca.gov/en/jobs_and_training/layoff_services_warn/ https://californiawarn.com/companies/biomarin-pharmaceutical https://www.fiercepharma.com/pharma/biomarin-lays-117-california-workers-consolidate-footprint","recorded_on":"2026-10-04"},{"company":"Enanta Pharmaceuticals","company_slug":"enanta-pharmaceuticals","country":null,"city":null,"announced_on":"2026-09-29","effective_on":null,"roles_reported":37,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Enanta Pharmaceuticals confirmed a 37-person workforce reduction across departments after reviewing the resources needed for its current antiviral and immunology priorities.","sources":"https://www.fiercebiotech.com/biotech/enanta-sheds-staffers-key-antiviral-and-immunology-readouts-loom","recorded_on":"2026-10-04"},{"company":"Novo Nordisk","company_slug":"novo-nordisk","country":"US","city":"Plainsboro","announced_on":"2026-09-30","effective_on":"2026-12-31","roles_reported":108,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"restructuring","summary":"Novo Nordisk disclosed 108 job cuts tied to its Plainsboro U.S. headquarters, effective December 31, while redesigning parts of its U.S. sales organization.","sources":"https://www.nj.gov/labor/assets/PDFs/WARN/2026_WARN_Notice_Archive.pdf https://www.fiercepharma.com/pharma/novo-trims-108-jobs-us-headquarters-new-jersey","recorded_on":"2026-10-04"},{"company":"Foghorn Therapeutics","company_slug":"foghorn-therapeutics","country":null,"city":null,"announced_on":"2026-10-01","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":"40.0","verification":"Confirmed","cause":"pipeline_setback","summary":"Foghorn Therapeutics announced an approximately 40% workforce reduction after discontinuing FHD-909 and ending a Lilly collaboration following disappointing early clinical results.","sources":"https://foghorntx.gcs-web.com/news-releases/news-release-details/foghorn-therapeutics-provides-update-fhd-909-and-strategic https://www.fiercebiotech.com/ai-and-machine-learning/foghorn-lays-40-employees-lilly-collab-collapses-over-poor-data https://finance.yahoo.com/healthcare/articles/foghorn-cut-40-workforce-scrapping-121315846.html","recorded_on":"2026-10-04"},{"company":"Adecto Pharmaceuticals","company_slug":"adecto-pharmaceuticals","country":"US","city":"Boston","announced_on":"2026-10-02","effective_on":null,"roles_reported":null,"workforce_before":null,"share_of_workforce":null,"verification":"Confirmed","cause":"funding","summary":"Adecto Pharmaceuticals announced that it had closed after being unable to secure sufficient financing in a difficult funding environment.","sources":"https://www.fiercebiotech.com/biotech/immmunotherapy-startup-adecto-blames-risk-adverse-funding-environment-closing-down","recorded_on":"2026-10-04"}]}